

This is a Patch II type separator sheet.

This is a Patch II type separator sheet.




Portrait Feed

New Document Follows...

Printed on 3/14/00 at 10:10.

Copyright ©Kofax Image Products 1994-1999





P050034
AMENDMENT 013¹⁴
VISIONCARE OPHTHALMIC TECHNOLOGIES
IMPLANTABLE MINIATURE TELESCOPE™ (IMT BY DR. ISAAC LIPSHITZ)

VOLUME II OF IV

SEPTEMBER 2, 2008

APPLICANT

VisionCare Ophthalmic Technologies, Inc.
14395 Saratoga Ave., Suite 150
Saratoga, CA 95070

CORRESPONDENT

Judy Gordon D.V.M.
ClinReg Consulting Services, Inc.
Tel: (949) 715-0609
Fax: (949) 715-0610
e-mail: judy@clinregconsulting.com

P050034 A013\14
VISIONCARE OPHTHALMIC TECHNOLOGIES, INC.
IMPLANTABLE MINIATURE TELESCOPE™ (IMT)

∞ **TABLE OF CONTENTS** ∞

		VOLUME	PAGE
1.0	BACKGROUND AND INTRODUCTION.....	I	1
2.0	IMT CLINICAL TRIALS.....	I	6
2.1	PROTOCOL IMT-002	I	6
2.2	PROTOCOL IMT-002-LTM (LONG-TERM MONITORING).....	I	11
3.0	DEMOGRAPHIC, BASELINE, AND ACCOUNTABILITY INFORMATION.....	I	12
4.0	EFFECTIVENESS.....	I	16
4.1	VISUAL ACUITY.....	I	16
4.2	QUALITY OF LIFE	I	28
5.0	SAFETY.....	I	32
5.1	PRESERVATION OF VISUAL ACUITY	I	33
5.2	CORNEAL ENDOTHELIAL CELL DENSITY AND FINDINGS	I	36
5.3	USE OF A GRID TO ALLOW PHYSICIANS AND PATIENTS TO ASSESS LIKELIHOOD THAT PATIENTS WILL RETAIN SUFFICIENT ENDOTHELIAL CELL DENSITY OVER THE PATIENT’S LIFE SPAN	I	59
5.4	COMPLICATIONS AND ADVERSE EVENTS.....	I	65
5.5	ANTERIOR CHAMBER DEPTH (ACD) AND CLEARANCE.....	I	77
5.6	INTRAOCULAR PRESSURE.....	I	81
5.7	POSTERIOR CAPSULE OPACIFICATION.....	I	82
5.8	RETINAL EXAMINATION AND FINDINGS.....	I	84
6.0	LABELING FOR RISK MITIGATION	I	85
7.0	CONCLUSION	I	91
8.0	BIBLIOGRAPHY.....	I	92

ATTACHMENTS

	VOLUME	PAGE
ATTACHMENT 1		
IN-TEXT AND ADDITIONAL TABLES (INCLUDES ALL TABLES FOUND IN AMENDMENT 13 AND ADDITIONAL TABLES NOT SHOWN IN THE NARRATIVE)	I	99
ATTACHMENT 2		
EXPERT OPINION ON ENDOTHELIAL MORPHOLOGY AND MORPHOMETRY, H. EDELHAUSER PH.D.	I	254
ATTACHMENT 3		
PROTOCOL IMT-002.....	II	1
ATTACHMENT 4		
PROTOCOL IMT-002 STUDY INVESTIGATORS	II	136
ATTACHMENT 5		
PROTOCOL IMT-002-LTM	II	147
ATTACHMENT 6		
PROTOCOL IMT-002-LTM STUDY INVESTIGATORS.....	II	183
ATTACHMENT 7		
PHAKIC IOL LABELING (ARTISAN [®] PHAKIC INTRAOCULAR LENS, DIRECTIONS FOR USE).....	II	187
ATTACHMENT 8		
BIEXPONENTIAL MODEL.....	II	193
BIBLIOGRAPHY AND CITATIONS	III & IV	1



P050034
AMENDMENT 014
VISIONCARE OPHTHALMIC TECHNOLOGIES
IMPLANTABLE MINIATURE TELESCOPE™ (IMT BY DR. ISAAC LIPSHITZ)

VOLUME II OF IV

SEPTEMBER 2, 2008

APPLICANT

VisionCare Ophthalmic Technologies, Inc.
14395 Saratoga Ave., Suite 150
Saratoga, CA 95070

CORRESPONDENT

Judy Gordon D.V.M.
ClinReg Consulting Services, Inc.
Tel: (949) 715-0609
Fax: (949) 715-0610
e-mail: judy@clinregconsulting.com

P050034 A014
VISIONCARE OPHTHALMIC TECHNOLOGIES, INC.
IMPLANTABLE MINIATURE TELESCOPE™ (IMT)

∞ TABLE OF CONTENTS ∞

		VOLUME	PAGE
1.0	BACKGROUND AND INTRODUCTION.....	I	1
2.0	IMT CLINICAL TRIALS.....	I	6
2.1	PROTOCOL IMT-002.....	I	6
2.2	PROTOCOL IMT-002-LTM (LONG-TERM MONITORING).....	I	11
3.0	DEMOGRAPHIC, BASELINE, AND ACCOUNTABILITY INFORMATION.....	I	12
4.0	EFFECTIVENESS.....	I	16
4.1	VISUAL ACUITY.....	I	16
4.2	QUALITY OF LIFE	I	28
5.0	SAFETY.....	I	32
5.1	PRESERVATION OF VISUAL ACUITY	I	33
5.2	CORNEAL ENDOTHELIAL CELL DENSITY AND FINDINGS	I	36
5.3	USE OF A GRID TO ALLOW PHYSICIANS AND PATIENTS TO ASSESS LIKELIHOOD THAT PATIENTS WILL RETAIN SUFFICIENT ENDOTHELIAL CELL DENSITY OVER THE PATIENT'S LIFE SPAN	I	59
5.4	COMPLICATIONS AND ADVERSE EVENTS.....	I	65
5.5	ANTERIOR CHAMBER DEPTH (ACD) AND CLEARANCE.....	I	77
5.6	INTRAOCULAR PRESSURE.....	I	81
5.7	POSTERIOR CAPSULE OPACIFICATION.....	I	82
5.8	RETINAL EXAMINATION AND FINDINGS.....	I	84
6.0	LABELING FOR RISK MITIGATION	I	85
7.0	CONCLUSION	I	91
8.0	BIBLIOGRAPHY.....	I	92

ATTACHMENTS

	VOLUME	PAGE
ATTACHMENT 1		
IN-TEXT AND ADDITIONAL TABLES (INCLUDES ALL TABLES FOUND IN AMENDMENT 14 AND ADDITIONAL TABLES NOT SHOWN IN THE NARRATIVE).....	I	99
ATTACHMENT 2		
EXPERT OPINION ON ENDOTHELIAL MORPHOLOGY AND MORPHOMETRY, H. EDELHAUSER PH.D.	I	254
ATTACHMENT 3		
PROTOCOL IMT-002.....	II	1
ATTACHMENT 4		
PROTOCOL IMT-002 STUDY INVESTIGATORS	II	136
ATTACHMENT 5		
PROTOCOL IMT-002-LTM	II	147
ATTACHMENT 6		
PROTOCOL IMT-002-LTM STUDY INVESTIGATORS.....	II	183
ATTACHMENT 7		
PHAKIC IOL LABELING (ARTISAN[®] PHAKIC INTRAOCULAR LENS, DIRECTIONS FOR USE).....	II	187
ATTACHMENT 8		
BIEXPONENTIAL MODEL.....	II	193
BIBLIOGRAPHY AND CITATIONS	III & IV	1

P050034 AMENDMENT 014
VISIONCARE OPHTHALMIC TECHNOLOGIES
IMPLANTABLE MINIATURE TELESCOPE™ (IMT)

~ LIST OF IN-TEXT TABLES ~

TABLE 1	DEMOGRAPHIC AND BASELINE CHARACTERISTICS OPERATED SUBJECTS (N=217)
TABLE 2	OPERATED EYES WITHOUT IMT PLACEMENT IMT-002
TABLE 3	AVAILABILITY AND ACCOUNTABILITY OPERATED SUBJECTS (N = 217) IMT-002
TABLE 4	AVAILABILITY AND ACCOUNTABILITY OPERATED SUBJECTS IMT-002-LTM
TABLE 5.1	MEAN BCVA AT BASELINE, 12 MONTHS, AND 24 MONTHS IMT-IMPLANTED EYES IMT-002
TABLE 6	SUMMARY OF IMPROVEMENT IN VISUAL ACUITY IMT-IMPLANTED EYES IMT-002
TABLE 7.1	SUMMARY OF IMPROVEMENT IN VISUAL ACUITY IMT-IMPLANTED EYES STRATIFIED BY PREOPERATIVE BCDVA IMT-002
TABLE 8	SUMMARY OF IMPROVEMENT IN VISUAL ACUITY IMT-IMPLANTED EYES STRATIFIED BY IMT MODEL IMT-002
TABLE 9.1	CUMULATIVE BCDVA IMPROVEMENT FROM BASELINE IMT-IMPLANTED EYES IMT-002-LTM
TABLE 9.2	MEAN BCDVA AT BASELINE, 36 MONTHS AND 48 MONTHS IMT-IMPLANTED EYES IMT-002 AND IMT-002-LTM
TABLE 10	CHANGE IN BCDVA FROM BASELINE FOLLOWING CATARACT REMOVAL AND IOL IMPLANTATION
TABLE 11	CHANGE IN BCDVA PRE-IOL IMPLANT IMT EYES WITH IMT REMOVAL POSTOPERATIVELY & WITH IOL IMPLANT

TABLE 12.1	BCDVA INCREASE ≥ 2 OR ≥ 3 LINES FELLOW EYES WITH CATARACT SURGERY AND IOL IMPLANT DURING STUDY AND CORRESPONDING IMT-IMPLANTED EYES
TABLE 13.1	MEAN SCORE CHANGE AT 12 MONTHS NEI 25-ITEM VISUAL FUNCTION QUESTIONNAIRE (VFQ-25) IMT-002
TABLE 13.2	VFQ-25 SCORE PERCENT OF PATIENTS ACHIEVING A CLINICALLY MEANINGFUL 5 POINT CHANGE IN COMPOSITE SCORE ALL IMT-IMPLANTED EYES IMT-002
TABLE 14	CHANGE FROM PREOPERATIVE IN ADL SCORES IMT-IMPLANTED EYES IMT-002
TABLE 15	PRESERVATION OF BCVA OPERATED EYES (N = 217) IMT-002
TABLE 16.1	LOSS OF BEST CORRECTED DISTANCE VISUAL ACUITY (BCDVA) IMT-IMPLANTED EYES IMT-002
TABLE 16.2	LOSS OF BEST CORRECTED DISTANCE VISUAL ACUITY (BCDVA) FELLOW EYES OF IMT-IMPLANTED EYES IMT-002
TABLE 17.1	LOSS OF BEST CORRECTED DISTANCE VISUAL ACUITY (BCDVA) IMT-IMPLANTED EYES IMT-002-LTM
TABLE 17.2	LOSS OF BEST CORRECTED DISTANCE VISUAL ACUITY (BCDVA) FELLOW EYES OF IMT-IMPLANTED EYES IMT-002-LTM
TABLE 18.1	ECD, PERCENT CHANGE IN ECD, AND ANNUALIZED PERCENT CHANGE IN ECD IMT-IMPLANTED EYES IMT-002 AND IMT-002-LTM
TABLE 19.1	PAIRED ANALYSIS BETWEEN 12 TO 48 MONTHS FOR THE DIFFERENCE IN ECD AND PERCENT CHANGE IN ECD BETWEEN IMT-IMPLANTED EYES AND FELLOW EYES IMT-002 AND IMT-002-LTM
TABLE 19.2	PAIRED ANALYSIS BETWEEN 12 TO 48 MONTHS FOR THE DIFFERENCE IN ECD AND PERCENT CHANGE IN ECD BETWEEN IMT-IMPLANTED EYES AND PHAKIC FELLOW EYES IMT-002 AND IMT-002-LTM
TABLE 19.3	PAIRED ANALYSIS BETWEEN 12 TO 48 MONTHS FOR THE DIFFERENCE IN ECD AND PERCENT CHANGE IN ECD BETWEEN IMT-IMPLANTED EYES AND PSEUDOPHAKIC FELLOW EYES IMT-002 AND IMT-002-LTM

TABLE 20.1	INCIDENCE OF RISK FACTORS IN EYES WITH MEAN ECD < 750 CELLS/MM ² IMT-IMPLANTED EYES (WITHIN-EYE MEAN FROM 6 TO 48 MONTHS) IMT-002 AND IMT-002 LTM
TABLE 20.2	COMBINATION OF RISK FACTORS IN EYES WITH MEAN ECD < 750 CELLS/MM ² IMT-IMPLANTED EYES IMT-002 AND IMT-002-LTM (WITHIN-EYE MEAN FROM 6 TO 48 MONTHS)
TABLE 20.3	WITHIN-EYE ECD FOR 6 TO 48 MONTHS PREDICTED PROBABILITY OF ECD < 750 CELLS/MM ² IMT-IMPLANTED EYES IMT-002 AND IMT-002-LTM
TABLE 21.1	BI-EXPONENTIAL MODEL FOR ECD $ECD_{MONTH} = P \times E^{-A \times MONTH} + Q \times E^{-B \times MONTH} + \epsilon$ NON-GUTTATA IMT-IMPLANTED EYES WITH ACD ≥ 3 MM BASED ON DATA FROM BASELINE TO 48 MONTHS IMT-002 AND IMT-002 LTM
TABLE 21.2	PREDICTED MEAN ECD BASED ON BI-EXPONENTIAL MODEL FOR NON-GUTTATA IMT-IMPLANTED EYES WITH ACD ≥ 3 MM BASED ON DATA FROM BASELINE TO 48 MONTHS IMT-002 AND IMT-002 LTM
TABLE 21.3	PREDICTED PROBABILITY OF ECD LESS THAN THRESHOLD BASED ON BI-EXPONENTIAL MODEL FOR NON-GUTTATA IMT-IMPLANTED EYES WITH ACD ≥ 3 MM BASED ON DATA FROM BASELINE TO 48 MONTHS IMT-002 AND IMT-002 LTM (EXCLUDING PREOP RESIDUALS)
TABLE 22.1	BI-EXPONENTIAL MODEL FOR ECD $ECD_{MONTH} = P \times E^{-A \times MONTH} + Q \times E^{-B \times MONTH} + \epsilon$ IMT-IMPLANTED EYES BASED ON DATA FROM BASELINE TO 48 MONTHS IMT-002 AND IMT-002-LTM
TABLE 22.2	PREDICTED MEAN ECD BASED ON BI-EXPONENTIAL MODEL FOR IMT-IMPLANTED EYES BASED ON DATA FROM BASELINE TO 48 MONTHS IMT-002 AND IMT-002-LTM
TABLE 22.3	PREDICTED PROBABILITY OF ECD LESS THAN THRESHOLD BASED ON BI-EXPONENTIAL MODEL FOR IMT-IMPLANTED EYES BASED ON DATA FROM BASELINE TO 48 MONTHS IMT-002 AND IMT-002-LTM (EXCLUDING PREOP RESIDUALS)

TABLE 32.1	OCCURRENCES OF LATE CORNEAL EDEMA WITH (EARLY) ECD LOSS (N = 12)
TABLE 32.2	OCCURRENCES OF LATE CORNEAL EDEMA WITH NO ECD LOSS FOLLOWING IMT IMPLANTATION (N = 1)
TABLE 33	PREOPERATIVE AND LAST AVAILABLE BCDVA EYES THAT UNDERWENT POSTOPERATIVE IMT REMOVAL (N = 12)
TABLE 34	SECONDARY SURGICAL INTERVENTIONS IN IMT-IMPLANTED EYES
TABLE 37.1	DISTRIBUTION OF EYES IMAGED BY PREOPERATIVE ACD
TABLE 37.2	CENTRAL CLEARANCE FROM ANTERIOR SURFACE OF IMT TO THE CORNEAL ENDOTHELIUM ALL EYES WITH IMAGES VS EYES GROUPED BY BASELINE ACD
TABLE 37.3	PERIPHERAL CLEARANCE FROM ANTERIOR SURFACE OF IMT TO THE CORNEAL ENDOTHELIUM ALL EYES WITH IMAGES VS EYES GROUPED BY BASELINE ACD
TABLE 37.4	COMPARISON OF ACD IN IMT-IMPLANTED EYES AND IOL-IMPLANTED FELLOW EYES AT ENTRY INTO PROTOCOL IMT-002
TABLE 38	INTRAOCULAR PRESSURE (IOP) AND CHANGE IN IOP FROM BASELINE IMT-002 AND IMT-002-LTM
TABLE 39	CURRENT VERSUS PREVIOUS LABELING ELEMENTS

P050034 AMENDMENT 014
VISIONCARE OPHTHALMIC TECHNOLOGIES
IMPLANTABLE MINIATURE TELESCOPE™ (IMT)

~ LIST OF FIGURES ~

- | | |
|------------|--|
| FIGURE 1 | IMPLANTABLE TELESCOPE AND COMPONENTS |
| FIGURE 2 | SURGICAL PROCEDURE AND DEVICE POSITION |
| FIGURE 3 | IMAGE ON SCARRED MACULA AND IMAGE ON IMT IMPLANTED EYE RETINA |
| FIGURE 4 | FIELD OF VIEW WITH EXTERNAL TELESCOPE VS IMT |
| FIGURE 5 | PRIMARY EFFECTIVENESS ENDPOINT
≥ 2 LINES GAIN IN EITHER DISTANCE OR NEAR BCVA FOR
IMT-IMPLANTED EYES |
| FIGURE 6 | CUMULATIVE DISTRIBUTION OF BCDVA LINE CHANGE AT 24
MONTHS, BASELINE IMT-IMPLANTED EYES AND FELLOW EYES OF
IMT-IMPLANTED EYES |
| FIGURE 7 | THEORETICAL GAIN COMPARED TO ACTUAL GAIN FROM EXTERNAL
TELESCOPES (2.2X AND 3.0X) USED FOR SUBJECT SCREENING
IMT-002 |
| FIGURE 8 | THEORETICAL GAIN COMPARED TO ACTUAL GAIN FROM IMT AT 12
MONTHS IMT MODELS WA 2.2X AND WA 3.0X IMT-002 |
| FIGURE 9.1 | ECD – OPERATED EYES VERSUS IMT-IMPLANTED EYES –
IMT-002 AND IMT-002-LTM STUDIES |
| FIGURE 9.2 | ECD % CHANGE FROM BASELINE, OPERATED EYES VERSUS
IMT-IMPLANTED EYES – IMT-002 AND IMT-002-LTM STUDIES |
| FIGURE 9.3 | ECD, 48-MONTH CONSISTENT COHORT – IMT-IMPLANTED EYES –
IMT-002 AND IMT-002-LTM STUDIES |
| FIGURE 9.4 | ECD % CHANGE FROM BASELINE – 48-MONTH CONSISTENT
COHORT OF IMT-IMPLANTED EYES – IMT-002 AND IMT-002-LTM
STUDIES |

- FIGURE 10 ECD % LOSS – NORMAL EYE, ECCE/IOL & PENETRATING KERATOPLASTY
- FIGURE 11 PERCENT ENDOTHELIAL CELL LOSS AT 3 MONTHS – STRATIFIED BY GUTTATA – IMT-IMPLANTED EYES – IMT-002
- FIGURE 12 PERCENT ENDOTHELIAL CELL LOSS AT 3 MONTHS – STRATIFIED BY SURGEON SPECIALTY – NON-GUTTATA IMT-IMPLANTED EYES – IMT-002
- FIGURE 13 PERCENT ENDOTHELIAL CELL LOSS AT 3 MONTHS – STRATIFIED BY SURGICAL ORDER – NON-GUTTATA IMT-IMPLANTED EYES – NON-CORNEA SPECIALIST – IMT-002
- FIGURE 14 PERCENT ENDOTHELIAL CELL LOSS AT 3 MONTHS – STRATIFIED BY ANTERIOR CHAMBER DEPTH – NON-GUTTATA IMT-IMPLANTED EYES – IMT-002
- FIGURE 15 ECD – NON-GUTTATA EYES WITH ACD ≥ 3 MM VERSUS OTHER EYES – IMT-002 AND IMT-002-LTM
- FIGURE 16 ECD % CHANGE FROM BASELINE – NON-GUTTATA EYES WITH ACD ≥ 3 MM VERSUS OTHER EYES – IMT-002 AND IMT-002-LTM
- FIGURE 17 NON-GUTTATA EYES WITH ACD ≥ 3 MM IMPLANTED BY CORNEA SPECIALIST VERSUS OTHER EYES – IMT-002 AND IMT-002-LTM
- FIGURE 18 ECD % CHANGE FROM BASELINE - NON-GUTTATA EYES WITH ACD ≥ 3 MM IMPLANTED BY CORNEA SPECIALIST VERSUS OTHER EYES – IMT-002 AND IMT-002-LTM
- FIGURE 19 PERCENT HEXAGONALITY – IMT-IMPLANTED EYES – IMT-002 AND IMT-002-LTM
- FIGURE 20 COEFFICIENT OF VARIATION - IMT-IMPLANTED EYES – IMT-002 AND IMT-002-LTM
- FIGURE 21 PACHYMETRY - IMT-IMPLANTED EYES – IMT-002 AND IMT-002-LTM
- FIGURE 22 PROPOSED GRID OF PREOPERATIVE EDC REQUIRED FOR IMT IMPLANTATION BASED ON IMT-IMPLANTED EYES WITHOUT GUTTATA AND WITH ACD ≥ 3.0 MM
- FIGURE 23 GRID OF PREOPERATIVE ECD REQUIRED FOR IMT IMPLANTATION BASED ON IMT-IMPLANTED EYES

FIGURE 24

CENTRAL CLEARANCE AND PERIPHERAL CLEARANCE
MEASUREMENTS

FIGURE 25

PARS PLANA CAPSULOTOMY

ATTACHMENT 3

**PROTOCOL IMT-002
PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF
THE IMPLANTABLE MINIATURE TELESCOPE (IMT™)
IN PATIENTS WITH CENTRAL VISION IMPAIRMENT
ASSOCIATED WITH AGE RELATED
MACULAR DEGENERATION OR STARGARDT'S
MACULAR DYSTROPHY**

**PROTOCOL IMT-002:
PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE IMPLANTABLE MINIATURE
TELESCOPE (IMT™) IN PATIENTS WITH CENTRAL VISION IMPAIRMENT ASSOCIATED
WITH AGE RELATED MACULAR DEGENERATION OR STARGARDT'S MACULAR
DYSTROPHY**

**A PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE
IMPLANTABLE MINIATURE TELESCOPE (IMT™) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE RELATED MACULAR
DEGENERATION OR STARGARDT'S MACULAR DYSTROPHY**

**PROTOCOL IMT-002
AMENDMENT #1**

February 10, 2003

**Study Sponsor :
VisionCare Ophthalmic Technologies, Inc.
14375 Saratoga Avenue, Suite 104
Saratoga, CA 95070**

I have read and agree to follow the study procedures as outlined in this protocol.

Print Name of Investigator

Investigator's Signature

Date

CONFIDENTIAL - DO NOT COPY

This protocol contains confidential proprietary information with respect to VisionCare products and clinical trials. I agree to hold this information in confidence and not to disclose it to any third parties for a period of three years from the date of this agreement, or until this information becomes a matter of public knowledge or until a formal agreement for that purpose has been entered into by the parties.

TABLE OF CONTENTS (CONT.)

8.	STATISTICAL METHODS	28
8.1	SAMPLE SIZE	28
8.2	STATISTICAL ANALYSIS	30
	8.2.1 PRIMARY EFFECTIVENESS ENDPOINT	30
	8.2.2 PRIMARY SAFETY ENDPOINT	30
	8.2.3 OTHER CLINICAL PARAMETERS	30
	8.2.4 INTERIM CLINICAL REPORTS	30
9.	ADVERSE EXPERIENCE REPORTING	32
9.1	ADVERSE EXPERIENCES	32
9.2	DEVICE MALFUNCTIONS.....	33
10.	MONITORING	33
11.	REFERENCES	34

APPENDICES

APPENDIX 1	PROPOSED PATIENT INFORMED CONSENT	35
APPENDIX 2	STUDY EXAMINATIONS	
	SCHEDULE & METHODS.....	41
	EXAMINATION SCHEDULE & CLINICAL PARAMETERS	42
	REFRACTION AND BCVA TESTING PROTOCOL.....	44
	INTRAOCULAR PRESSURE MEASUREMENT	54
	SPECULAR MICROSCOPY.....	58
	VISION TRAINING	60
APPENDIX 3	SPONSOR'S COMMITMENTS	67
APPENDIX 4	INVESTIGATOR'S QUALIFICATIONS AND RESPONSIBILITIES	68
	PROTOCOL AMENDMENTS	
	NATIONAL EYE INSTITUTE 25 ITEM VISUAL FUNCTION QUESTIONNAIRE (VFQ-25)	
	QUALITY OF LIFE QUESTIONNAIRE: ACTIVITIES OF DAILY LIFE	
	PATIENT CASE REPORT FORM (CRFs)	

VISIONCARE OPHTHALMIC TECHNOLOGIES, INC.

**A PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE
IMPLANTABLE MINIATURE TELESCOPE (IMT) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE-RELATED MACULAR
DEGENERATION (AMD) OR STARGARDT'S MACULAR DYSTROPHY**

**PROTOCOL IMT-002
AMENDMENT #1**

PERSONNEL AND FACILITIES

STUDY SPONSOR VisionCare Ophthalmic Technologies, Inc.
14375 Saratoga, Ave., Suite 104
Saratoga, CA 95070
(408) 872-9393 Phone
(408) 872-9395 Fax

MEDICAL MONITOR Stephen S. Lane, M.D.
Associated Eye Care
232 North Main Street, Stillwater, MN 55082

INVESTIGATORS This protocol will involve up to 30 clinical sites located in the continental United States. A complete list of Investigators is available from the Study Sponsor and will be kept on file with the U.S. Food & Drug Administration (FDA).

CLINICAL MONITOR DataMed Devices, LLC
Kathryn L. Tsang and Associates
22022 Apache Drive
Lake Forest, CA 92630
(949) 458-6330 Phone
(949) 581-8106 Fax

*Sponsor's Agent /
Representative*

**A PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE
IMPLANTABLE MINIATURE TELESCOPE (IMT) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE-RELATED MACULAR
DEGENERATION (AMD) OR STARGARDT'S MACULAR DYSTROPHY**
STUDY OUTLINE

OBJECTIVE The primary objective of this pivotal Phase II/III study is to evaluate the safety and effectiveness of the Implantable Miniature Telescope (IMT) for the improvement of visual acuity in patients with bilateral moderate to severe central vision impairment due to age-related macular degeneration or Stargardt's macular dystrophy. Given favorable 12 month follow-up results, this trial is intended to form the basis for the submission of a Pre-Market Approval (PMA) application with the U.S. Food & Drug Administration to seek approval to market the IMT in the U.S.

PATIENT POPULATION A total of 200 eyes with bilateral, stable untreatable central vision disorders (untreatable AMD or Stargardt's macular dystrophy) will be implanted. The procedure will only be performed monocularly.

STUDY DESIGN This will be a prospective multicenter clinical trial in which a total of 200 consecutive eyes will be implanted and followed over 24 months at up to thirty (30) clinical sites. Enrollment will be continuous; however VisionCare will provide interim clinical reports to the Food & Drug Administration (FDA) at the following intervals:

- 3-month follow-up on the first 25 patients
- 3-month follow-up on the first 50 patients
- 3-month follow-up on the first 100 patients
- 3-month follow-up on the first 150 patients.

Patients will be screened for eligibility, and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible patients will be examined preoperatively to obtain a medical history and to establish a baseline for ocular condition. Baseline measurements will include successful use of an external telescope.

NO PATIENT MAY BE ENROLLED IN THIS STUDY WITHOUT PRIOR WRITTEN ENROLLMENT AUTHORIZATION APPROVAL FROM VISIONCARE. AN ENROLLMENT AUTHORIZATION FORM MUST BE COMPLETED AND APPROVED BY VISIONCARE PERSONNEL FOR EACH PATIENT PRIOR TO TREATMENT.

Postoperatively, patients will undergo a complete ophthalmic evaluation at regular intervals as specified in this protocol.

**OUTCOME
PARAMETERS**

EFFECTIVENESS

The primary study outcome will be post-operative best corrected visual acuity. The procedure will be considered successful if there is an improvement of 2 lines or greater in either near or distance acuity in 50% of the implanted eyes at 12 months post-implantation.

Quality of Life (ADL and VFQ-25) will be used as secondary measurements of procedure success.

SAFETY

Primary safety outcomes will be endothelial cell loss, preservation of best corrected visual acuity (BCVA), and adverse events and complications.

ENDOTHELIAL CELL LOSS: The mean percentage endothelial cell loss will not exceed 17% one year post IMT implantation.

PRESERVATION OF BEST CORRECTED VISUAL ACUITY: No more than 10% of implanted eyes will experience a loss of more than 2 lines of either near or distance BCVA without a corresponding improvement (gain of 2 lines or more) in BCVA (a gain of 2 or more lines of near BCVA in eyes with loss of more than 2 lines distance BCVA, and vice versa).

**EXAMINATION
SCHEDULE**

The examination schedule is as following:

- Preoperative evaluation (Day -45 to -3)
- Operative evaluation (Day 0, the day from which all future visits are scheduled)
- Day 1 (18 to 36 hours postoperative)
- Day 7 (4 to 10 days postoperative)
- 1 Month (2 to 6 weeks postoperative)
- 3 Months (6 to 18 weeks postoperative)
- Vision training at 1, 2, 4, 6, 10 and 12 weeks (+/- 4 days)
- 6 Months (18 to 32 weeks postoperative)
- 9 Months (32 to 44 weeks postoperative)
- 12 Months (44 to 56 weeks postoperative)
- 18 Months (66 to 78 weeks postoperative)
- 24 Months (90 to 102 weeks postoperative)

NOTE: The visit windows described above allow for the possibility that two visits could be scheduled within one week of each other. *This should*

NOT occur. Follow-up visits from 1 month through 24 months should not be scheduled less than six weeks after the previous visit.

**CLINICAL
PARAMETERS**

The following clinical parameters will be measured:

1. Best corrected visual acuity (distance and near)
2. Manifest refraction
3. A-Scan (baseline only)
4. Intraocular pressure (by applanation tonometry)
5. Slit lamp examination
6. Fundus examination and photography (baseline only)
7. Fluorescein angiography (baseline only)
8. Endothelial cell count
9. Activities of Daily Life questionnaire/VFQ-25
10. Pachymetry

NOTE: All personnel at the study site who participate in the conduct of this study must be trained by the study Sponsor, the Clinical Monitor or their designee on the requirements of the protocol and the testing methods referenced therein. The Study Investigator or their designee familiar with the conduct of the Study is expected to train personnel who join the Study while it is in progress.

1.0 INTRODUCTION & RATIONALE

MACULAR DYSTROPHIES

Acquired and hereditary macular dystrophies are the leading cause of central vision impairment and blindness. Age related macular degeneration (AMD) is the most common form of macular dystrophy. Macular degeneration refers to the breakdown of cells in the macula (the center of the retina). Some degeneration is an inevitable consequence of the aging process. However, when it is coupled with the loss of sight in the central part of the field of vision, an underlying pathology is considered present. It is estimated that in the US, AMD affects 1% of all 55-year-olds, and the incidence increases with age, reaching approximately 15% among those aged 80 and over (1). With increasing longevity, it is anticipated that the incidence will increase significantly (1).

The main effect of AMD is to reduce the ability of the individual to engage in everyday activities that require clear central vision. It is associated with elevated risk of depression, increased levels of dependency, and an overall decrease in the quality of life (2-4). Currently there is no effective treatment for the majority of patients. For a minority of patients, (i.e., those with wet AMD resulting from choroidal neovascularization (CNV), advances in new therapies have led to improvements in the management of the rate of vision loss. New treatments include photodynamic therapy, trans-pupillary thermal therapy, submacular surgery and photocoagulation. However, no viable treatments are available for the several hundred thousand individuals with moderate to severe central vision loss due to late stage dry, atrophic AMD, end stage CNV with disciform scar and other maculopathies such as Stargardt's macular dystrophy.

The only corrective interventions currently available are low vision aids such as special spectacles and head-mounted or hand-held telescopes, which magnify images onto the retina. These aids are widely available but have only limited acceptance by patients. Patients find these aids bulky, uncomfortable and unattractive. In addition, use of external telescopes requires suppression of natural eye movements. Instead, the patient has to learn to scan the visual field by moving his/her entire head. If not properly adapted to this behavioral change requirement, a conflict between the visual and vestibular systems will arise, resulting in nausea.

**THE
IMPLANTABLE
MINIATURE
TELESCOPE
(IMT)**




Figure 1. The IMT

VisionCare's Implantable Miniature Telescope (IMT™) is an intraocular implant which, when combined with the optics of the cornea, constitutes a telephoto lens (Figure 1). The IMT contains two micro lenses, which magnify objects in the central visual field, allowing the patient to see without the need of external low-vision aids. A magnified image is projected by the IMT onto the retina, enabling the patient to recognize and identify objects that could not otherwise be seen. The IMT provides improved near or distance vision

correction in the same fashion as an external telescope (Figure 2). The optical component is embedded in a carrier, which is intended to be implanted in the capsular bag in the posterior chamber of the eye, in place of the eye's crystalline lens. It is held in position by haptic loops using a surgical procedure similar to that used in refractive cataract surgery.

The IMT is indicated for use in patients with bilateral, stable macular degeneration or Stargardt's macular dystrophy. Vision loss must be sufficiently advanced to have caused significant or complete loss of normal central vision, but adequate peripheral vision must be retained. The IMT is only implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.




Figure 2. Image quality distribution with the IMT

**ADVANTAGE OF
THE IMT OVER
ALTERNATIVE
LOW VISION
TREATMENTS**

The primary advantage of the IMT over alternative treatments for low vision is that the IMT allows scanning of reading materials and other images using natural eye movements, rather than head movements. Since there is no relative movement between the eye and the telescope, there are no optical aberrations and a wider visual field (central field of 20° or more on the retina) is achieved. The placement of the magnifying device entirely inside the eye eliminates increased speed of motion and vestibular conflict.

If there is further deterioration of the macula after the implantation, the amount of magnification can be significantly increased by bringing the object closer to the eye and adding low-plus eyeglasses (+1.00 to +3.2 D). With glasses, up to 8X magnification can be achieved at 18 cm with the Wide Angle (WA) 3.0X IMT.

**DIFFERENT
MAGNIFICATIONS
AVAILABLE**

For this study the IMT is available in two magnifications:

- Wide Angle (WA) 2.2X
- Wide Angle (WA) 3.0X

Both lenses are predominantly for the restoration of intermediate-far vision (increasing the ability to view objects several meters away from the patient; enables better spatial orientation).

Patients will be given the opportunity to choose which type of visual restoration is more meaningful in their lives by wearing the different corresponding external telescopes for a proper period of acclimation before selecting the IMT that is likely to provide the preferred vision enhancement.

INITIAL CLINICAL EXPERIENCE

**PHASE I
RESULTS**

Phase I of an FDA-approved IMT clinical study (IDE G000115) was completed with 12 months of patient follow-up. A total of 15 patients were enrolled, and the IMT was implanted in 14 eyes. One eye was not successfully implanted due to an inadequate capsulorhexis associated with capsular tear that was further complicated by vitreous loss and choroidal hemorrhage. As a result of these intraoperative complications, the surgical procedure was aborted. This patient was subsequently excluded from all data analyses. All remaining 14 patients completed the 3-month and 6-month examinations and 13 patients returned for the 12-month examination. One patient died before the 12-month visit.

NOTE: The model IMT used in this Phase I study was a 3.0X, since the study was conducted before the availability of any Wide Angle IMT's.

**PATIENT
DEMOGRAPHICS**

The study cohort was composed of 14 eyes from 14 patients with a mean age of 80 years (range 74-89 years). Over half of all patients (64.3%) were female. At baseline, all patients had normal slit lamp examination, other than the presence of a cataract, and normal intraocular pressures.

TABLE 1. PATIENT DEMOGRAPHICS

GENDER		AGE (YEARS)		RACE	
Male 5/14 (35.7%)	Female 9/14 (64.3%)	Range 74-89	Mean 80	Caucasian 14/14 100%	Other 0%

**IMPROVEMENT
OF 2 LINES OR
GREATER**

At 3 months, 11 (78.6%) of 14 patients were reported with an improvement of 2 lines or greater in either the distance or near BCVA. At 6 months, nine (64.3%) of 14 patients experienced an improvement of 2 lines or greater in either distance or near BCVA. At 12 months, ten (76.9%) of 13 patients experienced an improvement of 2 lines or greater in either distance or near BCVA. Thus, the majority of eyes had at least a 2-line improvement in either near or distance best corrected acuity over the course of the study. Figure 3 graphically displays the lines of improvement in either distance or near best corrected acuity 12 months post-IMT implantation.




FIGURE 3. Improvement of Vision 12 months post-implantation

**DISTANCE
VISUAL ACUITY**

Best corrected distance visual acuities for the 14 implanted patients are summarized in TABLE 2, below. Seven (50.0%) of the 14 patients at 3 months and 6 months had an improvement of 2 lines or more in distance BCVA and seven (53.8%) of the 13 patients examined at 12 months experienced an improvement of 2 lines or more in distance BCVA. One patient (001-01-003) had a loss of one line of best corrected distance acuity, from 20/100 to 20/163, at 3 months, however, best corrected near visual acuity improved from 20/533 (20/266 at 6") to 20/60 during the same period. At 6 months and 12 months, best corrected distance acuity for this eye improved to 20/100 and 20/80, respectively.

TABLE 2. BEST CORRECTED DISTANCE VISUAL ACUITY AT 3, 6 AND 12 MONTHS

DISTANCE VISUAL ACUITY	3 MONTHS (n =14)		6 MONTHS (n =14)		12 MONTHS (n =13)	
	n	%	n	%	n	%
Gained two or more lines from baseline	7	50.0%	7	50.0%	7	53.8%
Gained one line from baseline	1	7.1%	3	21.4%	5	38.5%
Less than one complete line change from baseline (no change)	5	35.7%	4	28.6%	1	7.7%
Lost one line from baseline	1	7.1%	0	0.0%	0	0.0%
Lost two or more lines from baseline	0	0.0%	0	0.0%	0	0.0%
TOTAL	14	100 %	14	100%	13	100.0%

NEAR VISUAL ACUITY

Results of best corrected near visual acuity are shown in TABLE 3. Of the 14 implanted patients, 8 (57.1%) and 6 (42.9%) of the 14 patients experienced an improvement of 2 lines or greater in near BCVA at 3 months and 6 months, respectively. Six (46.1%) of the 13 patients at 12 months experienced an improvement of 2 lines or greater in near BCVA.

TABLE 3. BEST CORRECTED NEAR VISUAL ACUITY AT 3, 6 AND 12 MONTHS

NEAR VISUAL ACUITY	3 MONTHS (n =14)		6 MONTHS (n =14)		12 MONTHS (n =13)	
	n	%	n	%	n	%
Gained two or more lines from baseline	8	57.1%	6	42.9%	6	46.1%
Gained one line from baseline	2	14.3%	2	14.3%	2	15.4%
Less than one complete line change from baseline (no change)	1	7.1%	2	14.3%	4	30.8%
Lost one line from baseline	2	14.3%	2	14.3%	1	7.7%
Lost two or more lines from baseline	1	7.1%	2	14.3%	0	0.0%
TOTAL	14	100 %	14	100%	13	100%

A total of six patients experienced a loss of one or more lines of near BCVA at either 3 or 6 months; only one of the patients who returned for examination at 12 months lost one or more lines of vision.

ENDOTHELIAL CELL DENSITY

Endothelial cell density (ECD) and change in ECD from baseline to 3, 6 and 12 months are shown in TABLE 4 below. Baseline endothelial cell counts ranged from 1733 to 2916 cells/mm² with a mean of 2247.6 cells/mm² and a standard deviation of 314.6 cells/mm². Mean endothelial cell loss was 6.7% (S.D. 16.4%) at 3 months, 13.0% (S.D. 13.6%) at 6 months, and 13.2% (S.D. 17.3%) at 12 months. These percentage changes from baseline to 3, 6 and 12 months are within 17%, the average endothelial cell loss reported in a survey of published literature on large-incision cataract surgery. However, the wide range of endothelial cell loss (-45.8% to +15.4%) led to an examination of the cell count data by patient. A single implanted eye (Patient 001-005) had a loss in endothelial cell density from 2,400 cells/mm² to 1,300 cells/mm² at 3 months, accounting for a loss of 45%. However, no further loss in cell density was reported at 6 or 12 months, at which time endothelial cell density remained stable at 1,300 cells/mm².

TABLE 4. RESULTS OF ENDOTHELIAL CELL DENSITY MEASUREMENTS AT 3, 6 AND 12 MONTHS

ENDOTHELIAL CELL DENSITY (CELLS/MM ²)	BASELINE	3 MONTHS (n = 14)	6 MONTHS (n = 14)	12 MONTHS (n = 13)
MEAN	2247.6	2085.6	1935.5	1934.23
STANDARD DEVIATION	314.6	425.1	292.4	354.7
RANGE	1733 to 2916	1300 to 2710	1300 to 2406	1086 to 2300
% CHANGE FROM BASELINE				
MEAN	---	-6.7%	-13.0%	-13.2%
STANDARD DEVIATION	---	16.4%	13.6%	17.3%
RANGE	---	-45.8% to 15.3%	-45.8% to 14.7%	-45.8% to 15.4%

COMPLICATIONS AND ADVERSE EVENTS

Of the 14 eyes implanted with an IMT, complications and/or adverse events were reported for 10 eyes. Additionally, two non-ocular events were reported; these included the death of one study patient 10 months after implantation of the IMT, and surgical removal of a kidney stone approximately 30 days following implantation of the IMT.

The 10 ocular events included one report of mild pigment on the lens at 1 month, that resolved without intervention, and a report of closure of a peripheral iridotomy with pigment, observed at 1 month. This was successfully treated with Nd:YAG iridotomy. The remaining 8

events consisted of late intraocular inflammation, i.e., observed one month or more postoperatively, with varying clinical signs, including anterior chamber cells, fibrin, conjunctival injection, iritis and anterior uveitis. Two of the 8 reports of late intraocular inflammation cases were mild and transient, resolving in approximately two weeks with appropriate steroid treatment. The other six cases required steroid treatment of longer duration, however, in all but a single eye with recurring symptoms, the inflammation resolved without sequelae. Investigation into the cause of this delayed intraocular inflammation revealed an inadequate course perioperative and postoperative steroid treatment, given the large incision and the size of the IMT. Additionally, late intraocular inflammation was not observed at clinical sites which followed a regimen consisting of a depot injection of steroid at the end of surgery, followed by longer-term postoperative steroid use, tapering over time.

**CONCLUSIONS
FROM THE
FEASIBILITY
STUDY**

The experience from this U.S. feasibility study of the IMT provides initial evidence of safety and effectiveness. The majority of patients experienced an improvement in best corrected distance and/or near visual acuity, and all but one of the complications and adverse events resolved without sequelae. Given the absence of treatment alternatives for this patient population, the benefits associated with implantation of the IMT appear to outweigh the risks to the patient, and support the conduct of a pivotal Phase II/III clinical trial as proposed in this protocol.

2.0 STUDY OBJECTIVE

The primary objective of this pivotal Phase II/III study is to evaluate the safety and effectiveness of the Implantable Miniature Telescope (IMT) for the improvement of visual acuity in patients with bilateral moderate to severe central vision impairment due to age-related macular degeneration or Stargard's macular dystrophy. Given favorable 12 month follow-up results, data from this trial is intended to form the basis for the submission of a Pre-Market Approval (PMA) application with the U.S. Food & Drug Administration to seek approval to market the IMT in the U.S.

3.0 STUDY DESIGN

This will be a prospective multicenter clinical trial in which a total of 200 consecutive patients will be implanted and evaluated at a maximum of thirty (30) clinical sites and followed over a 24-month period. No patient may be enrolled in this study without prior written enrollment authorization approval from the Sponsor or their designee. An Enrollment Authorization Form must be completed and approved by the Sponsor or designee for each patient prior to treatment.

4.0 SAFETY & EFFECTIVENESS PARAMETERS

4.1 EFFECTIVENESS

An improvement of 2 lines or greater in either near or distance best corrected acuity in 50% of the implanted eyes at 12 months post-implantation.

4.2 SAFETY

- 4.2.1 Endothelial cell loss: Mean percentage endothelial cell loss less than or equal to 17% at one year post IMT implantation.
- 4.2.2 Preservation of best corrected visual acuity, i.e., no more than 10% of implanted eyes will experience a loss of more than 2 lines of either near or distance BCVA without a corresponding improvement (gain of 2 lines or more) in BCVA (a gain of 2 or more lines of near BCVA in eyes with loss of more than 2 lines distance BCVA, and vice versa).
- 4.2.3 Adverse events and complications.

5.0 PATIENT POPULATION

A total of two hundred (200) consecutive patients who have provided informed consent, been implanted with the IMT, who are capable of comprehending the nature of the study, and who are likely to comply with the visit schedule, are to be entered into the study provided they conform to the following criteria.

5.1 INCLUSION CRITERIA

- Patients with bilateral, stable, untreatable central vision disorders (untreatable AMD or Stargardt's macular dystrophy) as determined by fluorescein angiography, and cataract.
- Patients must have distance BCVA between 20/80 and 20/800, and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation.
- Patients must achieve at least a five letter improvement on the ETDRS chart in the eye scheduled for surgery, with the external telescope.
- The planned operative eye must have an anterior chamber depth of ≥ 2.5 mm.
- Patients must be available for the study duration of approximately 24 months and be willing to attend all visits for training and evaluation.
- Patients must be alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and be personally motivated to abide by the requirements and restrictions of the clinical trial.

- Patients must be able to provide voluntary informed consent.
- Patients must not meet any of the exclusion criteria below.
- Patients must be at least 55 years of age.
- Patients must sign and be given a copy of the written Informed Consent form.

5.2 EXCLUSION CRITERIA

- Evidence of active CNV on fluorescein angiography or treatment for CNV within the past six months.
- Patients who may require cataract extraction and intraocular lens implantation during the first 12 months following IMT implantation in the fellow eye. If cataract extraction is anticipated, this procedure should be performed at least 30 days prior to enrollment in the clinical study.
- Patients who have had or are expected to have ophthalmic related surgery within the 30 days preceding implantation of the IMT.
- The planned operative eye has:
 - Myopia >6.0 D.
 - Hyperopia > 4.0 D.
 - Axial length less than 21 mm.
 - Endothelial cell density less than 1600 cells/mm²
 - Narrow angle, i.e., less than Schaefer grade 2.
 - Stromal or endothelial dystrophies or disorders.
 - Inflammatory ocular disease.
 - Zonular weakness/instability of crystalline lens; pseudoexfoliation.
 - Diabetic retinopathy.
 - Untreated retinal tears.
 - Retinal vascular disease.
 - Optic nerve disease.
 - History of retinal detachment
 - Retinitis pigmentosa.
 - Any intraocular tumor and medical or ophthalmic condition that in the opinion of the Investigator renders the subject unsuitable for participation in the study.
- Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye.
- Patients with an ocular condition that predisposes the patient to eye rubbing.
- Patients with significant communication impairments or severe neurological disorders that would prevent or interfere with the study requirements.
- Patients who have undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.
- Patients who have a history of steroid-responsive rise in

ocular implantation per ISO 10993. One of the internal components (not in contact with body fluids or tissue) of the IMT includes the use of stainless steel which may interfere with the safe use of Magnetic Resonance Imaging (MRI). Until the IMT's MRI compatibility has been established it is considered contraindicated. The IMT is assembled and packaged in a class 10,000 clean room and is sterilized by ethylene oxide. TABLE 5 compares the overall dimensions and physical characteristics of the two IMT models used in this study.

TABLE 5. OVERALL DIMENSIONS AND PHYSICAL CHARACTERISTICS OF THE IMT MODELS

	WA 2.2X	WA 3.0X
DIMENSIONS		
\varnothing_T	13.5 mm	13.5 mm
\varnothing_B	Max: 7.0 mm Min: 4.50 mm	Max: 7.0 mm Min: 4.50 mm
Length	4.4 mm	4.4 mm
WEIGHT		
Air	121.7 mg	117.5 mg
Aqueous	63.7 mg	59.6 mg

6.2 DEVICE COMPONENTS

6.2.1 TELESCOPE

The IMT provides sufficient image resolution for different tasks such as reading, face recognition and TV watching at graded visual fields of up to maximum of 12° (36.0° on the retina) for the wide angle 3.0X model and 16° (35.0° on the retina) for the wide angle 2.2X model. The wide angle IMTs provide patient orientation abilities at a visual angle of 20° (60.0° on the retina) for the 3.0X model and 24° (52.8° on the retina) for the 2.2X model.

TABLE 6 compares and contrasts the optics features for the IMT models used in this study.

TABLE 6. TELESCOPE OPTICAL FEATURES FOR THE IMT MODELS

	WA 2.2X	WA 3.0X
OVERALL DIMENSIONS		
DIAMETER	3.6 mm	3.6 mm
LENGTH	4.4 mm	4.4 mm
OPTICAL DIAMETER	3.2 mm	3.2 mm
MAGNIFICATION INSIDE	2.2X	3.0X

FEATURE	W.A. 2.2X IMT	W.A. 3.0X IMT
THE EYE		
OPTIMAL FOCUSING DISTANCE	3 m	3 m
DEPTH OF FOCUS	1.2 m – 6 m	1.2 m – 6 m
RELATIVE BRIGHTNESS	0.3	0.4
OPTICAL RESOLUTION	MTF ¹ ranges from 0.3 – 0.87 MTF ¹ measurable angles of 10° and 15°; values range from 0.02 (nominal) – 0.75	MTF ¹ ranges from 0.3 – 0.87 MTF ¹ measurable angles of 10° and 15°; values range from 0.02 (nominal) – 0.75

6.2.2 CARRIER & LOOPS

In the Wide Angle 2.2X and 3.0X models, the telescope is snap fit into a one-piece, transparent, medical grade PMMA carrier with loops. The loops range in thickness from 0.18 mm – 0.20 mm and are positioned at a 12.7° angulation from planar and have two sets of positioning holes, one set on the carrier body and another on the loops.

6.2.3 LIGHT RESTRICTOR

A blue PMMA light restrictor on the anterior surface of the device reduces the amount of light penetrating around the device optic to the retina.

¹ Modulation transfer function (MTF) is a set of numbers from 0-1, which characterizes the degradation caused by the tested optical system (eg, human eye), where 1 is a perfect optical system with no degradation of the image; for numbers close to 0, the image cannot be discerned at all. MTF for the IMT's is measured at acute half angles 2° and 5°.

7.0 INVESTIGATIONAL PROCEDURES

7.1 SUBJECT ENTRY

7.1.1 PATIENT SCREENING

Prior to enrollment in the study, interested patients will be evaluated to determine eligibility. The Investigator or a designee will explain the study purpose, procedures, and patient responsibilities to the potential participant. The patient's willingness and ability to meet the follow-up requirements will be determined. No patient may be implanted in this study without prior written enrollment authorization approval from the Sponsor or their designee. An Enrollment Authorization Form must be completed and approved by the Sponsor or their designee for each patient prior to treatment.

7.1.2 INFORMED CONSENT

When it has been established that the patient may be eligible, written informed consent will be obtained (**Appendix 1**). The patient will sign and date the consent form in the presence of a witness. The Investigator will also sign and date the consent form. One copy of the informed consent form will be retained with the patient records and a copy will be provided to the patient. The patient is now considered enrolled.

7.2 PREOPERATIVE PROCEDURES

7.2.1 EXTERNAL TELESCOPE EVALUATION

Visual acuity with an external telescope will be performed using ETDRS (Early Treatment Diabetic Retinopathy Trial) charts. Testing will be done in accordance with the BCVA & Refraction Testing Protocol in **APPENDIX 2.2**.

VisionCare will provide two or more sets of 2.2X and 3.0X external telescopes with reading caps to each site for use in the trial. These telescopes are to be used for all in-office testing and be given to potential patients to try at home for a period of at least three days.

Patients must achieve at least a five letter improvement on the ETDRS chart in the eye scheduled for surgery with at least one of the external telescopes in order to be allowed to proceed with the surgery. Patients who do not meet this criteria will be excluded from the trial. This exclusion will be noted in the screening log at each site.

Following is a table detailing the necessary steps for patient evaluation with the external telescope models.

TABLE 7. PREOPERATIVE EXTERNAL TELESCOPE EVALUATION

STEP	ACTION
1	With the patient sitting in a chair, the external wide angle 3.0X telescope is placed over the patient's distance correction in a trial frame. It should be communicated to the patient that the external telescope is intended to provide the patient with a simulated experience of the magnification, clarity and visual field (slightly less than the corresponding WA 2.2X or 3.0X IMT) that can be expected with the IMT.
2	Each eye should be tested individually. The fellow eye should be covered with a paddle, and then uncovered and the patient questioned on preference for one eye over the other. It is important to gauge the patient's ability to use the telescope with the fellow eye not covered. The patient should be able to use the telescope with the fellow eye uncovered. Failure to do so may indicate strong dominance of the second eye; this should be considered in the determination of the eye to be selected for surgery.
3	At a distance of approximately 3 meters, the patient should be asked to look at another person's face while an assistant repeatedly puts on and takes off the telescopes. The patient is asked to compare vision with each telescope. It is important to determine what the patient hopes to achieve through implantation of the IMT™ and to ensure that these goals are within the anticipated improvement in vision that may be provided by the device.
4	This testing should be repeated for the 2.2X telescope.
5	If the patient achieves a 5-letter improvement in visual acuity with either or both of the external telescopes, he/she is a candidate for implantation, and should be given external telescopes to take home and use in practice sessions for at least three days. Patients should be instructed to attempt daily tasks and activities such as watching television (from 2-3 meters), making coffee, reading, washing hands, etc., while wearing the external telescope(s) in order to provide the patient with a simulation of the visual acuity that may be achieved with the IMT.
6	For safety reasons, the patient should be trained in the use of the telescope while he / she practices walking. They should <u>NOT</u> be allowed to walk about unassisted until they have grown accustomed to the use of the telescope.

STEP	ACTION
7	The patient should return for examination following this in-home trial with the external telescopes. If it is determined that the patient is interested in participating in the study, ETDRS visual acuity should be measured using both external telescopes (refer to Appendix 2 for methods for refraction and ETDRS acuity). The patient must achieve a five letter or greater improvement in distance visual acuity with at least one of the telescope to be a candidate for IMT implant. Data should be collected and recorded on the use of both external telescopes regardless of which is preferred by the patient.
8	If the patient has BCVA better than 20/200 in either eye, the eye with worse visual acuity will be designated for implantation.
9	If BCVA is equal to or worse than 20/200, or if visual acuity is the same in both eyes, the choice of the eye to be implanted is left to the discretion of the physician and patient. NOTE: Patients with an IOL in one eye may have the IMT implanted only in the other eye.

7.2.2 SCREENING FOR ELIGIBILITY AND BASELINE EVALUATION

Once it has been determined that the patient experienced improvement in visual acuity during the trial period of use of external telescope(s), the patient will be further evaluated for eligibility, with the following measurements:

- Distance best spectacle corrected visual acuity
- Near best spectacle corrected visual acuity
- Manifest refraction
- Intraocular pressure by applanation tonometry
- Slit lamp exam
- Fluorescein angiography
- Dilated fundus examination and photography
- Specular microscopy (*may be performed before or after home use of external telescopes*)
- Pachymetry
- A-scan

Results from these procedures can be used for the baseline evaluation if they are obtained **within 45 days before IMT implantation**. Testing performed more than 45 days prior to surgery must be repeated prior to IMT implantation. Detailed information pertaining to patient examinations and the methods of examination is found in Appendix 2.

7.3 SURGICAL PROCEDURE

The IMT procedure will be performed on Day 0 of the study by the Investigator or a Co-Investigator, as described below.

7.3.1 PATIENT PREPARATION

STEP	PROCEDURE
1	Anesthesia is induced by retrobulbar or peribulbar injection.
2	Mydriatic agents are administered to ensure adequate pupil dilation during surgery.
3	A lid speculum is placed on the eye to be implanted, to provide the maximum corneal exposure.
4	The operating microscope, is positioned over or in front of the eye to be treated. Illumination from the operating microscope provides adequate visualization during the procedure.

7.3.2 IMT IMPLANTATION

The IMT procedure may be performed using either a limbal insertion technique or a scleral tunneling procedure. Both surgical approaches are described below.

7.3.3 LIMBAL INSERTION

STEP	ACTION
1	An 8 mm – 10 mm limbal incision is made at the 120 ^o -160 ^o meridians, as in standard cataract surgery.
2	A paracentesis is performed and ophthalmic viscosurgical device (Healon V or equivalent) is injected into the anterior chamber.
3	After the incisions are made, a continuous curvilinear capsulorhexis of approximately 6.5 mm is made in the lens capsule.
4	Phacoemulsification or extra-capsular cataract extraction (ECCE) is performed to remove the lens.
5	Ophthalmic viscosurgical device (Healon V or equivalent) is injected into the anterior chamber and the capsular bag, and used to coat the IMT.
6	The IMT is implanted in the capsular bag: <ol style="list-style-type: none">1. Both loops are placed inside the capsular bag;2. The cornea is sutured; and3. The loops of the IMT are rotated to the 12:6 o'clock position.

STEP	ACTION
7	The pupil is constricted.
8	The ophthalmic viscosurgical device (OVD) agent is removed.
9	A peripheral iridectomy is performed.
10	The incision is tested for leakage.

7.3.4 SCLERAL TUNNEL IMPLANTATION

STEP	ACTION
1	The conjunctiva and Tenon's fascia are opened from the 10 o'clock to the 2 o'clock position.
2	A paracentesis is performed and ophthalmic viscosurgical device (Healon V or equivalent) is injected into the anterior chamber.
3	A continuous curvilinear capsulorhexis of approximately 6.5 mm is created in the lens capsule.
4	A 10 mm scleral incision is performed 2.5 mm – 3 mm posterior to the limbus. A tunnel is then created which opens into the anterior chamber at the limbus.
5	Phacoemulsification or extra-capsular cataract extraction (ECCE) is performed to remove the lens.
6	The IMT is implanted in the capsular bag: <ol style="list-style-type: none"> 1. The IMT is inserted through the scleral tunnel into the capsular bag; 2. Both loops are placed inside the capsular bag; 3. The scleral tunnel is sutured; and 4. The loops of the IMT are rotated to the 12:6 o'clock position.
7	The pupil is constricted.
8	The ophthalmic viscosurgical device (OVD) agent is removed.
9	A peripheral iridectomy is performed.
10	The incision is tested for leakage.

Irrespective of the surgical technique utilized, a sub-Tenon's injection of betamethasone depot (or appropriate substitute) will be administered at the end of surgery.

7.4 POST-OPERATIVE CARE

Following surgery, based on the Phase I results discussed in Section 1 of this protocol (see Complications and Adverse Events) while taking into consideration individual

patient characteristics, the study Sponsor encourages Investigators to adhere to the following standardized regimen of topical ophthalmic medications:

1. One drop of a topical ophthalmic antibiotic solution should be administered following surgery, and then continued as per product labeling for at least two days.
2. One drop of Voltaren Ophthalmic (diclofenac sodium 0.1%, CIBA Vision Ophthalmics) or equivalent should be administered following surgery, and then continued as per product labeling for at least two days.
3. Prednisolone acetate (1%) or equivalent should be administered every 2 waking hours for the first two weeks post-implantation, followed by administration every 4 waking hours for 2-4 weeks.
4. The prednisolone acetate (1%) should be gradually tapered over the next 4 to 6 weeks for a total duration of postoperative steroid treatment of approximately 3 months.
5. Homatropine 5% or a similar drug should be administered twice daily for 4 to 6 weeks postoperatively. If homatropine is inadequate to maintain cycloplegia, atropine may be used.

NOTE: *The above postoperative regimen of anti-inflammatory medications may be too aggressive for some patients and could result in medicamentosa. The Investigator should, in considering the Phase I observations, exercise clinical judgment in deciding if a more moderate or rapid tapering of the topical steroid regimen is indicated for some patients.*

7.5 EXAMINATION SCHEDULE

Subjects will be examined and evaluated according to the following schedule of visits:

- Preoperative Evaluation (Day -45 to Day -3)
- Operative Evaluation (Day 0 – date from which all future visits are calculated)
- Day 1 (18 to 36 hours postoperative)
- Day 7 (4 to 10 days postoperative)
- 1 Month (2 to 6 weeks postoperative)
- 3 Month (6 to 18 weeks postoperative)
- Vision training (week 1, 2, 4, 6, 10 and 12, +/- 4 days)
- 6 Month (18 to 32 weeks postoperative)
- 9 Month (32 to 44 weeks postoperative)
- 12 Month (44 to 56 weeks postoperative)
- 18 Month (66 to 78 weeks postoperative)
- 24 Month (90 to 102 weeks postoperative)

A full description of the examination schedule and clinical parameters can be found in **APPENDIX 2**.

NOTE: *The visit windows described above allow for the possibility that two visits could be scheduled within one week of each other. This should NOT occur. Follow-up visits from 1 month through 24 months should not occur less than six weeks after the previous visit.*

7.6 CLINICAL PARAMETERS

The clinical parameters to be evaluated are:

1. Pinhole acuity (safety assessment) on day 1 and manifest refraction on day 7
2. Best spectacle-corrected distance acuity, using ETDRS VA charts: preoperative, months 1, 3, 6, 9, 12, 18, 24 and any interim visits
3. Best spectacle-corrected near visual acuity, using MN charts: preoperative, months 1, 3, 6, 9, 12, 18, 24 and any interim visits
4. Manifest refraction (no auto-refraction); preoperative, day 7, months 1, 3, 6, 9, 12, 18, 24 and any interim visits
5. Pachymetry: preoperative, 3, 6, 9, 12, 18 and 24 months
6. Intraocular pressure (applanation): all visits
7. Slit lamp examination: all visits
8. Fundus examination (dilated) and photography: preoperative
9. Fluorescein angiography: preoperative
10. Specular microscopy of the central cornea: preoperative, 3, 6, 9, 12, 18 and 24 months
11. Activities of Daily Life (ADL) & VFQ-25 questionnaire: preoperative, 3, 6, 9, and 12 months

Postoperative visual examinations may be performed by the Investigator, or by ophthalmic technicians, optometrists and/or ophthalmologists under the supervision of the Investigators using methods described in **APPENDIX 2**. At each postoperative visit, information concerning the preoperative examination and previous postoperative examinations should not be made available to the individual conducting the examination until all the postoperative examinations are completed. All preoperative and postoperative examinations will be performed using comparable pieces of equipment at each site.

7.7 DATA REPORTING

A Case Report Form (CRF) booklet will be provided by the Sponsor or its designee for each patient enrolled in the study. A sample Case Report Form may be found in **APPENDIX 6**. The appropriate Case Report Form will be completed and signed by the Investigator at each examination. All Case Report Forms will be completed in a legible manner in black ink. Any corrections will be made by drawing a single line through the incorrect entry, entering the correct information, and initialing and dating the change.

Data entries boxes or spaces should not be left blank, but instead should indicate: NA = not applicable, ND=not done or with a "-" for missing or not available data. The original signed forms, not copies, will be returned to the Sponsor.

All clinical data generated in the study will be submitted to the Sponsor or its designee for quality assurance review, data entry, and statistical analysis. All forms will be reviewed for completeness and evident recording errors will be rectified by contact with the appropriate clinical site. Double-entry routines will be utilized to reduce data entry errors, and computerized editing routines will be used to identify unusual data entries for verification prior to statistical analysis.

7.8 STUDY COMPLETION PROCEDURES -

7.8.1 PATIENT COMPLETION

Patients are considered to have completed the study if they have completed all follow-up examinations through 12 months and this data will be submitted as part of a Pre-Market Approval Application (PMA) to the Food and Drug Administration (FDA) as the basis for market approval. Patients will continue to be followed through the 18 and 24 month follow-up exams in order to provide long term safety data.

7.8.2 PATIENT TERMINATION

Patients may be terminated from the study at the discretion of the Investigator only if continuation of the treatment regimen would jeopardize the patients' health and/or welfare. Terminated patients will be considered to have completed the study and should not be replaced. However, every effort will be made to follow terminated patients for safety reasons using the appropriate case report forms until the planned end of the study period. NOTIFICATION OF A PATIENT TERMINATION WILL BE MADE IMMEDIATELY TO THE SPONSOR OR ITS DESIGNEE.

7.8.3 PATIENT EXIT

A patient exit form must be completed for all patients who either complete, discontinue, are considered lost to follow-up, or are terminated from the study. Before a patient is considered "lost to follow-up", there should be three documented attempts to reach patients. At least one of these attempts must be in writing by certified / return receipt mail, a copy of which should be included in the patient's medical / clinic chart.

8.0 STATISTICAL METHODS

8.1 SAMPLE SIZE

The sample size for this study is calculated based on the following criteria:

- The significance level is 0.05.
- The primary effectiveness endpoint is the proportion of eyes with an improvement of 2 lines or more in either distance or near BCVA at 12 months postoperatively, P_t .
- The statistical hypotheses for the primary effectiveness endpoint are $H_0: P_t \leq 0.5$ (50%) versus $H_a: P_t > 0.5$.
- The statistical power is 80% at the expected rate of 0.6 (60%). The expectation of 60% of the eyes achieving improvement is based on results in the feasibility clinical study in which ten of thirteen eyes that reached 12 months having an improvement of 2 lines or greater in either the distance or near BCVA from baseline.
- Binomial distribution is used to calculate the sample size for the effectiveness endpoint.
- The primary safety endpoint is the percentage loss in the endothelial cell counts from baseline at 12 months postoperatively.

Based on a review of the published literature, a mean endothelial cell loss of 10-17% within one year after surgery was observed for large incision surgeries. Therefore, the statistical objective is to prove that the mean percentage of cell loss is no more than 17% and the corresponding statistical hypotheses for the primary safety endpoint $H_0: \mu_t \geq 0.17$ (17%) versus $H_a: \mu_t < 0.17$, where μ_t is the mean percentage loss from baseline at 12 months postoperatively

- The statistical power is 80% at the expected mean loss of 0.135 (13.5%) which is the middle point of the literature's range of 10% to 17%.
- The standard deviation of percentage loss in the endothelial cell counts is assumed to be 0.175 (17.5%), which is estimated based on the feasibility clinical study.
- Normal distribution is used to calculate the sample size for the safety endpoint.

The sample size for the primary effectiveness endpoint is 158 implanted eyes. If 90 or more eyes have an improvement of 2 lines or greater in either distance or near BCVA at 12 months postoperative, the null hypothesis (H_0) will be rejected. Due to the advanced age of the study population, and potential problems with compliance with the visit schedule for patients who may not be independent due to low vision, a dropout rate of 20% is considered. Then the sample size for the primary effectiveness endpoint is 198 eyes.

The sample size for the primary safety endpoint is 156 implanted eyes. If a dropout rate of 20% is considered, the sample size for the primary effectiveness endpoint is 195 eyes.

Therefore, the sample size for this study is at least 198 eyes to fulfill the sample size required for the primary effectiveness endpoint. With this sample size, there is a 95% confidence level to observe at least one adverse event at a rate of 1.5%.

8.2 STATISTICAL ANALYSIS

8.2.1 PRIMARY EFFECTIVENESS ENDPOINT

The primary effectiveness endpoint, the proportion of eyes with at least a 2-line improvement in either distance or near BSCVA at 12 months, will be analyzed with an exact binomial test with a binomial parameter of 0.5. If 158 eyes complete the 12 month postoperative visit, 90 or more successful eyes will result in rejecting the null hypothesis.

8.2.2 PRIMARY SAFETY ENDPOINT

The primary safety endpoint, percentage loss in the endothelial cell counts, will be calculated for each eye. The Student t test will be used for testing the mean percentage cell loss. If 156 implanted eyes complete the 12-month postoperative examination and the standard deviation of the percentage of cell loss is 17.5%, there is a statistical power of at least 80% to prove that the mean percentage cell loss is at most 17%.

8.2.3 OTHER CLINICAL PARAMETERS

The percentages and the corresponding binomial 95% upper confidence limits will be calculated for the percentage of eyes experiencing a loss of more than 2 lines of near (or distance) BCVA without a corresponding improvement (gain of 2 lines or more) in distance (or near) BCVA. The expected rate of this safety event is 10%.

For continuous or ordinal measures such as age or IOP, the number of observations, mean, standard deviation, median, minimum, and maximum values will be presented. If necessary, the 95% confidence interval for the mean value will be provided. If it is appropriate, Analysis of Variance or rank-based methods will be used for comparing the difference among the Investigator sites. For categorical variables such as slit lamp findings or adverse event, the proportion with the characteristic will be presented. If it is necessary, the corresponding exact 95% confidence limits will be provided. If it is appropriate, Fisher's exact test or χ^2 test will be used for comparing the difference among the Investigator sites.

Throughout the analysis, all tests (except for the primary effectiveness and safety endpoints) will be two-sided and any p-values less than 0.05 will be considered statistically significant.

8.2.4 INTERIM CLINICAL REPORTS

Four planned interim analyses will be performed as follow.

- 3-month follow-up on the first 25 subjects
- 3-month follow-up on the first 50 subjects
- 3-month follow-up on the first 100 subjects
- 3-month follow-up on the first 150 subjects.

These interim analyses are for safety and administrative purposes. No statistical adjustment on the p-value will be made.

A Pre-Market Approval (PMA) application will be submitted when all study patients have completed 12 months of follow-up. The 18 and 24 month follow-up data are intended to provide additional long term safety information following the filing of a PMA.

9.0 ADVERSE EXPERIENCES REPORTING / DEVICE MALFUNCTIONS

9.1 ADVERSE EXPERIENCES

Throughout the course of the proposed study, all efforts will be made to remain alert to possible adverse experiences or untoward findings. If adverse experiences occur, the first concern will be the safety and welfare of the patient. Appropriate medical intervention will be made. Any adverse experiences or complications observed by the Investigator or reported by the patients, whether or not ascribed to the IMT, will be recorded in the appropriate section of the patient's Case Report Form.

ANY SERIOUS ADVERSE EXPERIENCES AND UNANTICIPATED, SEVERE, SIGHT-THREATENING ADVERSE REACTIONS, WHETHER OR NOT ASCRIBED TO THE IMT, WILL BE COMMUNICATED PROMPTLY, BY TELEPHONE, TO THE SPONSOR AND TO THE IRB. THESE REPORTS MUST BE CONFIRMED IN WRITING WITHIN FIVE DAYS OF THE OCCURRENCE. Any patients who are terminated from the study due to adverse experiences will be followed until their medical outcome is determined, and written reports will be provided to VisionCare Ophthalmic Technologies by the investigator.

Below is a list of potential or anticipated Adverse Events based on prior IMT clinical trials or known to be occasionally associated with similar types of anterior segment surgery. This list should not be considered comprehensive, but rather identifies events which can be reasonably anticipated.

➤ Acute corneal decompensation	➤ Anterior chamber cells
➤ Anterior segment neovascularization	➤ Anterior synechiae
➤ Choroidal detachment	➤ Closure of a peripheral iridotomy (with or without pigment)
➤ Corneal edema	➤ Corneal transplant
➤ Cortical remnants	➤ Cyclitic membrane
➤ Cystoid macular edema	➤ Distorted pupil
➤ Endophthalmitis	➤ Epithelial heaping
➤ Fibrin in the anterior chamber	➤ Flat anterior chamber
➤ Hyphema	➤ Hypopyon
➤ IMT dislocation	➤ Increased IOP requiring treatment
➤ Inflammatory deposits on IMT	➤ Intraocular infection
➤ Intraocular inflammation	➤ Iris atrophy
➤ Iris transillumination defects	➤ Iritis
➤ Optic atrophy	➤ Pigment deposits on IMT
➤ Posterior synechiae	➤ Pupillary block
➤ Removal of IMT	➤ Repeat iridectomy
➤ Repositioning of IMT	➤ Retinal detachment
➤ Retinal vascular occlusion	➤ Secondary glaucoma

➤ Secondary surgical intervention	➤ Uveitis/Vitritis
➤ Vitrectomy/vitreous aspiration	➤ Vitreous capture space incision
➤ Vitreous in anterior chamber	➤ Wound leak

9.2 DEVICE MALFUNCTIONS

A Device Malfunction is defined as a failure of the IMT to meet its performance specifications or otherwise perform as intended. Performance specifications include all claims made in this protocol or the product associated labeling included with the device. Examples of malfunctions could include:

- Missing product components;
- Missing or illegible product associated labeling;
- IMTs which appear malformed or disfigured;
- Packaging seals compromised;
- Broken haptic loops or ones which break during implantation; and
- Scratches to the IMT lens surfaces.

All device malfunctions will be recorded in the appropriate field on the patient Case Report Forms.

10.0 MONITORING

Sponsor personnel or their designee will monitor all clinical studies in a manner consistent with applicable health authority regulations and the clinical research standards adopted by the Sponsor. Study monitoring will involve the following elements:

- A. Sponsor personnel or designee may meet with Investigators prior to the initiation of the study in order to review the adequacy of the patient population, facilities, and equipment with respect to the needs of the study, and to familiarize the Investigator with the study protocol.
- B. Sponsor personnel or designee may meet with the Investigator(s) at the time study patients begin to be enrolled in order to ensure that patients are being properly selected and that study data are being correctly recorded.
- C. Sponsor personnel or designee may visit the clinical site at any time during the study to review and/or collect the Case Report Forms.
- D. Interim monitoring visits and telephone consultation will occur as necessary during the course of the study to ensure the proper progress and documentation of the study findings.

11.0 REFERENCES

1. Oneill C, et al: Age-related macular degeneration: cost-of-illness issues. *Drugs Aging* 18:233-41; 2001
2. Allikmets et al: Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science* 277: 1805-1807, 1997
3. Brody BL, et al: Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. *Ophthalmology* 108:1893-900; 2001
4. Stelmack J. Quality of life of low-vision patients and outcomes of low-vision rehabilitation. *Optom Vis Sci* 78:335-42; 2001
5. Scilley K, Jackson GR, Cideciyan AV, Maguire MG, Jacobson SG, Owsley C. Early age-related maculopathy and self-reported visual difficulty in daily life. *Ophthalmology* 109:1235-42; 2002
6. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. *Am J Ophthalmol.* 128:45-53; 1999
7. Mangione CM, Orav EJ, Lawrence MG, Phillips RS, Seddon JM, Goldman L. Prediction of visual function after cataract surgery. A prospectively validated model. *Arch Ophthalmol* 113:1305-11; 1995
8. Mangione CM, Phillips RS, Seddon JM, Lawrence MG, Cook EF, Dailey R, Goldman L. Development of the 'Activities of Daily Vision Scale'. A measure of visual functional status. *Med Care.* 30:1111-26; 1992

APPENDIX 1 SUBJECT CONSENT FORM

**THE IMPLANTABLE MINIATURE TELESCOPE (IMT) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION
OR STARGARDT'S MACULAR DYSTROPHY**

PROTOCOL IMT-002

1. PARTICIPANT'S NAME: _____

2. PURPOSE OF PROJECT:

You have been invited to participate in a research study sponsored by VisionCare Ophthalmic Technologies, Inc. (the study Sponsor) and

Dr. _____,

the study Investigator. The purpose of this study is to evaluate the safety and effectiveness of the Sponsor's Implantable Miniature Telescope (IMT™) for implantation in patients with age-related macular degeneration (AMD) or Stargardt's macular dystrophy, diseases that decrease vision as a result of scarring. You are a candidate for this study because you have experienced loss of vision as a result of these diseases, and you have a cataract.

The IMT is a visual aid for patients with low vision. It functions in a fashion similar to an external telescope, but is implanted inside the eye, following removal of the cataract. Once implanted inside the eye, the IMT magnifies images to improve vision. A small number of patients (14 patients) have received an IMT in a Phase 1 clinical trial conducted under a Food and Drug Administration (FDA) approved protocol. In this study, the majority of the patients experienced an improvement of 2 or more lines of visual acuity, and no one had a significant loss of vision as a result of implantation of the IMT. Some patients had an improvement in near vision, and other patients experienced an improvement in distance vision. Several adverse experiences were reported during this study, including inflammation that was successfully treated with steroids. All but one of the adverse events resolved completely, and none of them caused a loss of vision. Based on these results, FDA has approved implantation of an additional 200 patients in the clinical study you are being invited to participate in.

3. DESCRIPTION OF RESEARCH:

The study you are being asked to participate in is a 2-year study, although you may be asked to return for an examination at 36 months or 3 years after your surgery.

The first step in this study is to determine whether you are eligible for enrollment in the trial. This will be accomplished by performing standard ophthalmic testing. Your vision will be evaluated, intraocular pressure will be measured, and you will be asked to try an external telescope to see if this improves your vision, since it works in the same way as the IMT. You will then be given one or two different external telescopes, and you will be trained on the use of these telescopes for evaluation in your home for a minimum of three days.

After trying the external telescopes at home, you will return for another eye exam. At this examination, you will be asked which, if any, of the external telescopes improved your vision. If your vision was not improved by using an external telescope, it means you are not a candidate for the IMT and you will not continue in the study. However, if your vision improved with the external telescope, you will continue in the study, and additional testing will be performed. This testing will include fluorescein angiography. This involves injecting a dye into a vein in your arm; the dye then circulates through the bloodstream and to the retina, or the back of your eye, which has many blood vessels. The presence of the dye in the blood vessels of the retina allows your ophthalmologist to better examine your retina and determine whether you are eligible for this study.

If you are determined to be eligible, you will be scheduled for surgery to implant the IMT. The procedure used to implant the IMT inside the eye is similar to standard cataract surgery. Your cataract will be removed using standard methods used by all cataract surgeons, and the IMT will be placed in the eye, where the natural crystalline lens was before removal. After the surgery to implant your IMT, you will be provided with several types of topical ophthalmic medications for use when you return to your home. The schedule for using these medications will be explained to you before you go home.

You will need to return for examinations the first day after surgery, 1 week after surgery, and then 1, 3, 6, 9, 12, 18 and 24 months after surgery. You may also be asked to return for a 36 month or three year follow-up. At the follow-up examinations, much of the same testing that was performed before your surgery is repeated in order to evaluate changes in your vision. You will also be required to return for additional visits at weeks 1, 2, 4, 6, 10 and 12 after surgery for vision training with a low vision specialist. At these vision training sessions, you will perform exercises that will help you become accustomed to the IMT.

4. RISKS

You should recognize that any surgical procedure presents potential risks. As a result of the surgery to place the IMT, it is possible that your vision may not improve. In some cases, complications may occur during or after implantation. These complications include bleeding in the eye, loss of transparency of the front of your eye (the cornea), infection inside the eye, detachment of the retina (the sensory part of the back of the eye), elevated intraocular pressure, and loss of vision. Additionally, as a result of having the IMT in your eye, you may experience difficulties seeing simultaneously with both eyes, double vision, and dizziness.

As with any type of surgery, there is a possibility of other complications due to anesthesia, drug reactions, or other factors. Since it is not possible to identify every possible complication that may occur as a result of the IMT procedure, you should understand that this list of risks may be incomplete and that there may be risks that are currently unknown.

The materials which make up the IMT are used in other types of implantable medical devices and are generally believed to be acceptable for use in eye related implants, however, the IMT does contain a small amount of metal which could interfere with the safe use of a diagnostic imaging procedure called Magnetic Resonance Imaging or MRI. If you choose to participate in this study and are implanted with the IMT you must be certain to tell your other healthcare professionals and doctors that you were enrolled in a clinical trial involving an eye implant which contains metal. Your other healthcare professionals can contact the study Investigator for further information about the IMT which may effect your care.

5. POTENTIAL BENEFITS

The potential benefits from participating in this research study include improvement in your vision without the use of an external telescope, and a wider field of vision than would be achieved with an external telescope.

6. ALTERNATIVE TREATMENTS

Alternative treatments may include telescopic spectacles or other low-vision aids.

7. CONFIDENTIALITY AND PATIENT AUTHORIZATION

You should understand that your medical records pertaining to participation in this study will be made available for review by your doctor to the Sponsor of the study and to governmental agencies such as the U.S. Food and Drug Administration(FDA). You should also understand that the information in these records will be kept confidential, but, that on rare occasions, disclosure to third parties may be required by law. By signing this form, you authorize access to your study related medical records until such time that the marketing application for this technology is approved by FDA.

You agree that results of your surgery and photographs of your eyes made as part of the study may be published for scientific purposes provided your identity is not revealed. Results of this study may be presented at scientific meetings and published in journals, however, no names will be used in any data summaries or publications and all medical data will be protected.

8. COMPENSATION FOR INJURY

You will not be compensated for participation in this study.

You will not receive a bill or be asked to pay for the cost of the study tests or the procedure. The Sponsor will provide the IMT and will cover the costs of testing performed specifically for the study. If a research-related illness or injury occurs at any time during the study, you will receive medical care at

_____ Hospital under the supervision of the study Investigator. Any costs for the treatment of research related adverse events not covered by insurance will be paid for or reimbursed by the Sponsor. You will not be

compensated monetarily by the study Sponsor, the hospital or other institution, or the study Investigator for lost wages, disability, or discomfort resulting from this type of illness or injury. You should understand that treatment, payment, or enrollment in a health plan or eligibility for benefits is not contingent upon signing this form.

9. VOLUNTARY PARTICIPATION

You should understand that your participation in this study is completely voluntary and that you may withdraw from the study at any time without prejudice to your future medical care. Should you decide to withdraw from the study for any reason, you should contact the Investigator immediately. You may be discontinued from the study at any time if the Investigator considers it to be in your best medical interest. Should your participation in the study be terminated, regardless of the reason, you will not suffer any penalties or loss of benefits to which you are otherwise entitled.

You will be informed of any significant information regarding new findings that may develop during the course of the research study that may relate to your willingness to continue participating as a subject in the study.

10. CONTACT PERSON

If, at any time, you have questions regarding your participation in this study, you can call Dr. _____, your study Investigator, at: (____) _____.

11. CONSENT

I have been given an opportunity to ask any questions concerning the research, and my participation, and the study Investigator has answered my questions. By signing this consent form I understand that I have not waived any of my legal rights.

I understand that I will receive a copy of this consent and authorization form, which will show all signatures and dates.

I hereby willingly give my consent to participate in the above-described clinical study.

Patient Signature _____ Date: _____

Printed Name of Patient _____

Witness Signature _____ Date: _____

I have discussed this research study with the patient using language that is understandable and appropriate. I believe that I have fully informed this patient of the nature of this study, and its possible benefits and risks, and I believe the patient understood this explanation.

Investigator Signature _____ Date: _____

APPENDIX 2 STUDY EXAMINATIONS : SCHEDULE & METHODS

**APPENDIX 2
CONTENTS**

APPENDIX 2.1	EXAMINATION SCHEDULE & CLINICAL PARAMETERS.....	42
APPENDIX 2.2	REFRACTION AND BCVA TESTING PROTOCOL.....	44
APPENDIX 2.3	INTRAOCULAR PRESSURE MEASUREMENT	54
APPENDIX 2.4	SPECULAR MICROSCOPY.....	58
APPENDIX 2.5	VISION TRAINING.....	60
APPENDIX 2.6	ACTIVITIES OF DAILY LIFE	

APPENDIX 2.1

EXAMINATION SCHEDULE AND CLINICAL PARAMETERS

TABLE 8. SCHEDULE OF EXAMS AND CLINICAL PARAMETERS

EXAM / TEST	VISIT (SEE NOTE BELOW CONCERNING 18 & 24 MONTH FOLLOW-UP)						
	PRE- OPERATIVE	POSTOPERATIVE					
		1 and 7 days	1 month	3 month	6 month	9 month	12 month
DISTANCE BEST CORRECTED VISUAL ACUITY	✓	✓*	✓	✓	✓	✓	✓
NEAR BEST SPECTACLE CORRECTED VISUAL ACUITY	✓		✓	✓	✓	✓	✓
MANIFEST REFRACTION	✓	✓*	✓	✓	✓	✓	✓
IOP	✓	✓	✓	✓	✓	✓	✓
SLIT LAMP EXAM	✓	✓	✓	✓	✓	✓	✓
FLUORESCEIN ANGIOGRAPHY	✓						
DILATED FUNDUS EXAMINATION AND PHOTOGRAPHY	✓						
SPECULAR MICROSCOPY	✓			✓	✓	✓	✓
PACHYMETRY	✓			✓	✓	✓	✓
A-SCAN	✓						
ADL & VFQ-25 QUESTIONNAIRE	✓			✓	✓	✓	✓
VISION TRAINING		✓	2, 4, & 6 weeks	10 & 12 weeks			
ADVERSE EVENTS	✓	✓	✓	✓	✓	✓	✓

*Pinhole acuity will be measured on Day 1 as a safety assessment. Day 7 visual acuity testing should be by manifest refraction.

TABLE 8 NOTES

NOTE: All scheduled exams and clinical measurements noted for Month 12 are to be repeated at Month 18 and 24 except for the ADL & VFQ-25 Questionnaire.

The visit windows defined in Section 7.5 above allow for the possibility that two visits could be scheduled within one week of each other. This should NOT occur. Follow-up visits from 1 month through 24 months should not occur less than six weeks after the previous visit.

Twelve month data will be submitted as part of a Pre-Market Approval Application (PMA or PMAA) to the United States Food and Drug Administration (FDA) as the basis for market approval. Follow-up examinations at 18 and 24 months are intended to provide long term safety information following the filing of a PMA with FDA.

APPENDIX 2.2

REFRACTION AND BCVA TESTING PROTOCOL

INTRODUCTION & SCOPE

Each patient must successfully complete these visual acuity/refraction procedures in the preoperative evaluation prior to enrollment in the study. Patients must have a distance BCVA between 20/80 and 20/630, and adequate peripheral vision in one eye in order to be considered as candidates for implantation of the IMT. Any patient who is unable to complete these procedures should not be enrolled in the study, regardless of whether the patient meets all other inclusion/exclusion criteria.

Visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A set of two of these charts (Lighthouse Chart C-110 and C-105 respectively, which have different letter sequences or Precision Vision Chart R (Catalog #2110), Chart 1 (Catalog #2111) and Chart 2 (Catalog #2112) and a retro-illuminated box providing standardized chart illumination² will be used to determine visual acuity.

Distance visual acuity testing will be performed at a distance of 2 meters (or at 1 meter for patients who are unable to read 20 letters of the first four lines of the chart at 2 meters).

REFRACTION AND BCVA TESTING PROTOCOL

FACILITIES & MATERIALS

VISUAL ACUITY CHARTS

Charts 1 and 2 are used for testing visual acuity. Chart R is used for refraction. The ETDRS charts consist of 14 lines of 5 high-contrast Sloan letters of equal difficulty and geometric progression of letter size with results in an arithmetic progression of the logarithm of minimum angle of resolution from line to line. Charts 1, 2 and R have different letter sequences. Patients should be prevented from seeing Charts 1 and 2 until refraction has been completed and the visual acuity test begins.

VISUAL ACUITY BOX

The dimensions of the light box are 24-3/4 inches (62.9 cm) by 25-3/4 inches (65.4 cm) by 7 inches (17.8 cm). The light box should be mounted on the wall or on a cylindrical stand manufactured by the Lighthouse Low Vision Services (L-225). The stand is mounted on a five-pronged wheelbase, with each prong about 14 inches (35.6 cm) long. Two of the five wheels are lockable. When the box is mounted on the stand, its height can be varied. The light box should be mounted at a height such that the top of the third row of letters (0.8 log MAR) is 49 ± 2 inches (124.5 cm \pm 5 cm) from the floor.

² manufactured by Lighthouse Low Vision Products (L-220)

RETRO ILLUMINATED BOX

The room lights should be turned off during the visual acuity test. The box itself provides sufficient illumination for the examiner to record the results. Additional light can have an adverse effect. With the box light off, not more than 15 foot candles (161.4 candela/m²) of light should fall on the center of the chart. The luminance of the EDTRS VA chart in the plane of the entrance pupil of the eye to be tested should be within 10% of 160 candelas per square meter (cd/m² or nits). A photometer should be used for primary calibration. A secondary measuring device, a simple light meter, is calibrated to match the primary determination, and is then used for day-to-day calibration of the VA chart. This meter is placed against the surface of the transilluminated EDTRS chart at a predetermined and constant location. The calibration value is marked on the meter (e.g., an arrow, line, etc.) Luminous emittance of the light box containing the EDTRS chart is then adjusted to this predetermined level. (This secondary reference standard technique is similar to that used on the Goldmann Haag-Streit perimeter.)

The visual acuity light box is equipped with two 20-watt fluorescent tubes and ballast. The Sponsor recommends these lights be changed out for new bulbs at the start of the IMT-002 Study and at least yearly thereafter or in the event of a bulb failure. At the beginning of each examination, proper functioning of the two fluorescent tubes should be verified.

ROOM FOR VISION TESTING

The room for visual acuity testing must have space for a 2 meter (78.7 inches) lane, the visual acuity box, the stand, and the participant. The lane represents a distance of exactly 2 meters between the patient's eyes and the visual acuity chart. In addition to the 2 meter lane, 13 inches (33 cm) must be allowed for two of the stand's castors to touch the rear wall (or a line marked on the floor when there is no wall) plus space for the patient to sit.

Low level, ambient, indirect room illumination should be at a level of 10-12 cd/m² or less as measured with the photometer at the patient's eye. Not more than 15 foot-candles of light should fall on the center of the chart. No specular reflection from the chart surface directed towards the patient's eyes is permitted. This is determined with transillumination of the chart turned off and ambient light on.

MARKING THE 1 METER (39.7 INCHES) AND 2 METER (78.9 INCHES) DISTANCES

Floor marks cannot be used reliably to mark either the 1 or 2 meter distances. The horizontal distance between the patient's eye and the chart must be measured individually for each examination. The distance is best measured with one and two meter sticks or a measured non-elastic string from the eye of the patient, who is comfortably seated in a chair with his or her back firmly placed against the chair's back, to the center of the second letter (for left eye) or fourth letter (for right eye) of the third line of the chart.

PROCEDURES

All measurements should be obtained by a physician, optometrist or trained technician supervised directly by the physician or optometrist, before the patient's pupils have been dilated.

PUPIL DIAMETER

If required, the pupil diameter must be measured and recorded using a near vision card with a pupil calibration scale. The patient must view an object having the standard luminance condition (about 160 cd/m²). It is important that the patient be directed to focus on a distant object during the pupil diameter measurement procedure. The central large letter on the visual acuity test chart is acceptable. Tangential illumination may be introduced to provide sufficient light to compare the pupil of a patient with a dark iris with the calibration scale. The pupil diameter is measured and both uncorrected and best-corrected visual acuity are measured.

REFRACTION

The technique described in the following sections is required for all patients. The right eye is refracted first and then the left eye. Both eye's refraction applies for the preoperative and postoperative examinations.

DETERMINA- TION OF BEGINNING APPROXIMATE REFRACTION

A period of at least ten minutes must precede visual testing during which the eyes must not be exposed to light brighter than ordinary room illumination, except for retinoscopy.

If the patient wears contact lenses and also has glasses, he or she should be told not to wear the contact lenses on the day of the examination. If the patient appears for the examination wearing contact lenses, the contact lenses should be removed and refraction and visual acuity testing should not begin for at least 30 minutes.

At the pre-operative visit, in order to determine the lens corrections which will be used as the beginning approximate refractions for determining best-corrected visual acuity, the following steps should be taken:

1. If the patient's visual acuity is 20/200 or better with his/her present distance glasses, the glasses are measured with a lensometer and these measurements are used as the beginning approximate refraction.
2. If the patient's uncorrected visual acuity is less than 20/200 in either eye with his/her present distance glasses (or without correction, if the participant does not have glasses), a trial with lenses to bring visual acuity to 20/200 or better should be conducted.

3. If the patient's uncorrected visual acuity is 20/200 or better and he/she does not have glasses for distance vision, the beginning approximate refraction is no lens correction (plano).

Retinoscopy and the autorefractometer will not be able to determine the post-operative refraction of the implanted eye.

Refraction should be attempted at 1 meter. It will not be possible to perform a subjective refraction at 10 to 20 feet (3 to 6 meters) because this patient population's visual acuity is too poor. Add +1.00 and -1.00 spheres and change the spherical power by whole diopter increments of the appropriate sign until the participant perceives no improvement in vision. If the subjective refraction can be performed successfully at 1 meter, a +0.50 sphere should be subtracted from the 1 meter refraction to make the correction appropriate for the 2 meter distance. It is the latter correction that should be entered in the appropriate space for subjective refraction on the Visual Acuity Form.

At follow-up evaluations, the results of the subjective refraction from the previous visit may be used as the beginning approximate refractions.

**MEASUREMENT
OF SUBJECTIVE
REFRACTION**

The trial frame is placed and adjusted on the patient's face so that the lens cells are parallel to the anterior plane of the orbits and centered in front of the pupils. It is permissible to use a Phoropter for subjective refraction. The left eye (the IMT implanted eye after implantation) is occluded, and the beginning approximate refraction, as determined above, is placed in the right eye lens cell with the cylindrical correction anterior. If a phoropter or a distance other than 2 meters is used for subjective refraction, the lenses from this refraction must be placed in a trial frame and the final sphere must be rechecked at 2 meters according to the instructions described in *REFINING FINAL SPHERICAL POWER*, before visual acuity testing is performed.

**DETERMINATION
OF SPHERICAL
REFRACTION**

The visual acuity of the right eye is assessed and noted. A +0.50 sphere is then held in front of the right eye and the participant is asked if the vision is better, worse, or no different while he or she is looking at the smallest line read well. If the patient responds that it is not improved, he/she is asked if the vision is worse.

If vision is better or no different, the sphere in the trial frame is replaced with one that is one-half diopter more plus. The +0.50 sphere is held in front of the right eye again and the participant is again asked the same question.

This process of increasing the plus sphere in the trial frame is repeated until the patient says that the +0.50 sphere held in front of the trial frame makes the vision worse. When the patient responds that the vision is worse, the lens should be left in place for 10 to 15 seconds. If the vision clears during this period the +0.50 sphere may be added again. Whenever the patient says that the vision is worse and remains worse, the +0.50 sphere is removed from in front of the trial frame. By this process, the highest-plus or least-minus sphere that is tolerated without blurring the patient's vision is determined. After determining this highest plus or least-minus spheres, the patient is asked to read the smallest line possible.

Next, a -0.50 sphere is held in front of the trial frame and the patient is asked if the vision is better, worse, or no different. If vision is improved, the patient is requested to read the chart and if at least one more letter is read, the sphere in the trial frame is replaced by a sphere that is 0.25 diopter less plus. Minus spherical power is added in -0.25 diopter increments in the above fashion until the patient shows no further improvement in vision. If vision is not improved, the +0.50 sphere is tried again to see if the patient will accept more plus.

Record results on case report form and repeat testing for left eye.

**DETERMINATION
OF CYLINDRICAL
REFRACTION**

This procedure includes:

- Cylinder axis determination
- Cylinder power determination
- Correction for Astigmatism
- Refining Final Spherical Power

NOTE: If a phoropter or a distance other than 2 meters is used for subjective refraction, the lenses from this refraction must be placed in a trial frame and the final sphere must be rechecked at 2 meters according to the instructions described above (Refining Final Spherical Power).

CYLINDER AXIS DETERMINATION

If the beginning approximate refraction contains a cylinder correction, changes in cylindrical axis are tested by adding a 0.25, 0.37, or 0.50 diopter cross-cylinder, first with the positive axis 45 degrees to one side of the cylinder axis, and then with the positive axis 45 degrees to the opposite side of the cylinder axis. Since neither position may produce a clear image, the participant is encouraged to select the position producing "less blur" while fixing on a single round letter on the line above the lowest line on the chart he or she is able to read when the cross-cylinder is not held up before the trial frame.

If the participant cannot choose between the two positions of the cross-cylinder at the beginning of this test, the axis of the cylinder is

moved 5 to 15 degrees, first in one direction and then in the other, with the cross-cylinder being checked in each position to confirm that the original axis was indeed correct.

If the participant prefers one position of the cross-cylinder to the other and the cylinder in the trial frame is plus, the axis of the cylinder is moved 5 to 15 degrees toward the positive axis of the cross-cylinder when it is in the position found to be less blurry by the participant. (When the power of the cylinder is low or the participant's discrimination is poor, larger shifts will produce more clear-cut answers.) The cross-cylinder is tried again with the positive axis 45 degrees first to one side and then to the opposite side of the new cylinder axis to determine which position is producing less blur. If the participant finds one position less blurry, the axis of the plus cylinder is moved toward the positive axis of the cross-cylinder. Testing for change of axis is repeated until the participant finds neither position definitely better than the other.

CYLINDER POWER DETERMINATION

Change in cylinder power is tested by adding the cross-cylinder, first with the positive axis and then with the negative axis coincident with the cylinder axis. For this test, the participant is requested to focus attention on a round letter on the lowest line on the chart he or she is able to read. If the participant prefers the positive axis coincident with the cylinder axis, the power of the correcting plus cylinder is increased by an additional +0.25 diopter.

If the participant prefers the negative axis coincident with the cylinder axis, the total power of the correcting plus cylinder is reduced by 0.25 diopter. The process is repeated until the participant finds neither position definitely better than the other. As plus cylinder is added, the examiner should recognize that the spherical equivalent of the refraction is being changed. More minus spheres may be needed as plus cylinders are added. When using plus cylinders for every 0.50 diopter of cylinder power added, the sphere should be changed by -0.25 diopter. If, at any time, the preference with the cross-cylinder indicates that cylinder power should be removed entirely, the 0.25 cylinder should be rotated 90 degrees from its original position. The axis should be refined and the power should be tested again.

CORRECTION FOR ASTIGMATISM

If, the beginning refraction is a "pure" sphere, the presence of astigmatism is tested by arbitrarily placing a +0.25 cylinder at 180 degrees in the trial frame, after having determined the highest-plus or least-minus sphere producing minimal blurring of vision, as described above. The refraction is then continued by using the cross-cylinder to test for cylinder axis and then cylinder power using the cross-cylinder technique outlined above. If, at any time, the preference with the cross-cylinder indicates that cylinder power should be removed entirely, the 0.25 cylinder should be rotated 90 degrees from its

original position and the power should be tested again. At this point, if the participant prefers additional power, it should be added. If, on the other hand, the participant prefers to remove the +0.25, it should be removed and the final refraction is then purely spherical. An example of this procedure follows:

Beginning refraction: -2.50 + 0.25 axis 37 degrees. Use of the cross-cylinder to check cylinder axis indicates that the participant prefers the 37-degree axis. If, on using the cross-cylinder to check cylinder power, the participant wants the 0.25 cylinder removed, rotate the cylinder to 127 degrees and test for cylinder power again. If additional power is preferred, add it. If the preference with the cylinder at 127 degrees is to remove the 0.25 cylinder, this should be done and the resulting refraction is -2.50.

Minus cylinders may be used instead of plus cylinders to determine the best correction for the cylinder power and axis. If minus cylinders are used, the above procedure must be revised to reflect the change in sign.

REFINING FINAL SPHERICAL POWER

When neither the power nor the axis of the cylinder can be improved, the power of the sphere is refined by testing with +0.25 sphere and -0.37 sphere and changing the spherical power. If the sphere is changed at this point, the cylinder should be rechecked. This process is repeated until no further significant lens changes are made.

This refraction protocol can be summarized as follows. First, having eliminated any possible accommodation with plus spheres, the spherical equivalent power is placed on the retina. Then the cylinder power and cylinder axis are assessed. This process of checking sphere, cylinder axis, and cylinder power is repeated until there are no changes that result in an increased number of letters being read. Ideally, at the end of the refraction, the sphere is checked and the participant neither tolerates increased plus nor improves with increased minus spheres. Then the axis is checked and no change in axis is indicated. Finally, the cylindrical power is checked and no change in this is indicated. At this point, the refraction is completed. Sometimes this endpoint cannot be reached because there are an unending number of small corrections at each repetition of the process. When it becomes clear that these small changes are not resulting in an increased number of letters read correctly, the examiner can terminate the refraction.

The lens corrections obtained in this way for the right eye are recorded on the Visual Acuity Worksheet as the corrections obtained by subjective refraction for the right eye. The entire process is repeated for the left eye, and these lens corrections are also recorded on the Visual Acuity Worksheet as the corrections obtained by subjective refraction for the left eye.

TESTING BEST CORRECTED VISUAL ACUITY

TESTING DISTANCE

Visual acuity testing is performed at a distance of 2 meters for all patients, including those who could not be refracted at the two-meter distance. Visual acuity is tested at 1 meter only if the number of letters read correctly at 2 meters is less than 20.

The distance from the patient's eyes to the visual acuity chart must be exactly 2 meters. The patient must sit for the 2 meter visual acuity test. His or her back should be firmly touching the back of the chair. The examiner should ensure that the participant is sitting comfortably, that the head does not move forward or backward during the test, and that the participant's eyes remain at the 2 meter distance.

USING THE ETDRS CHART

First, the right eye is tested (non-implanted eye after surgery) and then the left eye (IMT implanted eye after surgery) is tested. All visual acuities will be evaluated with the subject's eyes in the straight-ahead, primary position of gaze. This will help to assure that visual acuity in the non-implanted eye is measured without the use of peripheral vision. The IMT implanted eye will have no peripheral vision, but for reasons of consistency should be conducted in the same manner.

TESTING PRINCIPLES

1. As previously mentioned, room lights should be turned off during visual acuity testing. The retro-illuminated box will provide sufficient light for the examiner to record results of the test.
2. The patient should be told that the chart has letters only and no numbers. If the patient forgets this instruction and reads a number, he or she should be reminded that the chart contains no numbers and the examiner should request a letter in lieu of the number. Examiners should point to the chart and to specific letters on the chart. Examiners should never read any of the letters during the test.
3. Because each letter will be scored, the patient should be asked to read slowly (at a rate not faster than about one letter per second) in order to achieve the best identification of each letter. The examiner should not proceed with the next letter or line of letters until the patient has given a definitive answer for each letter. It may be useful for the examiner to demonstrate the letter-a-second pace by reciting "A, B, C,...". If, at any point, the participant reads too quickly, he or she should be asked to stop and read slowly.
4. Each participant will be encouraged to read the letters on the chart as they become smaller and more difficult to read. Each time a

participant says he/she cannot read a letter, the examiner will encourage him/her to figure letters but not to randomly guess at them. If the participant identifies a letter as one of two or more letters, he/she should be asked to choose one only. The examiner should remind the participant to blink normally during all testing. All visual acuities are to be evaluated with the patient's eyes in the straight-ahead, primary position of gaze. The testing and recording of answers will continue until the patient states that he/she can no longer read or figure out the letters. The examiner may stop the test at this point provided that the patient has previously made some errors that indicate that the best possible acuity level has been reached. Patients are encouraged to make a best possible choice for several reasons: 1) statements that they cannot identify a letter are often unreliable, and 2) bias may be reduced when effort is maximized through guessing. Furthermore, inter-center variability of visual acuity measurement is minimized when uniform instructions for testing are employed.

5. Where a wrong answer is given, have the patient proceed with the next letter, but re-evaluate the "wrong" letter again after completing the line. If patient loses their place, he/she should be asked to go back to the top line, and start again, reading only the first or last letter in the line for those lines which were complete, once the missed line is reached, continue with standard examination. This procedure, called the First Letter Technique is used in all examinations with low vision charts, also during rehabilitation.

SCORING

The examiner records each letter identified correctly by circling the corresponding letters on the Visual Acuity Form. Letters read incorrectly and letters for which no guesses are made are not marked on the form. Each letter read correctly is scored as one point. The score for each line (which is zero if no letters are read correctly) and the total score for each eye is recorded on the Visual Acuity Form after testing is completed.

SCORING FOR 2 METER TESTING

If testing at 1 meter is not required, 15 points are automatically scored for the 1-meter test. The total combined score (i.e., the sum of the 2 meter and the 15 points awarded for the 1 meter test) is recorded on the Visual Acuity Form.

SCORING FOR 1 METER TESTING

Eyes reading less than 20 letters correctly at 2 meters should be tested at 1 meter. Both the 2 and 1 meter totals should be recorded on the Visual Acuity Form. If the trial frame is to be removed when changing the test distance from 2 meters to 1 meter, the testing chart should first be removed from view to prevent the participant from reading the chart with the fellow eye.

Before testing at 1 meter, a +0.50 sphere should be added to the 2-

meter correction already in the trial frame to compensate for the closer testing distance. The participant must sit for the 1-meter test. The avoidance of any head movement forward or backward is particularly important during the 1-meter test.

SCORING LIGHT PERCEPTION (LP) AND NO LIGHT PERCEPTION (NLP)

If visual acuity is so poor that the participant cannot read any of the largest letters at 1 meter (i.e., the number of letters read correctly at 1 meter is zero), light perception should be tested with an indirect ophthalmoscope in a darkened room. The indirect ophthalmoscope light should be in focus at 3 feet (91.5 cm) with the rheostat set at maximum voltage. From a distance of 3 feet (91.5 cm), the beam should be directed in and out of the eye at least four times, and the participant should be asked to respond when he or she sees the light. If the examiner is convinced that the participant perceives the light, vision should be recorded as light perception. Otherwise, vision should be recorded as hand movement or no light perception. **NOTE:** Patients with vision this poor at baseline are NOT qualified for participation in the IMT-002 Study.

NOTE: The above Refraction and BCVA Testing Protocol represents a modified version of one published by Lighthouse. The calibration requirements outlined involving a photometer are encouraged if the device is available, but is NOT required as part of the IMT-002 Study. The Sponsor does encourage the site to periodically confirm the luminance quality with the use of a standard light meter.

APPENDIX 2.3
INTRAOCULAR PRESSURE MEASUREMENT

Measuring Intraocular Pressure

Michael A. Kass, M.D.

Required at all Study Visits

Except Vision Training

Goldmann tonometry as the international gold standard for tonometry is quite accurate and reproducible if proper technique is used. Interobserver variability is in the range of 0 to 3 mm Hg, which is less than the diurnal variation of intraocular pressure. The technique of Goldmann tonometry is as follows:

1. The patient is told in advance not to drink alcoholic beverages for 12 hours or to smoke marijuana for at least 24 hours before tonometry. Food and liquid in usual quantities are permitted although large amounts of fluid (e.g., 500 ml or more) should be avoided for four hours before the test.
2. The patient is told the purpose of the test and is reassured that the measurement is not painful. The patient is instructed to relax, maintain his position, and hold his eyes open widely.
3. One drop of a topic anesthetic, such as 0.5% proparacaine or 0.4% benoxinate, is placed in each eye, and the tip of a moistened fluorescein strip is touched to the tear layer on the inner surface of each lower lid. Alternatively one drop of a combined anesthetic-fluorescein strip is touched to the tear layer on the inner surface of each lower lid. Alternatively one drop of a combined anesthetic-fluorescein solution can be instilled in each eye.
4. The tonometer and prism are set in correct position on the slit lamp.
5. The tension knob is set at 1 g. If the knob is set at 0, the prism head may vibrate when it touches the eye and damage the corneal epithelium. The 1 g position is used before each measurement. As a rule, it is more accurate to measure intraocular pressure by increasing rather than decreasing the force of applanation.
6. The 0 graduation mark of the prism is set at the white line on the prism holder. If the patient has more than 3 diopters of corneal astigmatism, the area of contact between the cornea and the prism is elliptic rather than circular. In this situation the prism should be rotated to 43 degrees from the long axis of the ellipse—that is, the prism graduation corresponding to the least curved meridian of the cornea should be set at the red mark on the prism holder. An alternative approach is to average the intraocular pressure readings obtained with the axis of the prism horizontal and then vertical.

REHABILITATION CHECKLIST

REHABILITATION BASICS

VISUAL SKILLS Localizing, Fixating, Scanning, Tracing and Tracking

- GRADUAL VISION PRACTICE**
- Recognizing large static objects.
 - Observing moving targets.
 - Walking while looking at stationary targets.
 - Walking while looking at moving targets.

REHABILITATION PROGRAM 1-2 Weeks Post-Op - Distance Vision – TV Watching

- Use Refraction Correction (+/- fellow-eye patching).
- Practice at 2-3 meters. Assure light dimming for contrast enhancement.
- Practice 3 times a day (5 minutes each, gradually increasing to 20 minutes).
- Ask patients to describe sight with operated eye (emphasize it is used).

2-3 Weeks Post-Op - Distance & Intermediate Vision

- Use updated refraction correction (+/- fellow-eye patching).
- Continue TV watching practice (3 times a day, 20 minutes each)
- Start outdoor practice in quiet familiar place (sunglasses/patching if needed).
- Assess the need for refraction correction.
- Create a personal list of basic intermediate activities according to patient's interests (e.g. playing cards, painting, arranging flowers and preparing meals).
- Start practicing intermediate activities (with high illumination). Identify difficult stages for each task, and practice until improvement is achieved.

3-4 Weeks Post-Op (and following sessions) – Distance, Intermediate and Near Vision

- Use updated refraction correction (+/- fellow-eye patching).
- Continue TV watching practice (3 times a day, 20 minutes each).
- Continue outdoors practice (in street or mall, with sunglasses or patching if needed).
- Continue practicing intermediate activities, emphasizing practice of difficult stages.
- Reading Program: Practice using adequate near correction (if needed, patch fellow eye)

7. The cobalt filter is used with the slit beam opened maximally. The angle between the illumination and the microscope should be approximately 60° . The room illumination is reduced.
8. The patient is seated in a comfortable position on an adjustable stool or examining chair facing the slit lamp. The heights of the slit lamp, chair and chin rest are adjusted until the patient is comfortable and in the correct position for the measurement. The patient's chin is supported by the chin rest and the forehead by the forehead bar. The forehead bar should be well above the patient's eyebrows so the frontalis muscle can be used to open the eyes widely. The patient's collar and tie should be loosened if necessary. The patient should breathe normally during the test to avoid Valsalva's maneuver.
9. The palpebral fissure is a little wider if the patient looks up. However, the gaze should be no more than 15° above the horizontal to prevent an elevation of intraocular pressure that is especially marked in the presence of restrictive neuromuscular disease. A fixation light may be placed in front of the fellow eye. The patient should blink his eyes once or twice to spread the fluorescein-stained tear film over the cornea and then should keep his eyes open widely. In some patients it is necessary for the examiner to hold the eyelids open with the thumb and forefinger of one hand. Care must be taken not to place any pressure on the globe because this raises intraocular pressure.
10. The operator sits opposite the patient in position to look through the microscope. The clinician moves the assembly toward the subject. When the black circle near the tip of the prism moves slightly, it indicates contact between the prism and the globe. Alternatively, the assembly is advanced toward the patient until the limbal zone has a bluish hue. The biprism should not touch the lids or lashes because this stimulates blinking and squeezing. Touching the lids also thickens the fluorescein rings, which may cause an overestimation of intraocular pressure.
11. The clinician observes the applanation through the biprism at low power. A monocular view is obtained of the central applanated zone and the surrounding fluorescein-stained tear film. Using the control stick, the observer raises and lowers and centers the assembly until two equal semicircles are seen in the center of the field of view. If the two semicircles are not equal in size, intraocular pressure is overestimated. The clinician turns the tension knob in both directions to assure himself or herself that the instrument is in good position. If the semicircles cannot be made "too small," the instrument is too far forward. If the semicircles cannot be made "too large," the instrument is too far from the eye.
12. The fluorescein rings should be approximately 0.25 to 0.3 mm in thickness that is one-tenth the diameter of the flattened area. If the rings are too narrow, the patient should blink two or three times to replenish the fluorescein; additional fluorescein may be added if necessary. If the fluorescein rings are too wide, the patient should blink two or three times to replenish the fluorescein; additional fluorescein may be added if necessary. If the fluorescein rings are too wide, the patient should dry his eyes lightly with a tissue, and the front surface of the prism should be dried with lint-free material. An excessively wide fluorescein ring is less of a problem than a very narrow ring but can cause the intraocular pressure to be overestimated.

13. The fluorescein rings normally undergo a rhythmic movement in response to the cardiac cycle. The tension knob is rotated until the inner borders of the fluorescein rings touch each other at the midpoint of their pulsations. The intraocular pressure is the mean of these 2 readings.
14. Intraocular pressure is measured in the right eye twice. If the 2 readings disagree by 1 mm Hg or less the average is the IOP. If the 2 readings disagree by 2 mm Hg or more, a third reading is taken. The IOP is the median of these readings. Intraocular pressure is then measured in the left eye.
15. The reading obtained in grams is multiplied by 10 to give the intraocular pressure in millimeters of mercury. This value is recorded along with the date, time of day, list of ocular medications, and time of last instillation of ocular medication if IOP is measured on different days, an attempt should be made to standardize the time \pm 1 hour.
16. It is possible to transfer bacteria, viruses, and other infectious agents with the tonometer head. This includes such potentially serious infections as epidemic keratoconjunctivitis, hepatitis B, acquired immunodeficiency syndrome, and Creutzfeld-Jacob disease. To prevent cross-contamination, the biprism should be rinsed and dried immediately after use. Between uses, the prism head should be cleaned with a solution such as chloramine-T diluted bleach, 3% hydrogen peroxide, 70% ethanol, or 70% isopropanol. An alternative approach is to cover the surface of the biprism with a plastic film.
17. The Goldmann tonometer should be calibrated at least once a month. The metal balance bar is attached to the main pivot above the force knob. With the testbar at its 0 position, the prism head should move when the knob is turned to 0 ± 0.1 g. When the bar is decentered to the 2-position, the prism should move when the knob is advanced to 2 ± 0.1 g. When the bar is decentered to the 6-position, the biprism should move when the knob is advanced to 6 ± 0.1 g. If the Goldmann tonometer is not within 0.1 g. of the correct calibration, the instrument must be repaired.

Although the Goldmann tonometer is reliable and accurate through a wide range of intraocular pressures, errors in measurement can arise from a number of factors, including the following:

1. Inadequate fluorescein staining of the tear film causes an underestimation of intraocular pressure.
2. Elevating the eyes more than 15° above the horizontal causes an overestimation of intraocular pressure. Widening the lid fissure excessively causes an overestimation of intraocular pressure.
3. Repeated tonometry reduces intraocular pressure, causing an underestimation of the true level. This effect is greatest between the first and second readings, but the trend continues through a number of repetitions.

4. A scarred, irregular cornea distorts the fluorescein rings and makes it difficult to estimate intraocular pressure.
5. The thickness of the cornea affects intraocular pressure readings. If the is thick because of edema, intraocular pressure is underestimated. If the cornea is thick because of additional tissue, intraocular pressure is overestimated. The Goldmann tonometer is accurate after epikeratophakia.
6. If the examiner presses on the globe or if the patient squeezes his eyelids, intraocular pressure is overestimated.
7. If corneal astigmatism is greater than 3 diopters, intraocular pressure is underestimated for with the rule astigmatism and overestimated for against the rule astigmatism. The intraocular pressure reading is inaccurate 1 mm Hg for every 3 diopters of astigmatism.

Appendix 2.4
SPECULAR MICROSCOPY

Required at Pre-operative and Months 3, 6, 9, 12, 18 & 24 post IMT implantation.

The main safety concern to be addressed by specular microscopy is the possibility of a chronic loss of endothelial cell density, which, even at a low yearly rate could, over time, lead to corneal edema and decompensation.

To determine endothelial cell density loss, specular microscopy will be performed preoperatively and at the Month 3, 6, 9, 12, 18 and 24 examinations. Losses due to surgical trauma may be determined by evaluating the cell counts at Month 3 (or Month 6) in comparison to the preoperative measurements. To determine losses over time, measurements from the Month 3 (or Month 6) and later time points will be analyzed.

Analyses of specular microscopy data will include the determination of the mean cell density loss over time and a frequency distribution. The mean rate of cell density loss will be calculated via a paired analysis in order to calculate the mean of the differences.

Collection of data

The methods used for the collection and analysis of specular microscopy data are critically important to minimizing the variability associated with these measurements. Common sources of variability in specular microscopy are:

- difficulty in returning to same location on the cornea at each visit;
- poor image quality (less than 100 countable cells);
- technician error; and
- improper reader analysis.

To address differences in location of the image within a given area of the cornea, three acceptable images should be taken at each visit. The mean density from the three images should be used.

Problems due to poor image quality and/or technician error will be avoided by using appropriate equipment and trained, experienced clinical sites equipped with non-contact specular microscopes. Images will be stored on 35 mm slides, half-inch video, or in electronic format such as CD's, floppy disks and/or zip drives. Sites may also produce high quality photographic images which can be electronically scanned and digitized.

Specular cameras that can record digitized images on disk are preferable for ease of data transfer.

Prior to the beginning of the study, each site will be required to take an initial set of images for an evaluation of image quality. Training (or retraining) will be performed as necessary and include the following important points:

An acceptable image has:

- distinct cells;
- at least 100 identifiable (countable) cells as a minimum, 150 cells preferred; and
- cells that can be grouped in a uniform area.

To capture a good image:

- make sure the patient is comfortable;
- instruct the patient to blink;
- instruct patient not to move and to open eyes wide;
- instruct patient to focus straight ahead or on the green light;
- be patient; and
- if necessary, use the manual setting. (Note that the use of the manual setting may require additional training.)

A central reading center will be retained for both obtaining specular micrographs of adequate quality, and for analyzing the specular images. The reading center or technician performing the image analysis will be advised of the following:

- A minimum of 100 cells (ideally 150 cells) in a contiguous area will be counted. The center method for counting cells is recommended.
- The quality of cells in an image is critical. Since the presence of disease can increase variability (e.g., polymegathism/pleomorphism post-contact lens wear, keratoconus), the area with the fewest distortions (not in shadow, washed-out, or blurred) should be used for the image analysis.

SPECULAR MICROSCOPY PROCEDURE A non-contact specular microscope will be used at each site. The mean density from three images of the same location of the cornea will be made.

ENDOTHELIAL IMAGE PHOTOGRAPHY

1. The location to be photographed is selected by clicking on the mark that indicates the location of the fixation target. An image will be taken of the central cornea.
2. Patients will be asked to place their chin on the left chin rest for photography of the right eye and on the right chin rest for photography of the left eye. Adjust the height of the chin rest so that an image of the patient's eye can be seen on the monitor screen with the pupil in the approximate center of the screen. The patient is asked to stare at the fixation target until an image is photographed.
3. An endothelial image is recorded by clicking on the appropriate indicator button on the instrument. The instrument aligns, focuses and takes the endothelial photograph automatically and the endothelial image will appear on the screen immediately.
4. All endothelial images will be recorded and sent to the specular microscopy reading center for image analysis.

APPENDIX 2.5

VISION TRAINING

REQUIRED AT VISITS Weeks 1, 2, 4, 6, 10 & 12

THE REHABILITATION CONCEPT

The goal for rehabilitation of low vision patients is to enhance independent living outcomes for individuals who have low vision. Traditional eye care treats the cause of the condition; low vision care addresses the consequences. Our goal is to provide the patient with the skills to adjust to the IMT and to its use in such a way that optimal function is achieved in minimal time.

In the traditional medical model of rehabilitation, the eye care professional is the source of action; the patient complies actively; and the patient's family provides mostly passive support. In this proposed rehabilitation model, the patient becomes the source of action (actively assisted by their families), while the eye care professional does the guiding. This is a significant shift in roles, one that needs to be thoroughly discussed at the pre-operative stage. It may also be necessary for the low vision professional to provide emotional support, due to the intensive nature of the pre- and post-op relationship.

The role of the family is critical since patients need the help of their relatives or friends for both emotional support and home training. Because patients often forget what they are told at the clinic, it is important to include the family in all explanations. It is the family member or friend who will verify that home training is performed, and assure that the correct environment is provided (such as lighting and contrast of objects), for optimal rehabilitation.

Initially, only distance correction should be prescribed. At six to eight weeks, the near correction should be added and clinical assessment of both near and distance should continue throughout the year.

REHABILITATION BASICS

FIVE FUNDAMENTAL SKILLS

There are five fundamental skills in vision:

LOCALIZING - locating an object of interest into the IMT's field of view. If difficult, the patient should first look at the object with both eyes, then obscure the fellow eye and try again with implanted eye.

FIXATING - performed by the operated eye. This means that the

operated eye fixates on the object, thus enabling object identification.

SCANNING – the natural eye movement performed by the operated eye.

TRACING – following a path between objects of interest. Perform initial training with a few lines of large size letters printed on a long piece of paper. Tell patients to follow the line from one letter to the next. Use the “thumb tracking technique” to locate the next line on the page.

TRACKING - the ability to follow a moving object. Patients first practice tracking on slow moving objects such as a walking person, and then progress to faster moving objects such as cars and buses. Tracing and tracking are expected to be almost natural with the IMT, as it uses natural eye movements.

GRADUAL VISION PRACTICE Gradual vision practice includes the following steps:

1. Have the seated patient try to recognize large static objects
2. While seated, observe moving targets such as a person walking
3. Walk while looking at stationary objects
4. Walk while looking at moving targets

Practice begins indoors, with training sequences proceeding from simple tasks to complex ones and from static to dynamic. For outdoors activities, start in a quiet, familiar environment with few moving objects. Assess light and glare requirements, if needed use sunglasses.

REHABILITATION PROGRAM

SCHEDULED REHABILITATION VISITS Rehabilitation is a very individual process, and it is best to meet with patients once every one or two weeks. Usually six to eight sessions will suffice. The basic schedule for the training is as follows:

1. Begin distance task practice one to two weeks after surgery.
2. Intermediate task training begins 2 to 3 weeks post-op.
3. Reading practice begins 3 to 4 weeks after surgery.

DISTANCE ACTIVITIES REHABILITATION Watching TV is a relatively easy task for IMT implanted patients. Start this training 1 to 2 weeks after surgery, from a distance of 2 to 3 meters. Practice daily, 3 times a day for 5-10 minutes each, increasing to 20 minutes. Use the prescribed glasses with or without

fellow-eye patching. Patients should describe what they see with the operated eye (i.e. details of figures). Encourage them to understand that they're using the operated eye. If the fellow-eye is patched, have them try to use both eyes once they feel comfortable.

Next, proceed to outdoor activities. Useful targets for outdoors distance training are building signs, cars or other large stationary objects. As vision improves, proceed to street signs, bus/house numbers and slow moving objects.

**INTERMEDIATE
DISTANCE
ACTIVITIES
REHABILITATION**

Intermediate distance activities vary between individuals, so create an activity list based on the patient's own interests. Remember the need for high illumination. Typical intermediate activities include playing cards or board games, painting pictures, arranging flowers or preparing meals. Identify the difficult stages of each task, and practice them repeatedly, until improvement is achieved.

Initially, select familiar activities. In advanced training it is valuable to engage in novel tasks. Novel tasks promote the development of the motor-eye coordination necessary for better skills.

**READING
REHABILITATION**

Reading is one of the most difficult tasks to do with low vision aids. It requires intense effort and concentration from the patient. More than for other tasks, high illumination is critical, and should always be directed over the shoulder to the text. If the patient prefers, reading can be done initially with fellow-eye patching. Encourage use of both eyes as patient progresses.

Start reading practice 3-4 weeks after surgery using adequate near correction. Reading at home is an essential part of rehabilitation. A family member should ensure high illumination and distance adjustment. Training should take place regularly, three times a day. Initially, sessions should be only 5 minutes long but should ultimately be increased to 20 minutes. Time increases should be individualized. A total of one hour of reading per day is sufficient for most patients.

**ADEQUATE
PRINT SIZE** Read letters sized 1-2 lines larger than near visual acuity threshold.

**TEXT
CALIBRATION** The standardized text used at the clinic should serve as the "personal calibration text" for home use. Patients start each session at home with this text. They should then try reading another text with the same print size. If this is difficult, they should refer back to the "personal calibration text". Knowing that this text was read clearly at the clinic, tells the patient if the home reading environment is correct. Potentially discouraging problems caused by low

illumination, inadequate distance or too small print can be significantly reduced through use of the "personal calibration text".

STABLE TEXT POSITIONING Text should be in a constant position. Rest it on a stable surface, rather than holding in the hands. The best way is to use a book-holder.

THUMB TRACKING TECHNIQUE This "trick" is critical for low vision patients. The most difficult task in reading is finding the beginning of the next line. Tell patients to place their thumb at the beginning of the first line, and keep it there while reading. When they reach the end of line, they can then look for their thumb. Since it's possible to find one's thumb even in total darkness, finding it becomes an easy thing to do. This simple trick can make a huge difference for most patients - both in reading rate and in confidence.

NATURAL EYE SCANNING Assure that patients read by moving their eyes along the line as in normal vision. Point out the difference between this mode of reading and the external telescope reading.

"ONE SIZE FITS ALL" PRINCIPLE An important design concept of the IMT is the "one size fits all" principle. Should a patient require larger magnification for reading due to disease progression, simply bring the text closer and add low diopter plus correction.

WRITING REHABILITATION Some patients may want to write. The principles of writing rehabilitation are:

1. Refraction: Use the same correction used for reading.
2. Documentation: All written material should be kept and dated for progress identification.
3. Reading: The patient should read the written material.

WRITING TECHNIQUES PAPER - Use non-ruled paper.

LETTERS - Use large letters. The patient may either PRINT or use *script* letters.

LINES & LOOPS - If letters are difficult, start by drawing lines and loops simulating handwriting.

TEXT - Start writing easy daily-life tasks: list 5-10 grocery items, write an address on an envelope, etc

(with dates).

READ TEXT - Have the patient read their written material. This will help them determine if the writing is sufficiently legible, and will demonstrate the impact of large letters on reading ability.

PROGRESS - Show the patient the progress made over the weeks. The patient should bring all the lists written to the follow-up and try reading the items. Since all items are dated, progress should be easily recognized.

FORMS & CHECKS - The use of structured forms (such as checks) can be taught if the patient shows interest. A blank check should be placed in front of the patient, who then fills it out. Encourage the patient to use large letters. In the USA, all banks carry large print checks for visually impaired customers (at no additional charge). Checks should be written for small amounts and voided once written. When writing a check the patient should first locate the place on the form to be filled in. This could be accomplished with the fellow eye for patients who can work with the fellow eye uncovered. Once the place on the check is located the pen's tip should be placed there and located using the operated eye. The patient should write the item (date, name or amount) while maintaining the pen's tip in the field of view. Large letters should be written, filling or even exceeding the space provided on the check.

**IMT BINOCULAR
FUNCTION**

Visual function with the IMT is based on the detail vision of the operated eye and the peripheral vision of the fellow eye. Ideally, patients will use the IMT with the fellow eye uncovered. However, if this presents a problem, initial training can proceed with the fellow eye patched or the spectacle lens taped. This promotes use of the IMT. With practice it is often possible to achieve use without the patch.

Remember that if patients report diplopia or anisocoria, it is a good sign that both eyes are being used. In most cases this state is transient, and simply requires temporarily patching, or taping the spectacle lens of one eye:

- Patch the fellow-eye in static vision.
- Patch the operated eye when in motion.

REHABILITATION CHECKLIST

REHABILITATION BASICS

VISUAL SKILLS Localizing, Fixating, Scanning, Tracing and Tracking

- GRADUAL VISION PRACTICE**
- Recognizing large static objects.
 - Observing moving targets.
 - Walking while looking at stationary targets.
 - Walking while looking at moving targets.

REHABILITATION PROGRAM 1-2 Weeks Post-Op - Distance Vision – TV Watching

- Use Refraction Correction (+/- fellow-eye patching).
- Practice at 2-3 meters. Assure light dimming for contrast enhancement.
- Practice 3 times a day (5 minutes each, gradually increasing to 20 minutes).
- Ask patients to describe sight with operated eye (emphasize it is used).

2-3 Weeks Post-Op - Distance & Intermediate Vision

- Use updated refraction correction (+/- fellow-eye patching).
- Continue TV watching practice (3 times a day, 20 minutes each)
- Start outdoor practice in quiet familiar place (sunglasses/patching if needed).
- Assess the need for refraction correction.
- Create a personal list of basic intermediate activities according to patient's interests (e.g. playing cards, painting, arranging flowers and preparing meals).
- Start practicing intermediate activities (with high illumination). Identify difficult stages for each task, and practice until improvement is achieved.

3-4 Weeks Post-Op (and following sessions) – Distance, Intermediate and Near Vision

- Use updated refraction correction (+/- fellow-eye patching).
- Continue TV watching practice (3 times a day, 20 minutes each).
- Continue outdoors practice (in street or mall, with sunglasses or patching if needed).
- Continue practicing intermediate activities, emphasizing practice of difficult stages.
- Reading Program: Practice using adequate near correction (if needed, patch fellow eye)

- Assure high illumination
- Use adequate print size
- Create a personal calibration text, which will serve for each home reading session
- Assure stable text positioning
- Teach patients to use thumb tracking technique.

Reading at home is an essential part of rehabilitation. A family member should monitor reading (high illumination, distance adjustment). Practice three times a day. At first only 5 minutes per session, gradually increasing to 20 minutes.

**BINOCULAR
REHABILITATION**

Repeat practice assessment and binocular preference every session.

Further reading in low-vision & rehabilitation

1. **Low Vision Rehabilitation-Caring for the whole person.** Fletcher DC (ed.) Ophthalmology Monograph (12), AAO, 1999.
2. **The Art and Practice of Low Vision, 2ed.** Freeman PB & Jose RT. Boston, Butterworth-Heinemann, 1997.
3. **Primary Low Vision Care.** Nowakowski RW. Norwalk, Appleton & Lange, 1994.

APPENDIX 3 SPONSOR'S COMMITMENTS

The Sponsor is committed to:

1. Complying with all applicable health authority regulations governing the conduct of clinical research studies, including the U.S. Food and Drug Administration.
2. Protecting the rights, health, safety and welfare of study subjects.
3. Informing the clinical investigators of any new information about the study which may affect the health, safety or welfare of the subjects, or may influence their decision to continue participation in the study.
4. Providing the clinical investigators with the study protocol, and a full set of Case Report Forms on which to document the study evaluation variables for each subject entered into the study.
5. Providing the statistical analysis and study report writing resources necessary to complete reporting of the study results.
6. Ensuring equity of consideration among all investigators in multicenter studies in all matters of publications, meeting presentations, etc.
7. Certifying that IRB approval of the protocol and Investigators Agreement will be completed prior to treatment at an investigational site.

APPENDIX 4 INVESTIGATOR'S QUALIFICATIONS AND RESPONSIBILITIES

Each Investigator must be a licensed physician who has completed a residency or preceptorship in ophthalmology. The Investigators have the following responsibilities:

1. Subject Selection

The Investigator is responsible for assuring that all subjects entering the study conform to the patient selection criteria.

2. Informed Consent

The Investigator is responsible for fully reviewing the nature of the study, the possible risks, and alternative treatments with prospective patients prior to their enrollment in the study. The Investigator is responsible for obtaining written Informed Consent in compliance with 21 CFR 50 for each patient, prior to enrollment in the trial. A copy of the signed Informed Consent Form will be maintained in the patient's medical record, and a copy of the signed Informed Consent Form will become an integral part of each Case Report file provided to the Sponsor.

3. Institutional Review Board (IRB) Approval

The Investigator must obtain approval for his participation in this protocol from the IRB for the institution at which the procedure will be performed, prior to entering any patients in the study. The Informed Consent document to be used will also be submitted by the Investigator to the IRB for approval prior to initiation of the study. Assurance that the IRB approval of the study protocol and Informed Consent has been obtained will be provided to the Sponsor prior to initiation of the study.

4. Subject Evaluations and Data Reporting

The Investigator is responsible for complying with the requirements of the study protocol, any amendment or clarifications as published by the study Sponsor (VisionCare) and performing the patient evaluations as described in the study protocol. All information generated by the patient evaluation will be recorded on the Subject Case Report Forms provided by the Sponsor. Case Report Forms will be filled out in black ink or will be typewritten. Any corrections will be made by single lining out and initialing. Correction fluid will not be used. The Investigator will sign and date each individual form upon its completion and will return the originals, not copies, to VisionCare Ophthalmic Technologies. Copies of all Case Report Forms will be retained in the Investigator's office in order to be available for monitoring by VisionCare Ophthalmic Technologies personnel or by authorized FDA personnel. Original laboratory reports will be retained by the Investigator, but as the results become available, they will be entered on appropriate Case Report Forms. Legible reproductions of the original laboratory reports will be included with the completed Case Report Form file.

Immediately upon completion of each patient examination the completed, signed and dated Subject Case Report Form shall be submitted to the Sponsor for review and statistical analysis.

Investigator(s) will not deviate from the study protocol without prior approval of VisionCare Ophthalmic Technologies unless protection of the health, safety or welfare of study subjects requires prompt action.

5. Record Retention

The Investigator shall maintain all patient records for whichever of the following periods is shortest:

- a. A period of two years after the date on which the FDA approves the marketing of the device for the purpose that was the subject of the study.
- b. A period of five years after the date on which the results of the study are submitted to the FDA in support of the marketing of the device for the purpose that was the subject of the study.

6. Investigational Material Accountability

The Investigator must maintain accurate records of the receipt of all investigational material shipped by VisionCare Ophthalmic Technologies, including the date, model and serial numbers of the product received. In addition, accurate records must be kept on the amount and date that investigational material, by serial number, was dispensed or returned to the Sponsor. The product label will be placed in the patient's chart and the number recorded on the Case Report Form. The Investigator must assure that study supplies be dispensed only to subjects enrolled in the study per the inclusion / exclusion criteria and under the direct supervision of the Investigator or his / her Co-Investigators.

Records of all investigational supplies received, used and returned must be kept by the Investigator. All unused investigational supplies will be returned to the Sponsor as soon as practical upon completion of the trial. Investigational material accounting procedures must be completed before the study is considered terminated.

PROTOCOL AMENDMENTS

AMENDMENT 002

AMENDMENT 003

AMENDMENT 004

PROTOCOL IMT-002
AMENDMENT 2

**A PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE
IMPLANTABLE MINIATURE TELESCOPE (IMT™) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE RELATED
MACULAR DEGENERATION OR STARGARDT'S MACULAR DYSTROPHY**

Protocol IMT-002 is hereby amended as follows:

1. The baseline examination must be performed within 90 days of IMT implantation (instead of 45 days), however best corrected distance acuity (BCVA) must be measured within 45 days of surgery.

**PROTOCOL IMT-002
AMENDMENT 03**

**A PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE
IMPLANTABLE MINIATURE TELESCOPE (IMT™) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE RELATED
MACULAR DEGENERATION OR STARGARDT'S MACULAR DYSTROPHY**

Protocol IMT-002 is hereby amended as follows:

1. The clinical protocol requires that the patient be given the opportunity to choose which type of visual restoration is preferred by wearing the different corresponding external telescopes (2.2X and 3.0X) for a proper period of acclimation before selecting the IMT that is likely to provide the preferred vision enhancement. This is being revised; patients will practice with the 2.2X corresponding external telescope at home only.

The reason for this change is that the corresponding 3.0X external telescope is not indicative of the postoperative results, since the external telescope field of view does not correspond directly to the field of view provided with an IMT.

The specific protocol modification is as follows:

5	If the patient achieves a 5-letter improvement in visual acuity with either or both of the external telescopes, he/she is a candidate for implantation, and should be given the 2.2 X external telescope to take home and use in practice sessions for at least three days. Patients should be instructed to attempt daily tasks and activities such as watching television (from 2-3 meters), making coffee, reading, washing hands, etc., while wearing the external telescope in order to provide the patient with a simulation of the visual acuity that may be achieved with the IMT.
---	--

1. 2. The process of subject entry as described in the study protocol has been clarified. In the original protocol, patients were considered enrolled after providing written informed consent. This is being revised under Amendment 03, such that a screening identification number will be assigned after

obtaining informed consent and prior to preoperative screening. When preoperative screening establishes that the patient is eligible, a subject identification number will be assigned and the patient will be considered enrolled in the trial.

The specific protocol modification is as follows:

When it is established that the patient may be eligible, written informed consent will be obtained. The patient will sign and date the consent form in the presence of a witness. The Investigator will also sign and date the consent form. One copy of the informed consent form will be retained with the patient records and a copy will be provided to the patient. A screening identification number will be assigned and preoperative screening will be performed. When preoperative screening establishes that the patient is eligible, a subject identification number will be assigned and the patient will be considered enrolled in the trial.

3. The clinical protocol currently specifies that an 8 mm – 10 mm incision be made at the 120^o-160^o meridians, as in standard cataract surgery. The size of the incision is being increased to 10 mm – 12 mm. This recommendation is being made based on the additional surgeon experience with IMT implantation, to better accommodate the IMT.

The specific protocol modification is as follows:

A 10 mm – 12 mm incision is made at the 120^o-160^o meridians, as in standard cataract surgery.

4. The protocol currently requires constriction of the pupil prior to ophthalmic viscosurgical device (OVD) removal. This is being revised; first, the viscoelastic material will be removed, followed by constriction of the pupil. This order of steps during the implantation procedure more closely reflects standard surgical practice since it is difficult to constrict the pupil with a high viscosity OVD around the IMT.

The specific protocol modification is as follows:

Limbal insertion and scleral tunnel implantation:

- Step 7: The ophthalmic viscosurgical device (OVD) agent is removed.
- Step 8: The pupil is constricted.

5. The protocol requires the Day 1 visit to occur 18 - 36 hours postoperatively and the Day 7 visit to occur 4 - 10 days following surgery. This is being revised; the Day 1 visit must occur 24 - 36 hours post-implantation and the Day 7 visit must occur 5 - 10

days post-implantation. These changes are being made to tighten the visit schedule requirements and reflect current postoperative follow-up schedules at the clinical sites.

The specific protocol modification is as follows:

Examination Schedule

- Day 1 (24 to 36 hours postoperative)
- Day 7 (5 to 10 days postoperative)

6. The protocol requires that data entries boxes or spaces should not be left blank, but instead should indicate: a "-" for missing or not available data. This is being revised to indicate "NAV" for missing or not available data. This change is being implemented to avoid ambiguity in the data review and management process.

The specific protocol modification is as follows:

Data entries boxes or spaces should not be left blank, but instead should indicate: NA = not applicable, ND=not done or NAV= missing or not available data.

**PROTOCOL IMT-002
AMENDMENT 04**

**A PROSPECTIVE, MULTICENTER CLINICAL TRIAL OF THE
IMPLANTABLE MINIATURE TELESCOPE (IMT™) IN PATIENTS WITH
CENTRAL VISION IMPAIRMENT ASSOCIATED WITH AGE RELATED
MACULAR DEGENERATION OR STARGARDT'S MACULAR DYSTROPHY**

Protocol IMT-002 is hereby amended as follows:

1. The visit window for the 24-month patient visit is expanded from 90-102 weeks to 84-102 weeks.

**THE NATIONAL EYE INSTITUTE 25 ITEM
VISUAL FUNCTION QUESTIONNAIRE (VFQ-25)
INTERVIEWER FORMAT**

**Required Preoperatively and at Months 3, 6, 9, & 12 post IMT
implantation.**

NOT Required after Month 12 post IMT implantation.

QUALITY OF LIFE QUESTIONNAIRE:

**THE NATIONAL EYE INSTITUTE 25 ITEM
VISUAL FUNCTION QUESTIONNAIRE (VFQ)
INTERVIEWER FORMAT**

The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25)

Version 2000

This final version of the VFQ-25 differs from the previous version in that it includes an extra driving item from the appendix of supplementary questions as part of the base set of items. Also, the revised scoring algorithm excludes the single-item general health rating question from the calculation of the vision-targeted composite score. Because of these 2 changes, the base set of items actually includes 26 questions; however, only 25 are vision-targeted and included in the composite score. Please see the "Frequently Asked Questions" (FAQ) section for additional clarifications of these changes.

Background

The National Eye Institute (NEI) sponsored the development of the VFQ-25 with the goal of creating a survey that would measure the dimensions of self-reported vision-targeted health status that are most important for persons who have chronic eye diseases. Because of this goal, the survey measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. Questions included in the VFQ-25 represent the content identified during a series of condition-specific focus groups with patients who had age-related cataracts, glaucoma, age-related macular degeneration, diabetic retinopathy, or CMV retinitis.¹

The VFQ-25 is the product of an item-reduction analysis of the longer field test version of the survey called the 51-item National Eye Institute Vision Function Questionnaire (NEI-VFQ).² The longer version contains 51 questions which represent 13 different sub-scales. The NEI-VFQ Field Test Study collected the data needed to examine the reliability and validity of the survey across all of the above-mentioned ocular diseases. Also, reliability and validity was assessed in a heterogeneous group of patients with low vision from any cause and a group of age-matched persons with normal vision. A published report describes the psychometric properties of the longer field test version of the survey.³ Additionally a number of clinical studies have used either the 51 or the 25-item version of the NEI-VFQ across a number of chronic ocular conditions.⁴⁻⁸ Despite the success of the longer field test version and its continued use, to enhance feasibility a short-form version was planned since the earliest developmental phase.

The VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. The VFQ-25 also includes an appendix of additional items from the 51-item version that researchers can use to expand the scales up to 39 total items. All items in the VFQ-25 are from the 51-item field test version; no new items were developed for use in the VFQ-25. Unless otherwise specified, the remainder of this document will use the term VFQ-25 to refer to the base set of items.

The VFQ-25 takes approximately 10 minutes on average to administer in the interviewer format. There is also a self-administered version of the survey; however, psychometric testing of the self-administered version has not been done. The VFQ-25 generates the following vision-targeted sub-scales: global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Additionally, the VFQ-25 contains the single general health rating question which has been shown to be a robust predictor of future health and mortality in population-based studies. Please see the FAQ section for more information about the general health rating question.

Development of the NEI VFQ-25

The guiding principles for the selection of the short-form items included: 1) low item-level missing data rates; 2) normal distribution of response choices; and 3) retention of items that explained the greatest proportion of variance in the 51-item sub-scales. The items retained in the VFQ-25 and the optional items (provided in the appendix to the survey) are listed on Table 1. A report describing the performance of the VFQ-25 relative to the Field Test version is currently under review.² The reliability and validity of the VFQ-25 is similar to that observed for the 51-item version of the survey. On average, each VFQ-25 sub-scale predicts 92% of the variance in the corresponding 51-item sub-scale score.

Optional Items

Appendix 1 consists of additional questions that users may add to a specific sub-scale. Inclusion of these may be helpful if a particular sub-scale represents the primary domain of vision-targeted HRQOL that is felt to be most important for the condition under study. For example, if a user is testing a new treatment for macular degeneration, by adding near vision questions A3, A4, and A5 to VFQ-25 questions 5, 6, and 7, the investigator would have a six-item near vision scale rather than a three-item scale. The addition of these items would enhance the reliability of the near vision sub-scale and is likely to improve the responsiveness of the sub-scale to the intervention over time (Table 6). If items from the appendix are used, the VFQ-25 developers would encourage users to incorporate all optional items for a given sub-scale. This strategy will enhance the comparability of results across studies.

Scoring

Scoring VFQ-25 with or without optional items is a two-step process:

- First, original numeric values from the survey are re-coded following the scoring rules outlined in Table 2. All items are scored so that a high score represents better functioning. Each item is then

converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.

- In step 2, items within each sub-scale are averaged together to create the 12 sub-scale scores. Table 3 indicates which items contribute to each specific sub-scale. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the sub-scale that the respondent answered.

Composite Score Calculation

To calculate an overall composite score for the VFQ-25, simply average the vision-targeted sub-scale scores, excluding the general health rating question. By averaging the sub-scale scores rather than the individual items we have given equal weight to each sub-scale, whereas averaging the items would give more weight to scales with more items.

Table 1. Item Number Translation from the 51-Item Field Test Version to the VFQ 25

S = retained in the VFQ-25, A = retained in the appendix should be used for the VFQ-39,

--- = deleted from the VFQ-25 & VFQ-39

Field Test Version Ques.#	Sub-scale	Status	VFQ-25 Ques. #	Field Test Version Ques.#	Sub-scale	Status	VFQ-25 Ques. #
1	general health	S	1	29	social fx	---	---
2	general health	A	A1	30	social fx	A	A9
3	general vision	S	2	31	social fx	S	13
4	expectations	---	---	32	distance vision	A	A8
5	well-being/ distress	S	3	33	distance vision	A	A7
6	well-being/ distress	---	---	34	distance vision	S	14
7	ocular pain	S	19	35	driving (filter item)	S	15
8	expectations	---	---	35a	driving (filter item)	S	15a
9	expectations	---	---	35b	driving (filter item)	S	15b
10	expectations	---	---	35c	driving	S	15c
11	well-being/ distress	S	25	36	driving	---	---
12	ocular pain	S	4	37	driving	S	16
13	well-being/ distress	---	---	38	driving	S	16a *
14	general vision	A	A2	39a	role limitations	S	17
15	near vision	S	5	39b	role limitations	A	A11a
16	near vision	A	A3	39c	well-being/ distress	---	---
17	near vision	S	6	39d	role limitations	---	---

18	near vision	---	---	39e	role limitations	A	A11b
19	near vision	S	7	39f	role limitations	S	18
20	distance vision	S	8	40	well-being/ distress	A	A12
21	distance vision	---	---	41	dependency	S	20
22	distance vision	S	9	42	well-being/ distress	S	21
23	peripheral vision	S	10	43	well-being/ distress	S	22
24	distance vision	A	A6	44	dependency	---	---
25	social fx	S	11	45	dependency	A	A13
26	near vision	A	A4	46	dependency	S	23
27	color vision	S	12	47	dependency	S	24
28	near vision	A	A5				

* VFQ-25 item 16a was listed in previous versions as part of the appendix of supplemental items (#A10).

Table 2. Scoring Key: Recoding of Items

Item Numbers	Change original response category (a)	To recoded value of:
1,3,4,15c ^(b)	1	100
	2	75
	3	50
	4	25
	5	0
2	1	100
	2	80
	3	60
	4	40
	5	20
	6	0
5,6,7,8,9,10,11,12,13,14,16,16a A3,A4,A5,A6,A7,A8,A9 ^(c)	1	100
	2	75
	3	50
	4	25
	5	0
	6	*
17,18,19,20,21,22,23,24,25, A11a,A11b,A12,A13	1	0
	2	25
	3	50
	4	75
	5	100
A1,A2	0	0
	to	to
	10	100

(a) Pre-coded response choices as printed in the questionnaire.

(b) Item 15c has four-response levels, but is expanded to a five-levels using item 15b.

Note: If 15b=1, then 15c should be recoded to "0"

If 15b=2, then 15c should be recoded to missing.

If 15b=3, then 15c should be recoded to missing.

(c) "A" before the item number indicates that this item is an optional item from the Appendix. If optional items are used, the NEI-VFQ developers encourage users to use all items for a given sub-scale. This will greatly enhance the comparability of sub-scale scores across studies.

* Response choice "6" indicates that the person does not perform the activity because of non-vision related problems. If this choice is selected, the item is coded as "missing."

Table 3. Step 2: Averaging of Items to Generate VFQ-25 Sub-Scales

Scale	Number of items	Items to be averaged (after recoding per Table 2)
General Health	1	1
General Vision	1	2
Ocular Pain	2	4, 19
Near Activities	3	5, 6, 7
Distance Activities	3	8, 9, 14
Vision Specific:		
Social Functioning	2	11, 13
Mental Health	4	3, 21, 22, 25
Role Difficulties	2	17, 18
Dependency	3	20, 23, 24
Driving	3	15c, 16, 16a
Color Vision	1	12
Peripheral Vision	1	10

Table 4. Step 2: Averaging of Items to Generate VFQ-39 Sub-Scales (VFQ-25 + Optional Items)

Scale	Number of items	Items to be averaged (after recoding per Table 2)
General Health	2	1, A1
General Vision	2	2, A2
Ocular Pain	2	4, 19
Near Activities	6	5, 6, 7, A3, A4, A5
Distance Activities	6	8, 9, 14, A6, A7, A8
Vision Specific:		
Social Functioning	3	11, 13, A9
Mental Health	5	3, 21, 22, 25, A12
Role Difficulties	4	17, 18, A11a, A11b
Dependency	4	20, 23, 24, A13
Driving	3	15c, 16, 16a
Color Vision	1	12
Peripheral Vision	1	10

Figure 1. Example of VFQ-25 Scoring Algorithm for Near Activities Sub-Scale

5. How much difficulty do you have reading ordinary print in newspapers? Would you say you have:

- No difficulty at all.....1
- A little difficulty2
- Moderate difficulty3
- Extreme difficulty(4)
- Stopped doing this because of your eyesight5
- Stopped doing this for other reasons or not interested in doing this.....6

6. How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing . . . ? Would you say you have:

- No difficulty at all.....(1)
- A little difficulty2
- Moderate difficulty3
- Extreme difficulty4
- Stopped doing this because of your eyesight5
- Stopped doing this for other reasons or not interested in doing this.....6

7. Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? Would you say you have:

- No difficulty at all.....1
 - A little difficulty2
 - Moderate difficulty3
 - Extreme difficulty(4)
 - Stopped doing this because of your eyesight5
 - Stopped doing this for other reasons or not interested in doing this.....6
-

Scoring example. Figure 1.

Items 5, 6, and 7 are used to generate the near activities sub-scale score (Table 3). Each of the items has 6 response choices. Response choice 6 indicates that the respondent does not perform the activity because of reasons that are unrelated to vision. If a respondent selects this choice, the answer is treated as missing and an average of the remaining items is calculated. Response choice 5 indicates that an activity is so difficult that the participant no longer performs the activity. This extremely poor near vision response choice is recoded to "0" points before taking an average of all three items. To score all items in the same direction, Table 2 shows that responses 1 through 5 for items 5, 6, and 7 should be recoded to values of 100, 75, 50, 25, and 0 respectively. If the respondent is missing one of the items, the person's score will be equal to the average of the two non-missing items.

Formula:

$$\text{Mean} = \frac{\text{(Score for each item with a non-missing answer)}}{\text{Total number of items with non-missing answers}}$$

Example:

$$\text{With responses converted: } = \frac{(25 + 100 + 25)}{3} = 50$$

Note: 100 = Best, 0 = Worst possible score.

Psychometric properties of VFQ-25 sub-scales

Psychometric data for VFQ-25 reported in the earlier pre-publication version of the scoring manual have been updated and submitted for peer-reviewed publication.² The values reported in this document are identical to those reported in the future publication and should be used when citing the performance characteristics of the VFQ-25.

Statistical Power Calculations

Tables 8, 9, and 10 are provided to estimate statistical power when using the VFQ-25 and VFQ-39. These tables estimate the number of subjects needed per group to attain 80% power ($\alpha = 0.05$, two-tailed) depending on the anticipated difference in scores between groups. Table 8 contains power calculations for changes over time between two experimental (i.e. randomized) groups using a repeated-measures design. For example, if one were interested in being able to detect a 5-point difference for the VFQ-25 General Vision sub-scale, one would need 271 subjects per group. Table 9 shows power calculations for two experimental groups using a single, post-intervention measurement design. Such a design is not as precise as a design that uses a baseline and post-intervention measurement points (i.e., more subjects are needed per group to detect the same difference). Table 10 provides corresponding sample size information for a non-experimental (i.e. non-randomized) repeated-measures design where subjects self-select into the two groups. One sees that the number of subjects needed per group is more than that needed for a randomized experiment (Table 8) and less than the number needed for a randomized, post-intervention-only measurement design (Table 9).

Table 8. Sample sizes needed per group to detect differences in *change over time* between two experimental groups for the VFQ-25, repeated measures design

Scale Name	SD	Number of Points Difference				
		2	5	10	20	
VFQ-25:						
General Health		26.00	1696	271	68	17
General Vision	21.00	1106	177	44	11	
Ocular Pain	17.00	725	116	29	7	
Near Activities		29.00	2110	338	84	21
Distance Activities	29.00	2110	338	84	21	
Social Functioning	27.00	1829	293	73	18	
Mental Health	27.00	1829	293	73	18	
Role Difficulties	29.00	2110	338	84	21	
Dependency	28.00	1967	315	79	20	
Driving		35.00	3073	492	123	31
Color Vision	23.00	1327	212	53	13	
Peripheral Vision	27.00	1829	293	73	18	
VFQ-25 Composite	20.00	1004	161	40	10	
VFQ-39:						
General Health		21.00	1106	177	44	11
General Vision	19.00	906	145	36	9	
Ocular Pain	17.00	725	116	29	7	
Near Activities		28.00	1967	315	79	20
Distance Activities	26.00	1696	271	68	17	
Social Functioning	25.00	1568	251	63	16	
Mental Health	26.00	1696	271	68	17	
Role Difficulties	28.00	1967	315	79	20	
Dependency	27.00	1829	293	73	18	
Driving		35.00	3073	492	123	31
Color Vision	23.00	1327	212	53	13	
Peripheral Vision	27.00	1829	293	73	18	
VFQ-39 Composite	21.00	1106	177	44	11	

Note: Scales are all scored on 0-100 possible range. Estimates assume alpha = 0.05, two-tailed t-test, power = 80%, and an inter-temporal correlation between scores of 0.60.

Table 9. Sample sizes needed per group to detect differences between two experimental groups for the VFQ-25, *post-intervention measures only*.

Scale Name	SD	Number of Points Difference				
		2	5	10	20	
VFQ-25:						
General Health		26.00	2650	424	106	26
General Vision	21.00	1729	277	69	17	
Ocular Pain	17.00	1133	181	45	11	
Near Activities		29.00	3297	527	132	33
Distance Activities	29.00	3297	527	132	33	
Social Functioning	27.00	2858	457	114	29	
Mental Health	27.00	2858	457	114	29	
Role Difficulties	29.00	3297	527	132	33	
Dependency	28.00	3073	492	123	31	
Driving		35.00	4802	768	192	48
Color Vision	23.00	2074	332	83	21	
Peripheral Vision	27.00	2858	457	114	29	
VFQ-25 Composite	20.00	1568	251	63	16	
VFQ-39:						
General Health		21.00	1729	277	69	17
General Vision	19.00	1415	226	57	14	
Ocular Pain	17.00	1133	181	45	11	
Near Activities		28.00	3073	492	123	31
Distance Activities	26.00	2650	424	106	26	
Social Functioning	25.00	2450	392	98	25	
Mental Health	26.00	2650	424	106	26	
Role Difficulties	28.00	3073	492	123	31	
Dependency	27.00	2858	457	114	29	
Driving		35.00	4802	768	192	48
Color Vision	23.00	2074	332	83	21	
Peripheral Vision	27.00	2858	457	114	29	
VFQ-39 Composite	21.00	1729	277	69	17	

Note: Scales are all scored on 0-100 possible range. Estimates assume alpha = 0.05, two-tailed t-test, and power = 80%.

Table 10. Sample sizes needed per group to detect differences between two *self-selected groups* for the VFQ-25, repeated measures design

Scale Name	SD	Number of Points Difference					
		2	5	10	20		
VFQ-25:							
General Health		26.00	2120	339	85	21	
General Vision	21.00	1383	221	55	14		
Ocular Pain	17.00	906	145	36	9		
Near Activities		29.00	2637	422	105	26	
Distance Activities	29.00	2637	422	105	26		
Social Functioning	27.00	2286	366	91	23		
Mental Health	27.00	2286	366	91	23		
Role Difficulties	29.00	2637	422	105	26		
Dependency	28.00	2459	393	98	25		
Driving		35.00	3842	615	154	38	
Color Vision	23.00	1659	265	66	17		
Peripheral Vision	27.00	2286	366	91	23		
VFQ-25 Composite	20.00	1254	201	50	13		
VFQ-39:							
General Health		21.00	1383	221	55	14	
General Vision	19.00	1132	181	45	11		
Ocular Pain	17.00	906	145	36	9		
Near Activities		28.00	2459	393	98	25	
Distance Activities	26.00	2120	339	85	21		
Social Functioning	25.00	1960	314	78	20		
Mental Health	26.00	2120	339	85	21		
Role Difficulties	28.00	2459	393	98	25		
Dependency	27.00	2286	366	91	23		
Driving		35.00	3842	615	154	38	
Color Vision	23.00	1659	265	66	17		
Peripheral	27.00	2286	366	91	23		
VFQ-39 Composite	21.00	1383	221	55	14		

Note: Scales are all scored on 0-100 possible range. Estimates assume alpha = 0.05, two-tailed t-test, power = 80%, and an inter-temporal correlation between scores of 0.60.

References

1. Mangione CM, Berry S, Lee PP, et al. Identifying the content area for the National Eye Institute Vision Function Questionnaire (NEI-VFQ): Results from focus groups with visually impaired persons. *Arch Ophthalmol.* 1998;116:227-238.
2. Mangione CM, Lee PP, Gutierrez PR, Spritzer, K., Berry, S., & Hays, R.D. (in press). Development reliability, and validity of the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). *Arch of Ophthalmol.*
3. Mangione CM, Lee PP, Pitts J, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire, the NEI-VFQ. *Arch Ophthalmol.* 1998;116:1496-1504.
4. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R; Sherwood M, Meng K, Mangione CM. Influence of glaucomatous visual field loss on health-related quality of life. *Arch Ophthalmol.* 1997;115:777-84.
5. Parrish RK 2nd, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC, Mangione CM, Montenegro-Piniella A. Visual function and quality of life among patients with glaucoma. *Arch Ophthalmol.* 1997;115:1447-55.
6. Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. COMS Quality of Life Study Group. *Ophthalm. Epidemiology.* 1999;6:5-17.
7. Scott IU, Smiddy WE, Schiffman J, Feuer WJ, Pappas CJ. Quality of life of low-vision patients and the impact of low-vision services. *Amer. J. Ophthalmol.* 1999;128:54-62.
8. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. *Invest Ophthalmol Vis Sci* 2000;41:1017-21.
9. Mangione CM, Lee PP, Hays RD. Measurement of visual functioning and health-related quality of life in eye disease and cataract surgery. In B. Spilker (ed.), *Quality of Life and Pharmacoeconomics in clinical trials*, 2nd edition. New York: Raven Press 1996:1045-1051.

10. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item Health Survey 1.0. *Health Econ* 1993;2:217-227.

11. Ware J Jr, Kosinski M, Keller SD. 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220-33A.

PB/IA

National Eye Institute
Visual Functioning Questionnaire - 25
(VFQ-25)

version 2000

(INTERVIEWER ADMINISTERED FORMAT)

January 2000

RAND hereby grants permission to use the "National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25) July 1996, in accordance with the following conditions which shall be assumed by all to have been agreed to as a consequence of accepting and using this document:

1. Changes to the NEI VFQ-25 - July 1996 may be made without the written permission of RAND. However, all such changes shall be clearly identified as having been made by the recipient.
2. The user of this NEI VFQ-25 - July 1996 accepts full responsibility, and agrees to hold RAND harmless, for the accuracy of any translations of the NEI VFQ-25 Test Version - July 1996 into another language and for any errors, omissions, misinterpretations, or consequences thereof.
3. The user of this NEI VFQ-25 - July 1996 accepts full responsibility, and agrees to hold RAND harmless, for any consequences resulting from the use of the NEI VFQ-25.
4. The user of the NEI VFQ-25 - July 1996 will provide a credit line when printing and distributing this document or in publications of results or analyses based on this instrument acknowledging that it was developed at RAND under the sponsorship of the National Eye Institute.
5. No further written permission is needed for use of this NEI VFQ-25 - July 1996.

7/29/96

© R 1996

Instructions:

I'm going to read you some statements about problems which involve your vision or feelings that you have about your vision condition. After each question I will read you a list of possible answers. Please choose the response that best describes your situation.

Please answer all the questions as if you were wearing your glasses or contact lenses (if any).

Please take as much time as you need to answer each question. All your answers are confidential. In order for this survey to improve our knowledge about vision problems and how they affect your quality of life, your answers must be as accurate as possible. Remember, if you wear glasses or contact lenses for a particular activity, please answer all of the following questions as though you were wearing them.

Visual Functioning Questionnaire - 25

PART 1 - GENERAL HEALTH AND VISION

1. In general, would you say your overall health is*:

(Circle One)

READ CATEGORIES:

- Excellent 1
- Very Good 2
- Good..... 3
- Fair..... 4
- Poor 5

2. At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?

(Circle One)

READ CATEGORIES:

- Excellent 1
- Good..... 2
- Fair..... 3
- Poor 4
- Very Poor 5
- Completely Blind 6

* Skip Question 1 when the VFQ-25 is administered at the same time as the SF-36 or RAND 36-Item Health Survey 1.0

3. How much of the time do you worry about your eyesight?

(Circle One)

- READ CATEGORIES:
- None of the time..... 1
 - A little of the time..... 2
 - Some of the time 3
 - Most of the time 4
 - All of the time?..... 5

4. How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? Would you say it is:

(Circle One)

- READ CATEGORIES:
- None 1
 - Mild..... 2
 - Moderate 3
 - Severe, or..... 4
 - Very severe?..... 5

PART 2 - DIFFICULTY WITH ACTIVITIES

The next questions are about how much difficulty, if any, you have doing certain activities wearing your glasses or contact lenses if you use them for that activity.

5. How much difficulty do you have reading ordinary print in newspapers? Would you say you have:
(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

6. How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around the house, or using hand tools? Would you say:
 (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

7. Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?
 (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

8. How much difficulty do you have reading street signs or the names of stores?
 (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

10. Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

11. Because of your eyesight, how much difficulty do you have seeing how people react to things you say?

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

12. Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?
 (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

13. Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants ?
 (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

14. Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?
 (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

15. Now, I'd like to ask about driving a car. Are you currently driving, at least once in a while?

(Circle One)

Yes 1 Skip To Q 15c

No 2

15a. IF NO, ASK: Have you never driven a car or have you given up driving?

(Circle One)

Never drove 1 Skip To Part 3, Q 17

Gave up..... 2

15b. IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason, or because of both your eyesight and other reasons?

(Circle One)

Mainly eyesight 1 Skip To Part 3, Q 17

Mainly other reasons 2 Skip To Part 3, Q 17

Both eyesight and other reasons ... 3 Skip To Part 3, Q 17

15c. IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in familiar places? Would you say you have:

(Circle One)

No difficulty at all 1

A little difficulty 2

Moderate difficulty 3

Extreme difficulty 4

16. How much difficulty do you have driving at night? Would you say you have: (READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Have you stopped doing this because of your eyesight..... 5
- Have you stopped doing this for other reasons or are you not interested in doing this 6

16a. How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic?

Would you say you have:
(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Have you stopped doing this because of your eyesight..... 5
- Have you stopped doing this for other reasons or are you not interested in doing this 6

PART 3: RESPONSES TO VISION PROBLEMS

The next questions are about how things you do may be affected by your vision. For each one, I'd like you to tell me if this is true for you all, most, some, a little, or none of the time.

(Circle One On Each Line)

READ CATEGORIES:	All of the time	Most of the time	Some of the time	A little of the time	None of the time
17. <u>Do you accomplish less than you would like because of your vision?</u>	1	2	3	4	5
18. <u>Are you limited in how long you can work or do other activities because of your vision?</u>	1	2	3	4	5
19. <u>How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing? Would you say:</u>	1	2	3	4	5

For each of the following statements, please tell me if it is definitely true, mostly true, mostly false, or definitely false for you or you are not sure.

(Circle One On Each Line)

	Definitely True	Mostly True	Not Sure	Mostly False	Definitely False
20. I <u>stay home most of the time</u> because of my eyesight.....	1	2	3	4	5
21. I feel <u>frustrated</u> a lot of the time because of my eyesight.....	1	2	3	4	5
22. I have <u>much less control</u> over what I do, because of my eyesight.	1	2	3	4	5
23. Because of my eyesight, I have to <u>rely too much on</u> <u>what other people tell me..</u>	1	2	3	4	5
24. I <u>need a lot of help</u> from others because of my eyesight.....	1	2	3	4	5
25. I worry about <u>doing things</u> <u>that will embarrass myself</u> <u>or others</u> , because of my eyesight.....	1	2	3	4	5

That's the end of the interview. Thank you very much for your time and your help.

Appendix of Optional Additional Questions

SUBSCALE: GENERAL HEALTH

A1. How would you rate your overall health, on a scale where zero is as bad as death and 10 is best possible health?

(Circle One)

0	1	2	3	4	5	6	7	8	9	10	
Worst											Best

SUBSCALE: GENERAL VISION

A2. How would you rate your eyesight now (with glasses or contact lens on, if you wear them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as bad or worse than being blind, and 10 means the best possible eyesight?

(Circle One)

0	1	2	3	4	5	6	7	8	9	10	
Worst											Best

SUBSCALE: NEAR VISION

A3. Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms?

Would you say:

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

A4. Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate?

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

A5. Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup?

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

SUBSCALE: DISTANCE VISION

A6. Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?

(READ CATEGORIES AS NEEDED)

(Circle One)

- No difficulty at all..... 1
- A little difficulty..... 2
- Moderate difficulty..... 3
- Extreme difficulty..... 4
- Stopped doing this because of your eyesight 5
- Stopped doing this for other reasons or not interested in doing this 6

A7. Because of your eyesight, how much difficulty do you have taking part in active sports or other outdoor activities that you enjoy (like golf, bowling, jogging, or walking)?
(READ CATEGORIES AS NEEDED)

- (Circle One)*
- No difficulty at all..... 1
 - A little difficulty..... 2
 - Moderate difficulty..... 3
 - Extreme difficulty..... 4
 - Stopped doing this because of your eyesight 5
 - Stopped doing this for other reasons or not interested in doing this 6

A8. Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV?
(READ CATEGORIES AS NEEDED)

- (Circle One)*
- No difficulty at all..... 1
 - A little difficulty..... 2
 - Moderate difficulty..... 3
 - Extreme difficulty..... 4
 - Stopped doing this because of your eyesight 5
 - Stopped doing this for other reasons or not interested in doing this 6

SUBSCALE: SOCIAL FUNCTION

A9. Because of your eyesight, how much difficulty do you have entertaining friends and family in your home?
(READ CATEGORIES AS NEEDED)

- (Circle One)*
- No difficulty at all..... 1
 - A little difficulty..... 2
 - Moderate difficulty..... 3
 - Extreme difficulty..... 4
 - Stopped doing this because of your eyesight 5
 - Stopped doing this for other reasons or not interested in doing this 6

SUBSCALE: DRIVING

A10. [This items, "driving in difficult conditions", has been included as item 16a as part of the base set of 25 vision-targeted items.]

SUBSCALE: ROLE LIMITATIONS

A11. The next questions are about things you may do because of your vision. For each item, I'd like you to tell me if this is true for you all, most, some, a little, or none of the time.
(READ CATEGORIES AS NEEDED)

(Circle One On Each Line)

	All of the time	Most of the time	Some of the time	A little of the time	None of the time
a. <u>Do you have more help from others because of your vision?</u>	1	2	3	4	5
b. <u>Are you limited in the kinds of things you can do because of your vision?</u>	1	2	3	4	5

SUBSCALES: WELL-BEING/DISTRESS (#A12) and DEPENDENCY (#A13)

The next questions are about how you deal with your vision. For each statement, please tell me if it is definitely true, mostly true, mostly false, or definitely false for you or you don't know.

(Circle One On Each Line)

	Definitely True	Mostly True	Not Sure	Mostly False	Definitely False
A12. I am often <u>irritable</u> because of my eyesight.....	1	2	3	4	5
A13. I <u>don't go out of my home alone</u> , because of my eyesight.....	1	2	3	4	5

Site No.: Investigator No: Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y Patient Initials:

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

VISUAL FUNCTIONING QUESTIONNAIRE - 25

Page 2 of 4

Part 2 - Difficulty with Activities continued

7. Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? (check one)
READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

8. How much difficulty do you have reading street signs or the names of stores? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

10. Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

11. Because of your eyesight, how much difficulty do you have seeing how people react to things you say? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

12. Because of your eyesight, how much difficulty do you have picking out and matching your own clothes? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

13. Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

14. Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events? (check one) READ CATEGORIES AS NEEDED

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty

White: Sponsor Yellow: Investigator's Copy Pink: VisionCare

VFQ-25 12.14.02

Site No.: Investigator No: Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y Patient Initials: **ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.**

- 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

VISUAL FUNCTIONING QUESTIONNAIRE – 25

Page 3 of 4

Part 2 – Difficulty with Activities continued15. Now, I'd like to ask about **driving a car**. Are you **currently driving**, at least once in a while? (check one)

- 1 Yes (skip to Q 15c) 2 No

15a. IF NO, ASK: Have you **never** driven a car or have you **given up driving**? (check one)

- 1 Never drove (skip to Part 3, Q 17) 2 Gave up

15b. IF GAVE UP DRIVING: Was that **mainly because of your eyesight, mainly for some other reason**, or because of **both your eyesight and other reasons**? (check one)

- 1 Mainly eyesight (skip to Part 3, Q 17) 2 Mainly other reasons (skip to Part 3, Q 17)
 3 Both eyesight and other reasons (skip to Part 3, Q 17)

15c. IF CURRENTLY DRIVING: How much difficulty do you have **driving during the daytime in familiar places**? Would you say you have: (check one)

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty

16. How much difficulty do you have **driving at night**? Would you say you have: (check one) **READ CATEGORIES AS NEEDED**

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

16a. How much difficulty do you have **driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic**? Would you say you have: (check one) **READ CATEGORIES AS NEEDED**

- 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

Part 3 – Responses to Vision ProblemsThe next questions are about how things you do may be affected by your vision. For each one, I'd like you to tell me if this is true for you **all, most, some, a little**, or **none** of the time.17. **Do you accomplish less** than you would like because of your vision? (check one) **READ CATEGORIES**

- 1 All of the time 2 Most of the time 3 Some of the time 4 A little of the time 5 None of the time

18. **Are you limited** in how long you can work or do other activities because of your vision? (check one) **READ CATEGORIES**

- 1 All of the time 2 Most of the time 3 Some of the time 4 A little of the time 5 None of the time

19. How much does pain or discomfort **in or around your eyes**, for example, burning, itching, or aching, keep you from doing what you'd like to be doing? Would you say: (check one) **READ CATEGORIES**

- 1 All of the time 2 Most of the time 3 Some of the time 4 A little of the time 5 None of the time



Site No.: [] [] []

Investigator No: [] [] []

Patient No.: [] [] []

Protocol: IMT - 002

Date of Exam: M [] [] D [] [] Y [] []

Patient Initials: [] [] []

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

VISUAL FUNCTIONING QUESTIONNAIRE - 25

Page 4 of 4

Part 3 - Responses to Vision Problems continued

For each of the following statements, please tell me if it is definitely true, mostly true, mostly false, or definitely false for you or you are not sure.

- 20. I stay home most of the time because of my eyesight. (check one)
21. I feel frustrated a lot of the time because of my eyesight. (check one)
22. I have much less control over what I do, because of my eyesight. (check one)
23. Because of my eyesight, I have to rely too much on what other people tell me. (check one)
24. I need a lot of help from others because of my eyesight. (check one)
25. I worry about doing things that will embarrass myself or others, because of my eyesight. (check one)

That's the end of the interview. Thank you very much for your time and your help.

Interviewer's Signature: _____ Date: _____

White: Sponsor Yellow: Investigator's Copy Pink: VisionCare

VFQ-25 12.14.02

Site No.: Investigator No: Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y Patient Initials:

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

VISUAL FUNCTIONING QUESTIONNAIRE - 25

Page 1 of 4

- Preoperative R report (DAY -45 TO 0) 3 Months (6-18 weeks) 6 Months (18-32 weeks)
- 9 Months (32-44 weeks) 12 Months (44-56 weeks) 18 Months (56-86 weeks)
- 24 Months (86-104 weeks) Interim, reason: _____

Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

Instructions: I'm going to read you some statements about problems, which involve your vision, or feelings that you have about your vision condition. After each question I will read you a list of possible answers. Please choose the response that describes your situation. Please answer all the questions as if you were wearing your glasses or contact lenses (if any). Please take as much time as you need to answer each question. All your answers are confidential. In order for this survey to improve our knowledge about vision problems and how they affect your quality of life, your answers must be as accurate as possible. Remember, if you wear glasses or contact lenses for a particular activity, please answer all of the following questions as though you were wearing them. **Part 1 -**

General Health and Vision

1. **In general**, would you say your overall **health** is*: (check one) **READ CATEGORIES**
 1 Excellent 2 Very Good 3 Good 4 Fair 5 Poor
2. At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is **excellent, good, fair, poor, or very poor** or are you **completely blind**? (check one) **READ CATEGORIES**
 1 Excellent 2 Good 3 Fair 4 Poor 5 Very Poor 6 Completely blind
3. How much of the time do you **worry** about your eyesight? (check one) **READ CATEGORIES**
 1 None of the time 2 A little of the time 3 Some of the time 4 Most of the time 5 All of the time
4. How much **pain or discomfort** have you had **in and around your eyes** (for example, burning, itching, or aching)? Would you say it is: (check one) **READ CATEGORIES**
 1 None 2 Mild 3 Moderate 4 Severe, or 5 Very severe

Part 2 - Difficulty with Activities

The next questions are about how much difficulty, if any, you have doing certain activities wearing your glasses or contact lenses if you use them for that activity.

5. How much difficulty do you have **reading ordinary print in newspapers**? Would you say you have: (check one) **READ CATEGORIES AS NEEDED**
 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this
6. How much difficulty do you have doing work or hobbies that require you to **see well up close**, such as cooking, sewing, fixing things around the house, or using hand tools? Would you say: (check one) **READ CATEGORIES AS NEEDED**
 1 No difficulty at all 2 A little difficulty 3 Moderate difficulty 4 Extreme difficulty
 5 Stopped doing this because of your eyesight 6 Stopped doing this for other reasons or not interested in doing this

White: Sponsor Yellow: Investigator's Copy Pink: VisionCare

VFQ-25 12.14.02

QUALITY OF LIFE QUESTIONNAIRE:
ACTIVITIES OF DAILY LIFE
EVALUATION FOR IMPLANT PATIENTS

Site No.: Investigator No.:

Protocol: IMT- 002

Patient Initials.: Date of Exam: M D Y Patient No.:

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

ACTIVITIES OF DAILY LIFE EVALUATION FOR
IMT™ IMPLANTED PATIENTS

Page 1 of 3

- Preoperative Report (DAY -45 TO 0) 3 Months (6-18 weeks) 6 Months (18-32 weeks)
 9 Months (32-44 weeks) 12 Months (44-56 weeks) 18 Months (56-86 weeks)
 24 Months (86-104 weeks) Interim, reason: _____

- Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

The purpose of the following questionnaire is to evaluate your visual function as you experience it. In this questionnaire, we will ask you to answer 12 questions regarding daily life activities. For each activity, we will ask you to rate the degree of visual difficulty you have doing it, if any. In your answers, refer to performing the activity with both eyes open and your glasses on (if one eye is taped or patched - leave it on).

Questionnaire:

1a. During the past 3 months, have you watched television?

- 1 Yes (go to 1b) 2 No (go to 1c)

1b. Would you say that you watch television with: (Please check only ONE answer)

- 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty

1c. Is it because of visual problems that you cannot watch television?

- 1 Yes 0 No

2a. During the past 3 months, have you read numbers on the telephone pad?

- 1 Yes (go to 2b) 2 No (go to 2c)

2b. Would you say that you read the numbers on the telephone pad with: (Please check only ONE answer)

- 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty

2c. Is it because of visual problems that you cannot read the numbers on the telephone pad?

- 1 Yes 0 No

3a. During the past 3 months, have you been able to tell the different values of paper money (\$1 versus \$5 bills)?

- 1 Yes (go to 3b) 2 No (go to 3c)

3b. Would you say that you can tell the different values of money bills with: (Please check only ONE answer)

- 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty

3c. Is it because of visual problems that you cannot tell the different values of money bills?

- 1 Yes 0 No

4a. During the past 3 months, have you done any household activities (e.g., washing dishes, setting table, folding laundry, etc.)?

- 1 Yes (go to 4b) 2 No (go to 4c)



Site No.: [][][] Investigator No.: [][]

Protocol: IMT- 002

Patient Initials.: [][][]

Date of Exam: M [][] D [][] Y [][]

Patient No.: [][][]

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

ACTIVITIES OF DAILY LIFE EVALUATION FOR IMT™ IMPLANTED PATIENTS

Page 2 of 3

4b. Would you say that you do household activities with: (Please check only ONE answer)

- [] 5 No difficulty at all [] 4 A little difficulty [] 3 Moderate difficulty [] 2 Extreme difficulty

4c. Is it because of visual problems that you do not do household activities?

- [] 1 Yes [] 0 No

5a. During the past 3 months, have you been able to prepare a cup of tea or coffee by yourself?

- [] 1 Yes (go to 5b) [] 2 No (go to 5c)

5b. Would you say that you can prepare tea or coffee with: (Please check only ONE answer)

- [] 5 No difficulty at all [] 4 A little difficulty [] 3 Moderate difficulty [] 2 Extreme difficulty

5c. Is it because of visual problems that you cannot prepare tea or coffee?

- [] 1 Yes [] 0 No

6a. During the past 3 months, can you distinguish the facial features of people who are standing in front of you?

- [] 1 Yes (go to 6b) [] 2 No (go to 6c)

6b. Would you say that you can distinguish the facial features of people who are standing in front of you with: (Please check only ONE answer)

- [] 5 No difficulty at all [] 4 A little difficulty [] 3 Moderate difficulty [] 2 Extreme difficulty

6c. Is it because of visual problems that you cannot distinguish the facial features of people who are standing in front of you?

- [] 1 Yes [] 0 No

7a. During the past 3 months, have you tried to read the headlines in newspapers?

- [] 1 Yes (go to 7b) [] 2 No (go to 7c)

7b. Would you say that you can read headlines in newspapers with: (Please check only ONE answer)

- [] 5 No difficulty at all [] 4 A little difficulty [] 3 Moderate difficulty [] 2 Extreme difficulty

7c. Is it because of visual problems that you cannot read headlines in newspapers?

- [] 1 Yes [] 0 No

8a. During the past 3 months, have you tried to read the ordinary print in newspapers or other printed material?

- [] 1 Yes (go to 8b) [] 2 No (go to 8c)

8b. Would you say that you read ordinary print in newspapers or other printed material with: (Please check only ONE answer)

- [] 5 No difficulty at all [] 4 A little difficulty [] 3 Moderate difficulty [] 2 Extreme difficulty

8c. Is it because of visual problems that you cannot read ordinary print in newspapers or other printed material?

Site No.: Investigator No.:

Protocol: IMT-002

Patient Initials.: Date of Exam: M D Y Patient No.: **ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.** 1 Yes 0 No**ACTIVITIES OF DAILY LIFE EVALUATION FOR
IMT™ IMPLANTED PATIENTS**

Page 3 of 3

9a. During the past 3 months, have you tried to play cards or board games? 1 Yes (go to 9b) 2 No (go to 9c)**9b. Would you say that you play cards, board games with: (Please check only ONE answer)** 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty**9c. Is it because of visual problems that you cannot play cards, board games?** 1 Yes 0 No**10a. During the past 3 months, have you tried to go shopping?** 1 Yes (go to 10b) 2 No (go to 10c)**10b. Would you say that you can go shopping with: (Please check only ONE answer)** 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty**10c. Is it because of visual problems that you cannot go shopping?** 1 Yes 0 No**11a. During the past 3 months, have you been able to identify the products on sale?** 1 Yes (go to 11b) 2 No (go to 11c)**11b. Would you say that you can identify the products on sale with: (Please check only ONE answer)** 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty**11c. Is it because of visual problems that you are not able to identify the products on sale?** 1 Yes 0 No**12a. During the past 3 months, have you been able to read street signs in daylight, while standing in one place?** 1 Yes (go to 12b) 2 No (go to 12c)**12b. Would you say that you can read street signs in daylight with: (Please check only ONE answer)** 5 No difficulty at all 4 A little difficulty 3 Moderate difficulty 2 Extreme difficulty**12c. Is it because of visual problems that you are not able to read street signs in daylight?** 1 Yes 0 No

Interviewer's Signature: _____ Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: VisionCare

DAILY-EVAL 12.14.02

**PATIENT CASE REPORT FORMS
(CRFs)**



Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT- 002

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

PATIENT ELIGIBILITY FORM

Page 1 of 1

PATIENT QUALIFICATIONS

INCLUSION CRITERIA: Please check "Yes" or "No" for each question.

If any of the answers are "No", the patient may not participate in the study:

- | | <u>Yes</u> | <u>No</u> |
|--|--------------------------|--------------------------|
| 1. The patient has bilateral stable, untreatable central vision disorder (AMD or Stargardt's macular dystrophy) as determined by fluorescein angiography and cataract in the eye scheduled for surgery. | <input type="checkbox"/> | <input type="checkbox"/> |
| 2. The patient has visual acuity between 20/80 and 20/630 in both eyes. | <input type="checkbox"/> | <input type="checkbox"/> |
| 3. The patient has no ocular pathology, as called out in the protocol, in the operative eye except for cataract..... | <input type="checkbox"/> | <input type="checkbox"/> |
| 4. The fellow eye has no ocular disease that may affect peripheral visual field... .. | <input type="checkbox"/> | <input type="checkbox"/> |
| 5. The eye being considered for surgery shows an improvement in visual acuity of at least five letters on the EDTRS Chart with the use of an external telescope..... | <input type="checkbox"/> | <input type="checkbox"/> |
| 6. The patient has anterior chamber depth of at least 2.5 mm. | <input type="checkbox"/> | <input type="checkbox"/> |
| 7. The patient understands and has the mental ability to undergo the testing required for the study and is likely to complete the entire course of follow-up for the next 2 years. | <input type="checkbox"/> | <input type="checkbox"/> |
| 8. The patient has shown interest and understands the need for visual rehabilitation. | <input type="checkbox"/> | <input type="checkbox"/> |
| 9. The patient has given written informed consent. | <input type="checkbox"/> | <input type="checkbox"/> |
| 10. The patient is at least 55 years of age. | <input type="checkbox"/> | <input type="checkbox"/> |

Answers to questions "1 through 10" must all be "Yes" for the patient to be eligible for enrollment.

EXCLUSION CRITERIA: Please check "Yes" or "No" for each question.

If any of the answers are "Yes", the patient may not participate in the study:

- | | <u>Yes</u> | <u>No</u> |
|---|--------------------------|--------------------------|
| 11. The patient has active CNV or had treatment within the past six months | <input type="checkbox"/> | <input type="checkbox"/> |
| 12. Planned operative eye has myopia >6.0 D, hyperopia >4.0 D, axial length less than 21 mm, narrow angle less than Schaefer grade 2..... | <input type="checkbox"/> | <input type="checkbox"/> |
| 13. Endothelial cell density <1600 cells/mm | <input type="checkbox"/> | <input type="checkbox"/> |
| 14. The patient has severe communication impairment or severe neurological disorder which would prevent or interfere with the study requirements. | <input type="checkbox"/> | <input type="checkbox"/> |
| 15. Patient has a history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP >22 mm Hg | <input type="checkbox"/> | <input type="checkbox"/> |
| 16. Patient is pregnant, plans to be pregnant or is lactating during the course of the study..... | <input type="checkbox"/> | <input type="checkbox"/> |
| 17. Patient has undergone previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes | <input type="checkbox"/> | <input type="checkbox"/> |
| 18. The patient is currently, or has been in last 30 days, has been involved in any other clinical trial of an investigational drug or device. | <input type="checkbox"/> | <input type="checkbox"/> |
| 19. The patient is expected to require surgery or Intraocular Lens (IOL) placement in a non-IMT implanted eye within 12 months of the IMT placement..... | <input type="checkbox"/> | <input type="checkbox"/> |
| 20. Patient has who have had or are expected to have ophthalmic related surgery within the 30 days preceding the IMT implantation | <input type="checkbox"/> | <input type="checkbox"/> |

If the answers to questions "1 through 10" are all "Yes" and the answers to questions "11 through 20" are all "No", proceed to the preoperative form on the next page.

Investigator's Signature: _____

Date: _____

White: Sponsor Pink: Investigator's copy Yellow: Sponsor

PT-ELIG 12.14.02



Site No.: [][] [][]

Patient Initials: [][] [][]

Investigator No.: [][] [][]

Patient No.: [][] [][]

Protocol: IMT - 002

Date of Exam: M [][] [][] D [][] [][] Y [][] [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

PREOPERATIVE REPORT (DAY -45 TO 0)

Page 1 of 4

1. Sex: Male Female

2. Race: Caucasian Black Hispanic Asian Other (specify): _____

3. Date of Birth: M [][] [][] D [][] [][] Y [][] [][]

4. Manifest Refraction: (indicate + or - sphere and - cylinder)

OD			OS		
<input type="checkbox"/> +/-	[][] [][]	[][] [][]	<input type="checkbox"/> +/-	[][] [][]	[][] [][]
	Sphere	Cylinder		Sphere	Cylinder
					Axis

5. Distance Best Corrected Visual Acuity (ETDRS)*:

Without External Telescope

Distance chart used: (check 1)

OD 1m 2m OS 1m 2m

LogMar:

[][] [][] [][] OS [][] [][] [][]

With WA3.0X External Telescope

Distance chart used: (check 1)

OD 1m 2m OS 1m 2m

LogMar:

[][] [][] [][] OS [][] [][] [][]

With WA2.2X External Telescope

Distance chart used: (check 1)

OD 1m 2m OS 1m 2m

LogMar:

[][] [][] [][] OS [][] [][] [][]



Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

PREOPERATIVE REPORT (DAY -45 TO 0)

Page 2 of 4

6. Near Best Corrected Visual Acuity* (M units): (check one)

Without External Telescope

16"
(Make sure patient is wearing +2.5 cap.)

8"
(Make sure patient is wearing + 5 cap.)

Number of correct letters: OD OS
M/ . M/ .

Number of correct letters: OD OS
M/ . M/ .

With WA3.0X External Telescope

16"
(Make sure patient is wearing +2.5 cap.)

8"
(Make sure patient is wearing + 5 cap.)

Number of correct letters: OD OS
M/ . M/ .

Number of correct letters: OD OS
M/ . M/ .

With WA2.2X External Telescope

Distance used 16"
(Make sure patient is wearing +2.5 cap.)

8"
(Make sure patient is wearing + 5 cap.)

Number of correct letters: OD OS
M/ . M/ .

Number of correct letters: OD OS
M/ . M/ .

7. Intraocular Pressure: (Applanation)

OD mm Hg OS mm Hg

8. Pupil Size:

OD mm OS mm

9. Endothelial Cell Count:

OD Cells/mm² OS Cells/mm²
 Cells/mm² Cells/mm²
 Cells/mm² Cells/mm²

Disk submitted for evaluation: Yes No



Site No.: [] [] []

Patient Initials: [] [] []

Investigator No.: [] []

Patient No.: [] [] []

Protocol: IMT - 002

Date of Exam: M [] [] D [] [] Y [] []

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

PREOPERATIVE REPORT (DAY -45 TO 0)

Page 3 of 4

10. Biometry:

A.C. Depth OD [] . [] [] mm OS [] . [] [] mm
(by A-Scan) Axial Length [] [] . [] [] mm [] [] . [] [] mm

11. Fundus Photograph Performed:

OD No Yes (If yes, attach photo)
OS No Yes (If yes, attach photo)

12. Fluorescein Angiography Performed: (including red free photos)

OD No Yes
OS No Yes

13. ADL Score: (in %)

Mobility: [] [] . [] [] Distance: [] [] . [] [] Near: [] [] . [] [] Total: [] [] . [] []

14. VFQ Scoring: (in %)

Health [] [] . [] [] Activities: [] [] . [] [] VA Problems: [] [] [] []
Total: [] [] . [] []

15. Slit Lamp Examination:

Cornea: OD OS [] [] 1. Normal [] [] 2. 1 + Edema [] [] 3. 2 + Edema [] [] 4. 3 + Edema [] [] 5. 4 + Edema
Endothelium: OD OS [] [] 1. Normal [] [] 2. 1 + Folds [] [] 3. 2 + Folds [] [] 4. 3 + Folds [] [] 5. Keratic precipitates [] [] 6. Guttata
Iris: OD OS [] [] 1. Normal [] [] 2. Fibrin deposits [] [] 3. Other (specify) OD OS

Anterior Chamber:

Cells: OD OS [] [] 1. Normal [] [] 2. Trace (0-5 cells) [] [] 3. 6-10 cells [] [] 4. 11-20 cells [] [] 5. 21-50 cells [] [] 6. >50 cells
Flare: OD OS [] [] 1. None [] [] 2. Trace [] [] 3. Moderate [] [] 4. Marked [] [] 5. Severe [] [] 6. Other (specify): OD OS



Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

PREOPERATIVE REPORT (DAY -45 TO 0)

Page 4 of 4

16. Type of AMD: (Select all that apply)

- OD [] GA [] Drusen [] Disciform Scar
OS [] GA [] Drusen [] Disciform Scar

17. Pachymetry: (Central Cornea)

OD OS
[] [] [] mm [] [] [] mm
[] [] [] mm [] [] [] mm
[] [] [] mm [] [] [] mm

18. Cataract Type: (Select all that apply)

- OD [] Nuclear [] Cortical [] Posterior subcapsular [] Aphakia [] Pseudophakic [] Other
OS [] Nuclear [] Cortical [] Posterior subcapsular [] Aphakia [] Pseudophakic [] Other

19. Eye Scheduled for IMT Implantation: [] OD [] OS IMT Model: [] WA 3.0 X [] WA 2.2 X

*Please submit Visual Acuity Worksheet with this form

Investigator Signature: _____ Date: _____

PLEASE FAX THE PREOPERATIVE FORM (pages 1-4) TO DATAMED DEVICES AT (949) 581-8106 FOR APPROVAL

FOR SPONSOR USE ONLY:

Does patient meet entry criteria?: [] Yes [] No

Approved by: _____ Signature: _____ Date: _____
(print name)



Site No.: [] [] []

Patient Initials: [] [] []

Investigator No.: [] []

Patient No.: [] [] []

Protocol: IMT- 002

Date of Surgery: M [] [] D [] [] Y [] []

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

OPERATIVE REPORT (DAY 0)

Page 1 of 1

1. IMT Serial Number: [] [] - [] [] [] - [] [] (Place label in patient's medical chart)

2. IMT Model: (check one)
 WA 3.0 X WA 2.2 X

3. Incision Type: (check one)
 Limbal Scleral tunnel

4. Type of Extraction: (check one)
 Phacoemulsification Planned ECCE

5. Capsulorhexis Size: [] [] mm

6. Other Surgical Procedures: (check procedures performed)
 Iridectomy (required) Posterior capsulotomy Vitrectomy Other (specify) _____

7. Iris Position Post Implantation: (check one)
 Flat Bulging (Convex) Concave

8. Haptic Placement:
Sulcus Bag Superior loop Inferior loop

Clock Hour Position:
 12:6 1:7 2:8 3:9 4:10 5:11 Unknown

9. IMT Positioning: (check all that applies)
 Centered
 Tilted
 Malpositioned (specify): _____
 Other (specify): _____

10. Surgery Time: [] [] [] min (first incision to final suture placement)

11. Surgical Complications/Adverse Event: No Yes (If Yes, check all that apply)
 Corneal endothelial touch Iris damage
 Posterior capsular opacity remaining Vitreous bulge
 Posterior capsular rupture Vitreous loss - vitrectomy not required
 Iridotomy Vitreous loss - vitrectomy required
 Significant anterior chamber bleeding Other (specify): _____
 Other (specify): _____

12. Type of Viscoelastic Used: Healon V and/or Other (specify) _____

13. Subtenon injected: No Yes

Investigator's Signature: _____ Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor

OP 12.14.02



Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT-002

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT-DAY 1 (24 to 36 hours)

Page 1 of 2

Interim, reason: _____

Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

1. Visual Acuity: (operative eye)

NLP LP HM CF @ _____ cm

2. IOP:

. mmHg

3. Slit Lamp Examination:

Cornea:

OD OS

- 1. Normal
- 2. 1 + Edema
- 3. 2 + Edema
- 4. 3 + Edema
- 5. 4 + Edema

Endothelium:

OD OS

- 1. Normal
- 2. 1 + Folds
- 3. 2 + Folds
- 4. 3 + Folds
- 5. Keratic precipitates
- 6. Guttata

Anterior Chamber:

Cells

OD OS

- 1. Normal
- 2. Trace (0-5 cells)
- 3. 6-10 cells
- 4. 11-20 cells
- 5. 21-50 cells
- 6. >50 cells

Flare

OD OS

- 1. None
- 2. Trace
- 3. Moderate
- 4. Marked
- 5. Severe
- 6. Other (specify): OD _____

Iris:

OD OS

- 1. Normal
- 2. Fibrin deposits
- 3. Other (specify)

OD _____

OS _____

OS _____



Site No.: [][] [][]

Patient Initials: [][] [][]

Investigator No.: [][] [][]

Patient No.: [][] [][]

Protocol: IMT- 002

Date of Exam: M [][] [][] D [][] [][] Y [][] [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT-DAY 1 (24 to 36 hours)

Page 2 of 2

4. Complications: Yes No If Yes, check any that are present and complete an Adverse Event Form.

- Anterior segment neovascularization
- Anterior synechiae (If yes, extend in no. of clock hours): _____
- Choroidal detachment
- Cortical remnants
- Cyclitic membrane
- Cystoid macular edema
- Distorted pupil
- Endophthalmitis
- Flat anterior chamber
- Hyphema
- Increased IOP requiring treatment
- Inflammatory deposits on IMT
- Iris atrophy
- Iris transillumination defects
- Optic atrophy
- Posterior synechiae (If yes, extend in no. of clock hours): _____
- Pupillary block
- Retinal detachment
- Retinal vascular occlusion
- Secondary glaucoma
- Significant pigment deposits on IMT
- Vitreous capture space incision
- Vitreous in anterior chamber
- Vitritis
- Wound leak
- Other (specify): _____
- Other (specify): _____
- Other (specify): _____

5. IMT Positioning: (check all that apply)

- Centered
- Tilted
- Malpositioned (specify) _____

6. Haptic Placement:

- | | | |
|--------------------------|--------------------------|---------------|
| Sulcus | Bag | |
| <input type="checkbox"/> | <input type="checkbox"/> | Superior loop |
| <input type="checkbox"/> | <input type="checkbox"/> | Inferior loop |

Investigator's Signature: _____ Date: _____



Site No.: [] [] []

Patient Initials: [] [] []

Investigator No.: [] []

Patient No.: [] [] []

Protocol: IMT-002

Date of Exam: M [] [] D [] [] Y [] []

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT-DAY 7 (5 to 10 days)

Page 1 of 2

Interim, reason: _____

Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

1. Manifest Refraction: (indicate + or - sphere and - cylinder)

+/- [] [] [] . [] [] [] - [] [] [] . [] [] [] [] [] []
Sphere Cylinder Axis

2. Distance Best Corrected Visual Acuity (ETDRS):

*Please submit Visual Acuity Worksheet with this form

Distance chart used: (check 1) 1m 2m

LogMar: [] . [] []

3. IOP : [] [] . [] mmHg

4. Slit Lamp Examination:

Cornea:

OD OS

- 1 Normal
- 2 1 + Edema
- 3 2 + Edema
- 4 3 + Edema
- 5 4 + Edema

Endothelium:

OD OS

- 1 Normal
- 2 1 + Folds
- 3 2 + Folds
- 4 3 + Folds
- 5 Keratic precipitates
- 6 Guttata

Anterior Chamber:

Cells

OD OS

- 1 Normal
- 2 Trace (0-5 cells)
- 3 6-10 cells
- 4 11-20 cells
- 5 21-50 cells
- 6 >50 cells

Flare

OD OS

- 1 None
- 2 Trace
- 3 Moderate
- 4 Marked
- 5 Severe
- 6 Other (specify): OD _____

Iris:

OD OS

- 1 Normal
- 2 Fibrin deposits
- 3 Other (specify)
OD _____
OS _____

OS _____



Site No.: [][]

Patient Initials: [][]

Investigator No.: [][]

Patient No.: [][]

Protocol: IMT- 002

Date of Exam: M [][] D [][] Y [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT

Page 2 of 2

5. Complications: Yes No If Yes, check any that are present and complete an Adverse Event Form.

- Anterior segment neovascularization
Anterior synechiae (If yes, extend in no. of clock hours):
Choroidal detachment
Cortical remnants
Cyclitic membrane
Cystoid macular edema
Distorted pupil
Endophthalmitis
Flat anterior chamber
Hyphema
Increased IOP requiring treatment
Inflammatory deposits on IMT
Iris atrophy
Iris transillumination defects
Optic atrophy
Posterior synechiae (If yes, extend in no. of clock hours):
Pupillary block
Retinal detachment
Retinal vascular occlusion
Secondary glaucoma
Significant pigment deposits on IMT
Vitreous capture space incision
Vitreous in anterior chamber
Vitritis
Wound leak
Other (specify):

6. IMT Positioning: (check all that apply)

- Centered
Tilted
Malpositioned (specify)

7. Haptic Placement:

- Sulcus Bag
Superior loop
Inferior loop

Investigator's Signature: _____ Date: _____

Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT 1 MONTH (2 to 6 weeks)

Page 1 of 2

Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

1. Manifest Refraction: (indicate + or - sphere and - cylinder)

OD			OS				
<input type="checkbox"/> +/-	<input type="text"/> <input type="text"/> <input type="text"/>	- <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>	<input type="checkbox"/> +/-	<input type="text"/> <input type="text"/> <input type="text"/>	- <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>
	Sphere	Cylinder	Axis		Sphere	Cylinder	Axis

2. Distance Best Corrected Visual Acuity* (ETDRS):

Distance chart used: (check 1)	<input type="checkbox"/> 1m <input type="checkbox"/> 2m	<input type="checkbox"/> 1m <input type="checkbox"/> 2m
Logmar:	<input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>

3. Near Best Corrected Visual Acuity* (M units):

Distance used	16"	8"
Number of correct letters:	OD <input type="text"/> <input type="text"/> OS <input type="text"/> <input type="text"/>	OD <input type="text"/> <input type="text"/> OS <input type="text"/> <input type="text"/>
	M/ <input type="text"/> <input type="text"/> M/ <input type="text"/> <input type="text"/>	M/ <input type="text"/> <input type="text"/> M/ <input type="text"/> <input type="text"/>

4. Slit Lamp Examination:

Cornea:	Endothelium:
OD OS	OD OS
<input type="checkbox"/> <input type="checkbox"/> 1. Normal	<input type="checkbox"/> <input type="checkbox"/> 1. Normal
<input type="checkbox"/> <input type="checkbox"/> 2. 1 + Edema	<input type="checkbox"/> <input type="checkbox"/> 2. 1 + Folds
<input type="checkbox"/> <input type="checkbox"/> 3. 2 + Edema	<input type="checkbox"/> <input type="checkbox"/> 3. 2 + Folds
<input type="checkbox"/> <input type="checkbox"/> 4. 3 + Edema	<input type="checkbox"/> <input type="checkbox"/> 4. 3 + Folds
<input type="checkbox"/> <input type="checkbox"/> 5. 4 + Edema	<input type="checkbox"/> <input type="checkbox"/> 5. Keratic precipitates
	<input type="checkbox"/> <input type="checkbox"/> 6. Guttata

Anterior Chamber:

Cells	Flare	Iris:
OD OS	OD OS	OD OS
<input type="checkbox"/> <input type="checkbox"/> 1. Normal	<input type="checkbox"/> <input type="checkbox"/> 1. None	<input type="checkbox"/> <input type="checkbox"/> 1. Normal
<input type="checkbox"/> <input type="checkbox"/> 2. Trace (0-5 cells)	<input type="checkbox"/> <input type="checkbox"/> 2. Trace	<input type="checkbox"/> <input type="checkbox"/> 2. Fibrin deposits
<input type="checkbox"/> <input type="checkbox"/> 3. 6-10 cells	<input type="checkbox"/> <input type="checkbox"/> 3. Moderate	<input type="checkbox"/> <input type="checkbox"/> 3. Other (specify)
<input type="checkbox"/> <input type="checkbox"/> 4. 11-20 cells	<input type="checkbox"/> <input type="checkbox"/> 4. Marked	OD _____
<input type="checkbox"/> <input type="checkbox"/> 5. 21-50 cells	<input type="checkbox"/> <input type="checkbox"/> 5. Severe	OS _____
<input type="checkbox"/> <input type="checkbox"/> 6. >50 cells	<input type="checkbox"/> <input type="checkbox"/> 6. Other (specify): OD _____	

OS _____



Site No.:

[][] [][]

Patient Initials:

[][] [][]

Investigator No.:

[][]

Patient No.:

[][] [][]

Protocol: IMT - 002

Date of Exam: M

[][]

D

[][]

Y

[][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT 1 MONTH (2 to 6 weeks)

Page 2 of 2

5. Intraocular Pressure:

OD [][] mm Hg OS [][] mm Hg

6. Posterior Capsular Opacification: (Operative Eye only) (check one)

None Minimal Opacity Moderate Opacity Dense Opacity

7. IMT Positioning: (check each that applies)

Centered
 Tilted
 Malpositioned (specify) _____

8. Complications: Yes No

If Yes, check any that are present and complete an Adverse Event Form.

- | | |
|---|--|
| <input type="checkbox"/> Anterior segment neovascularization | <input type="checkbox"/> Optic atrophy |
| <input type="checkbox"/> Anterior synechiae (If yes, extend in no. of clock hours): _____ | <input type="checkbox"/> Posterior synechiae (If yes, extend in no. of clock hours): _____ |
| <input type="checkbox"/> Choroidal detachment | <input type="checkbox"/> Pupillary block |
| <input type="checkbox"/> Cortical remnants | <input type="checkbox"/> Retinal detachment |
| <input type="checkbox"/> Cyclitic membrane | <input type="checkbox"/> Retinal vascular occlusion |
| <input type="checkbox"/> Cystoid macular edema | <input type="checkbox"/> Secondary glaucoma |
| <input type="checkbox"/> Distorted pupil | <input type="checkbox"/> Significant pigment deposits on IMT |
| <input type="checkbox"/> Endophthalmitis | <input type="checkbox"/> Vitreous capture space incision |
| <input type="checkbox"/> Flat anterior chamber | <input type="checkbox"/> Vitreous in anterior chamber |
| <input type="checkbox"/> Hyphema | <input type="checkbox"/> Vitritis |
| <input type="checkbox"/> Increased IOP requiring treatment | <input type="checkbox"/> Wound leak |
| <input type="checkbox"/> Inflammatory deposits on IMT | <input type="checkbox"/> Other (specify): _____ |
| <input type="checkbox"/> Iris atrophy | <input type="checkbox"/> Other (specify): _____ |
| <input type="checkbox"/> Iris transillumination defects | <input type="checkbox"/> Other (specify): _____ |

* Please submit Visual Acuity Worksheet with this form

Signature: _____

Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor

PO 1M 12.14.02



Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT - 002

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT

Page 1 of 3

3 Months (6-18 weeks) 6 Months (18-32 weeks) 9 Months (32-44 weeks) 12 Months (44-56 weeks)

18 Months (66-78 weeks) 24 Months (90-102 weeks) Interim, reason: _____

Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

1. Manifest Refraction: (indicate + or - sphere and - cylinder)

OD			OS		
<input type="checkbox"/> +/-	<input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>	- <input type="text"/> . <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>	- <input type="text"/> . <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>
	Sphere	Cylinder	Sphere	Cylinder	Axis

2. Distance Best Corrected Visual Acuity* (ETDRS):

	OD		OS	
Distance chart used: (check 1)	<input type="checkbox"/> 1m	<input type="checkbox"/> 2m	<input type="checkbox"/> 1m	<input type="checkbox"/> 2m
Logmar:	<input type="text"/> . <input type="text"/> <input type="text"/>			

3. Near Best Corrected Visual Acuity* (M units):

Distance used :	16"		8"	
Number of correct letters:	OD <input type="text"/> <input type="text"/>		OS <input type="text"/> <input type="text"/>	
	M/ <input type="text"/> . <input type="text"/> <input type="text"/> M/	<input type="text"/> <input type="text"/> <input type="text"/>	M/ <input type="text"/> . <input type="text"/> <input type="text"/> M/	<input type="text"/> . <input type="text"/> <input type="text"/>

4. Slit Lamp Examination:

Slit Lamp Examination:

Cornea:
OD OS

- 1 Normal
- 2 1 + Edema
- 3 2 + Edema
- 4 3 + Edema
- 5 4 + Edema

Endothelium:
OD OS

- 1 Normal
- 2 1 + Folds
- 3 2 + Folds
- 4 3 + Folds
- 5 Keratic precipitates
- 6 Guttata



Site No.: [][][]

Patient Initials: [][][]

Investigator No.: [][]

Patient No.: [][][]

Protocol: IMT - 002

Date of Exam: M [][] D [][] Y [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT

Page 2 of 3

Anterior Chamber:

Cells

- 1 Normal
- 2 Trace (0-5 cells)
- 3 6-10 cells
- 4 11-20 cells
- 5 21-50 cells
- 6 >50 cells

Flare

- 1 None
- 2 Trace
- 3 Moderate
- 4 Marked
- 5 Severe
- 6 Other (specify): OD _____

Iris:

- 1 Normal
 - 2 Fibrin deposits
 - 3 Other (specify)
- OD _____
OS _____

5. Pachymetry: (Central Cornea)

OD	[][][] mm	[][][] mm	[][][] mm
OS	[][][] mm	[][][] mm	[][][] mm

6. Intraocular Pressure:

OD [][] mmHg OS [][] mmHg

7. Posterior Capsular Opacification: (Operated Eye only) (check one)

- None Minimal Opacity Moderate Opacity Dense Opacity

8. IMT Positioning: (check each that applies)

- Centered
 Tilted
 Malpositioned (specify) _____

9. Endothelial Cell Count: Sent to Lab: Yes No

OD	[][][][] Cells/mm ²	[][][][] Cells/mm ²	[][][][] Cells/mm ²
OS	[][][][] Cells/mm ²	[][][][] Cells/mm ²	[][][][] Cells/mm ²



Site No.: [][] [][]

Patient Initials: [][] [][]

Investigator No.: [][] [][]

Patient No.: [][] [][]

Protocol: IMT - 002

Date of Exam: M [][] [][] D [][] [][] Y [][] [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT

Page 3 of 3

10. Complications: Yes No

If Yes, check any that are present and complete an Adverse Event Form.

- | | |
|---|--|
| <input type="checkbox"/> Anterior segment neovascularization | <input type="checkbox"/> Optic atrophy |
| <input type="checkbox"/> Anterior synechiae (If yes, extend in no. of clock hours): _____ | <input type="checkbox"/> Posterior synechiae (If yes, extend in no. of clock hours): _____ |
| <input type="checkbox"/> Choroidal detachment | <input type="checkbox"/> Pupillary block |
| <input type="checkbox"/> Cortical remnants | <input type="checkbox"/> Retinal detachment |
| <input type="checkbox"/> Cyclitic membrane | <input type="checkbox"/> Retinal vascular occlusion |
| <input type="checkbox"/> Cystoid macular edema | <input type="checkbox"/> Secondary glaucoma |
| <input type="checkbox"/> Distorted pupil | <input type="checkbox"/> Significant pigment deposits on IMT |
| <input type="checkbox"/> Endophthalmitis | <input type="checkbox"/> Vitreous capture space incision |
| <input type="checkbox"/> Flat anterior chamber | <input type="checkbox"/> Vitreous in anterior chamber |
| <input type="checkbox"/> Hyphema | <input type="checkbox"/> Vitritis |
| <input type="checkbox"/> Increased IOP requiring treatment | <input type="checkbox"/> Wound leak |
| <input type="checkbox"/> Inflammatory deposits on IMT | <input type="checkbox"/> Other (specify): _____ |
| <input type="checkbox"/> Iris atrophy | <input type="checkbox"/> Other (specify): _____ |
| <input type="checkbox"/> Iris transillumination defects | <input type="checkbox"/> Other (specify): _____ |

11. ADL Score: (in %)

Mobility: [][] [][] Distance: [][] [][] Near: [][] [][]

Total: [][] [][]

12. VFQ Scoring: (in %)

Health: [][] [][] Activities: [][] [][] VA Problems: [][] [][]

Total: [][] [][]

***Please submit Visual Acuity Worksheet with this form**

Investigator's Signature: _____

Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor

PO 3M 12.14.02

ATTACHMENT 4

**LIST OF CLINICAL INVESTIGATORS
FOR PROTOCOL IMT-002**

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
003	Baruch D. Kuppermann, M.D. Lawrence Chao, M.D. University of California at Irvine 118 Med Surge I Irvine, CA 92697 Phone (949) 824-6256 Fax: (949) 824-4015 Email: bdkupper@uci.edu	University of California Irvine David Imagawa, M.D., Chair 118 Med Surge I Irvine, CA 92697 Phone: (949) 824-6256
004	Howard Fine, M.D. Richard Hoffman, M.D. Mark Packer, M.D. Oregon Eye Surgery Center 1550 Oak Street, Suite 5 Eugene, OR 97401 Phone: (541) 687-2110 Fax: (541) 484-3883 Howard Fine, M.D. Email: hfine@finemd.com Richard Hoffman, M.D. Email: rshoffman@finemd.com Mark Packer, M.D. Email: mpacker@finemd.com	Western International Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498
005	Paul R. Lichter, R.N. University of Michigan W.K. Kellogg Eye Center 1000 Wall Street Ann Arbor, MI 48105 Phone: (734) 764-6468 Email: plichter@umich.edu	The University of Michigan Medical School Institutional Review Board for Human Subject Research (IRBMED) Vernon K. Sondak, M.D., Professor of Surgery, Co-Chair, IRBMED 4558 Krerge Medical Research Building 200 Zina Picher Place Ann Arbor, MI 48109-0570 Phone: (734)4634768

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
006	<p>Doug Dehning, M.D. Kristi Chevalier, O.D. Discover Vision Centers 4741 South Cochise Drive Independence, MO 64055 Phone: (816) 478-1230 Fax: (816) 478-4413 Doug Dehning, M.D. Email: ddehning@discovervision.com Kristi Chevalier, O.D. Email: kchevalier@discovervision.com</p>	<p>Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498</p>
008	<p>Daniel Berinstein, M.D. Michael Osman, M.D. Geoffrey Kaplan, M.D. Reginald Sanders, M.D. Robert Murphey, M.D. Thomas E. Clinch, M.D. Neil Martin, M.D. Retina Group of Washington 5454 Wisconsin Ave., Ste 1540 Chevy Chase, MD 20815 Daniel Berinstein, M.D. Phone: (301) 656-8100 Fax: (301) 652-2957 Email: danberi@yahoo.com Michael Osman, M.D. Phone: (301) 315-2198 Fax: (301) 315-2187 Geoffrey Kaplan, M.D. Reginald Sanders, M.D. Robert Murphey, M.D. Phone: (301) 315-2198</p>	<p>Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498</p>

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-102

Site Number	Investigators	Institutional Review Board (IRB)
009	<p>Jason S. Slakter, M.D. K. Bailey Freund, M.D. Antonio Ciardella, M.D. Nicole Gross, M.D. James Klancnik, M.D. Sidney Mandelbaum, M.D. Vitreous-Retina-Macula Consultants of NY, PC 519 E. 72nd St., Suite 203 New York, NY 10021 Manhattan Eye & Ear 210 E. 64th St., 8th floor New York, NY 10021 Phone: (212) 861-9797 Fax: (212) 628-0698 Jason S. Slakter, M.D. Email: jslakter@aol.com, vmnny@aol.com K. Bailey Freund, M.D. Antonio Ciardella, M.D. Nicole Gross, M.D. Phone: (610) 636-1879 James Klancnik, M.D. Sidney Mandelbaum, M.D. Phone: (212) 650-0400 Fax: (212) 288-4223 Email: sidmandelbaum@yahoo.com</p>	<p>Manhattan Eye, Ear & Throat Hospital Lauren Privitera, Director, Institutional Review Board 210 East Sixty-Fourth Street New York, NY 10021 Phone: (212) 838-9200</p>
010	<p>Jeffrey Heier, M.D. Ken Chern, M.D. Michael Raizman, M.D. Ophthalmic Consultants of Boston 50 Staniford Street Suite 600 Boston, MA 02114 Jeffrey Heier, M.D. Phone: (617) 314-2611 Fax: (617) 314-1825 Email: jsheier@eyeboston.com</p>	<p>Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498</p>

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-012

Site Number	Investigators	Institutional Review Board (IRB)
011	<p>Kathryn Colby, M.D. Joan Miller, M.D. Massachusetts Eye & Ear Infirmary Schepens Eye Research Institute 243 Charles St. Suite 808 Boston, MA 02114 Kathryn Colby, M.D. Phone: (617) 573-5537 Fax: (617) 573-3364 Email: kacolby@meei.harvard.edu Joan Miller, M.D. Phone: (617) 573-3915 Fax: (617) 573-3698 Email: jwmiller@meei.harvard.edu</p>	<p>Massachusetts Eye and Ear Infirmary Carolyn Carlson, Research Compliance Officer, Human Studies Committee 243 Charles Street Boston, Massachusetts 02114 Phone: (617) 573-4080</p>
012	<p>Henry Hudson, M.D. George Novalis, M.D. Kristin Carter, M.D. Retina Centers P.C. 6585 N. Oracle Road, Suite A Tucson, AZ 85704 Henry Hudson, M.D. Phone: (520) 742-7444 Fax: (520) 297-2267 George Novalis, M.D. Kristin Carter, M.D. Phone: (520) 795-4202 Fax: (520) 319-1841 Mobile) 520/603-8019 kristincp@cox.net</p>	<p>Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498</p>

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
013	Robert Leonard, M.D. Ronald Kingsley, M.D. Reagan Bradford, M.D. David Parke, M.D. Cynthia Bradford, M.D. Dean A. McGee Eye Institute 608 Stanton L. Young Blvd. Suite 554 Oklahoma City, OK 73104 Robert Leonard, M.D. Phone: (405) 271-1692 Fax: (405) 271-6136 Email: Robert-leonard@ouhsc.edu	The University of Oklahoma Health Sciences Center Institutional Review Board Martina Jelley, M.D., Chairperson P.O. Box 28901 1000 S. L. Young Blvd., Room 176 Oklahoma City, Oklahoma 73180 Phone: (405) 271-2045 Fax: (405) 271-1677
014	R. Doyle Stulting, M.D. Dan Martin, M.D. Emory Eye Center 1365B Clifton Rd. N.E. Atlanta, GA 30322 Phone: (404) 250-9700 Fax: (404) 250-9006 Email: doylestulting@emoryvision.com Dan Martin, M.D. Phone: (404) 778-4182 Fax: (404) 778-4380 Email: dmart04@emory.edu	Emory University Institutional Review Board James W. Keller, M.D., Chairperson 4 th Floor, South Wing 5256 Briarcliff Road Atlanta, GA 30306 Phone: (404) 727-5646 Fax: (404) 727-8358
015	Stephen Fisher, M.D. Michael Singer, M.D. Medical Center Ophthalmology 9157 Heubner road San Antonio, TX 78240 Phone: (210) 697-2020 x2006 Fax: (210) 558-7679 Email: msinger@earthlink.net	Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
016	Manus Kraff Coleman Kraff, M.D. Kraff Eye Institute 3115 North Harlem Chicago, IL 60634 Phone: (773) 777-4444 Fax: (773) 736-7873 Email: mkraff@msu.com	Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498
017	Seth Yoser, M.D. Vitreoretinal Foundation 825 Ridgelake Blvd. Memphis, TN 38120 Phone: (901) 685-2208 Fax: (901) 820-2314 Email: myoser@aol.com	Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498
019	Carl Baker, M.D. Mark Gillespie, MD Paducah Retinal Center 1900 Broadway, Suite 2 Paducah, KY 42001 Phone: (270) 443-4393 Fax: (270)443-7779 Email: eyedude3@ssi-net.net	Lourdes and Western Baptist Hospitals Joint Institutional Review Board James P. O'Rourke, MD, Chairperson Western Baptist Address: 2501 KY Avenue Paducah, KY 42003 Lourdes Address: 2530 Lone Oak Road Paducah, KY 42003
020	David Chang, M.D. Altos Eye Physician 762 Altos Oaks Drive, Suite 1 Los Altos, CA 94024 Phone: (650) 948-9123 Fax: (650) 948-0563 Email: dceye@earthlink.net	Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
022	Keye Wong, M.D. Melvin Chen, M.D. Richard Johnston, M.D. Sarasota Retinal Institute 3400 Bee Ridge Road, Suite 200 Sarasota, FL 34239 Phone: (941) 921-5335 Fax: (941)921-1741 Keye Wong, M.D. Email: iskeye@comcast.com	Sarasota Memorial Institutional Review Board Mark J. Magenheimer, M.D., Chairperson Pharmacy Department 1700 South Tamiami Trail Sarasota, FL 34239-1555
023	Donald Stewart, M.D. Andrew Antoszyk, M.D. Southeast Clinical Research 6035 Fairview Road Charlotte, NC 28210 Donald Stewart, M.D. Phone: (704) 295-3552 Fax: (704) 295-3565 Email: dstewart@ceenta.com Andrew Antoszyk, M.D. Phone: (704) 295-3388 Fax: (704) 295-3395	Presbyterian Hospital Robert Farnham, M.D., Chairperson 200 Hawthorne Lane P.O. Box 33549 Charlotte, NC 28233-3549 Phone: (704) 384-4000
025	Srinivas Reddy Satta, M.D. Tom S. Chang, M.D. Christina J Flaxel, M.D. Mark S. Humayun, M.D. Jennifer I. Lim, M.D. Lawrence P. Chong, M.D. John A. Irvine, M.D. Doheny Retina Institute University of Southern California 1450 San Pablo Street, DEI 3615 Los Angeles, Ca 90033 Srinivas Reddy Satta, M.D. Phone: (323) 442-6503 Tom S. Chang Phone: (323)442-6538 Fax: (323) 442-6460 Christina J Flaxel, M.D. Mark S. Humayun, M.D.	Institutional Review Board Health Research Association and Institutional Review Board University of Southern California School of Medicine Robert Larsen, M.D., Chairperson Interns Residence Dorm Suite 425 2020 Zonal Avenue Los Angeles, CA 90033 (323) 223-2340

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
	Phone: (323) 442-6523 Email: humayun@usc.edu Jennifer I. Lim Phone: (323) 442-6430 Fax: (323) 442-6460 Lawrence P. Chong, M.D. Phone: (323) 442-6466	
026	Lawrence J Singerman, M.D. Michael Novak, M.D. Hernando Zegarro, M.D. Nicholas Z. Sakov, M.D. Scott Perdergast, M.D. David Miller, M.D. Martin Markowitz, M.D. Retina Associates of Cleveland 3401 Enterprise Pkwy. Suite 300 Beachwood, OH 44122 Lawrence J Singerman, M.D. Phone: (216) 831-5700 Fax: (216) 360-2196	Hillcrest Hospital Cheryl A. Petersilge, M.D., Chairperson 6780 Mayfield Road Mayfield Heights, OH 44124 Phone: (440)449-4500
027	Paul Sternberg, M.D. Anita Agarwal, M.D. Vanderbilt University Department of Ophthalmology & Visual Sciences 8000 Medical Center East-8808 Nashville, TN 37232 Paul Sternberg, M.D. Phone: (615) 936-3465 Fax: (615) 936-1540 Anita Agarwal, M.D. Phone: (615) 936-2096 Fax: (615) 936-1540 Email: anita.agarwal@vanderbilt.edu	Vanderbilt University Margaret Rush, M.D., Chairperson D-3232 Medical Center North Nashville, TN 37232-2598 Phone: (615) 322-2918 Fax: (615) 343-2648

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-012

Site Number	Investigators	Institutional Review Board (IRB)
028	Carl Regillo, M.D. Jack Dugan, M.D. Wills Eye Hospital, Retina Research 840 Walnut St. Suite 1020 Philadelphia, PA 19107 Email: drbpconn@yahoo.com Carl Regillo, M.D. Phone: (215) 928-3092 Fax: (215) 928-3484 Email: cregillo@aol.com	Wills Eye Hospital Ralph Eagle, M.D., Chairperson 840 Walnut Street Philadelphia, PA 19107-5109 Phone: (215)928-3000
029	Michael T. Trese, M.D. George Williams, M.D. G. Robert Lesser, M.D. Associated Retinal Consultants 3535 W. 13 th Mile Road, Suite 636 Royal Oak, MI 48073 Michael T. Trese, M.D. Phone: (248) 288-2280 Fax: (248) 288-5644 Email: mgjt46@aol.com	William Beaumont Hospital Richard L. Lucarotti, Pharm D., Chairperson 3811 West Thirteen Mile Road Royal Oak, MI 48073-6769 Phone: (248) 551-0662
031	Sharon Fekrat, M.D. - PI M. Cooney, C. Roth, B. McCuen, G. Jaffe, E. Postel Terry Kim, M.D. Duke University Eye Center Box 3802, Erwin Rd. Room 304 Durham, NC 27710 Sharon Fekrat, M.D. - PI Phone: (919) 681-0341 Fax: (919) 681-6474 fekrad001@mc.duke.edu	Duke University Health System John M. Harrelson, M.D., Chairperson 2400 Pratt Street, Suite 9000 Box 2991, Durham, NC 27705 Phone: (919) 668-5111 Fax: (919) 668-5125

INVESTIGATORS AND IRB PARTICIPATING IN PROTOCOL IMT-002

Site Number	Investigators	Institutional Review Board (IRB)
032	Oliver D. Schein, M.D. MPH Wilmer Ophthalmological Institute Johns Hopkins University School of Medicine 116 Wilmer Building 600 North Wolfe St. Baltimore, MD 21287-9277 Phone: (410)955-8179	Western Institutional Review Board William C. Jacobs, Chairperson 3535 Seventh Avenue, SW Olympia, WA 98508-2029 Phone: (800) 562-4789 Fax: (360) 252-2498

ATTACHMENT 5

PROTOCOL IMT-002-LTM



VISIONCARE OPTHALMIC TECHNOLOGIES, INC.

**FIVE YEAR FOLLOW-UP OF IMT-002 PATIENTS
A LONG-TERM MONITORING STUDY OF IMT-002 PATIENTS**

PROTOCOL IMT-002-LTM

April 1, 2006

**VisionCare Ophthalmic Technologies, Inc.
14395 Saratoga Avenue, Suite 150
Saratoga, CA 95070**

I have read and agree to follow the study procedures as outlined in this protocol.

Print Name of Investigator

Investigator's Signature

Date

CONFIDENTIAL - DO NOT COPY

This protocol contains confidential proprietary information with respect to VisionCare products and clinical trials. I agree to hold this information in confidence and not to disclose it to any third parties for a period of three years from the date of this agreement, or until this information becomes a matter of public knowledge or until a formal agreement for that purpose has been entered into by the parties.

TABLE OF CONTENTS

TABLE OF CONTENTS.....	2
PERSONNEL AND FACILITIES.....	3
STUDY OUTLINE	4
INTRODUCTION & RATIONALE.....	6
STUDY OBJECTIVE.....	8
STUDY DESIGN	8
MONITORING PARAMETERS.....	8
PATIENT POPULATION.....	8
INCLUSION CRITERIA.....	8
EXCLUSION CRITERIA.....	8
INVESTIGATIONAL PROCEDURES	9
PATIENT ENTRY	9
EXAMINATION SCHEDULE	9
CLINICAL PARAMETERS	10
DATA COLLECTION AND VALIDATION	10
STUDY COMPLETION PROCEDURES	11
STATISTICAL METHODS, REPORTING, DATA COLLECTION, DATA VALIDATION	11
STATISTICAL METHODS	11
REPORTING	11
ADVERSE EXPERIENCE REPORTING.....	13
ADVERSE EXPERIENCES.....	13
DEVICE MALFUNCTIONS	14
MONITORING.....	15

APPENDICES

APPENDIX 1	PROPOSED PATIENT INFORMED CONSENT	16
APPENDIX 2	STUDY EXAMINATIONS	
	SCHEDULE & METHODS.....	21
	EXAMINATION SCHEDULE & CLINICAL PARAMETERS	22
	BCVA TESTING PROTOCOL.....	23
	SPECULAR MICROSCOPY.....	28
APPENDIX 3	CASE REPORT FORMS.....	30

VISIONCARE OPHTHALMIC TECHNOLOGIES, INC.

**FIVE YEAR FOLLOW-UP OF IMT-002 PATIENTS
A LONG-TERM MONITORING STUDY OF IMT-002 PATIENTS**

PROTOCOL IMT-002-LTM

PERSONNEL AND FACILITIES

STUDY SPONSOR VisionCare Ophthalmic Technologies, Inc.
14395 Saratoga, Ave., Suite 150
Saratoga, CA 95070
(408) 872-9393 Phone
(408) 872-9395 Fax

MEDICAL MONITOR Stephen S. Lane, M.D.
Associated Eye Care
232 North Main Street
Stillwater, MN 55082

INVESTIGATORS All sites that participated in Protocol IMT-002

CLINICAL MONITOR DataMed Devices, Inc.
Kathryn L. Tsang and Associates
22022 Apache Drive
Lake Forest, CA 92630
(949) 458-6330 Phone
(949) 581-8106 Fax

**FIVE YEAR FOLLOW-UP OF IMT-002 PATIENTS
A LONG-TERM MONITORING STUDY OF IMT-002 PATIENTS**

PROTOCOL IMT-002-LTM

∞ STUDY OUTLINE ∞

BACKGROUND	Protocol IMT-002-LTM is intended to provide an additional 36 months of safety data, for a total of 5 years of follow-up on patients participating in the IMT-002 trial, a 24 month pivotal trial conducted to support a marketing application for the IMT (Premarket Application P050034).
OBJECTIVE	The primary objective of IMT-002 LTM is to monitor the long-term safety of the IMT in patients who participated in the IMT-002 trial, a 24-month clinical trial of patients with bilateral moderate to severe central vision impairment due to age-related macular degeneration.
PATIENT POPULATION	Patients who participated in Protocol IMT-002, approved under G000115.
STUDY DESIGN	<p>This is a 5-year study of patients implanted with the IMT under Protocol IMT-002. All patients implanted with the IMT who completed the IMT-002 trial, approximately 178 patients, will be contacted and asked to participate in this study to monitor the long-term safety of the Implantable Miniature Telescope.</p> <p>Patients will undergo examination at six-month intervals to monitor endothelial cell density, posterior capsular opacification, intraocular pressure, visual acuity, device failures, complications and adverse events.</p>
STUDY PARAMETERS	Endothelial cell density, posterior capsular opacification, intraocular pressure, distance visual acuity, device failures, complications and adverse events.
EXAMINATION SCHEDULE	<p>The examination schedule is as following:</p> <ul style="list-style-type: none">• Six-month anniversaries of IMT implantation through 5 years of post-implant follow-up:<ul style="list-style-type: none">Month 30 –34 (Initial Visit)Month 36 (3 years)Month 42Month 48 (4 years)Month 54Month 60 (5 years)

**CLINICAL
PARAMETERS**

The following clinical parameters will be measured at each visit:

1. Intraocular pressure
2. Slit lamp examination
3. Endothelial cell count (implanted and fellow eyes)
4. Best corrected distance visual acuity (implanted and fellow eyes)
5. Complications and adverse events
6. Device failures

NOTE: All personnel at the study site who participate in the conduct of this study must be trained by the study sponsor, the clinical monitor or their designee on the requirements of the protocol and the testing methods referenced therein. The Study Investigator or their designee familiar with the conduct of the study is expected to train personnel who join the study while it is in progress.

1.0 INTRODUCTION & RATIONALE

MACULAR DYSTROPHIES

Acquired and hereditary macular dystrophies are the leading cause of central vision impairment and blindness. Age related macular degeneration (AMD) is the most common form of macular dystrophy. Macular degeneration refers to the breakdown of cells in the macula (the center of the retina). Some degeneration is an inevitable consequence of the aging process. However, when it is coupled with the loss of sight in the central part of the field of vision, an underlying pathology is considered present. It is estimated that in the US, AMD affects 1% of all 55-year-olds, and the incidence increases with age, reaching approximately 15% among those aged 80 and over (1). With increasing longevity, it is anticipated that the incidence will increase significantly (1).

The main effect of AMD is to reduce the ability of the individual to engage in everyday activities that require clear central vision. It is associated with elevated risk of depression, increased levels of dependency, and an overall decrease in the quality of life (2-4). Currently there is no effective treatment for the majority of patients. For a minority of patients, (i.e., those with wet AMD resulting from choroidal neovascularization (CNV), advances in new therapies have led to improvements in the management of the rate of vision loss. New treatments include photodynamic therapy, trans-pupillary thermal therapy, submacular surgery and photoablation. However, no viable treatments are available for the several hundred thousand individuals with moderate to severe central vision loss due to late stage dry, atrophic AMD, end stage CNV with disciform scar.

The only corrective interventions currently available are low vision aids such as special spectacles and head-mounted or hand-held telescopes, which magnify images onto the retina. These aids are widely available but have only limited acceptance by patients. Patients find these aids bulky, uncomfortable and unattractive. In addition, use of external telescopes requires suppression of natural eye movements. Instead, the patient has to learn to scan the visual field by moving his/her entire head. If not properly adapted to this behavioral change requirement, a conflict between the visual and vestibular systems will arise, resulting in nausea.

**THE
IMPLANTABLE
MINIATURE
TELESCOPE
(IMT)**




Figure 1. The IMT

VisionCare's Implantable Miniature Telescope (IMT™) is an intraocular implant which, when combined with the optics of the cornea, constitutes a telephoto lens (Figure 1). The IMT contains two micro lenses, which magnify objects in the central visual field, allowing the patient to see without the need of external low-vision aids. A magnified image is projected by the IMT onto the retina, enabling the patient to recognize and identify objects that could not otherwise be seen. The IMT provides improved near or distance vision

correction in the same fashion as an external telescope. The optical component is embedded in a carrier, which is intended to be implanted in the capsular bag in the posterior chamber of the eye, in place of the eye's crystalline lens. It is held in position by haptic loops using a surgical procedure similar to that used in refractive cataract surgery.

The IMT is indicated for use in patients with bilateral, stable macular degeneration. Vision loss must be sufficiently advanced to have caused significant or complete loss of normal central vision, but adequate peripheral vision must be retained. The IMT is only implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.

**ADVANTAGE OF
THE IMT OVER
ALTERNATIVE
LOW VISION
TREATMENTS**

The primary advantage of the IMT over alternative treatments for low vision is that the IMT allows scanning of reading materials and other images using natural eye movements, rather than head movements. Since there is no relative movement between the eye and the telescope, there are no optical aberrations and a wider visual field (central field of 20° or more on the retina) is achieved. The placement of the magnifying device entirely inside the eye eliminates increased speed of motion and vestibular conflict.

If there is further deterioration of the macula after the implantation, the amount of magnification can be significantly increased by bringing the object closer to the eye and adding low-plus eyeglasses (+1.00 to +3.2 D). With glasses, up to 8X magnification can be achieved at 18 cm with the Wide Angle (WA) 3.0X IMT.

2.0 STUDY OBJECTIVE

The primary objective of this study is to monitor the long-term safety of the Implantable Miniature Telescope (IMT) in patients with bilateral moderate to severe central vision impairment due to age-related macular degeneration. Data from this study is intended to provide long-term safety information on the IMT.

STUDY DESIGN

IMT-002-LTM is 5-year study designed to generate safety data on patients implanted with IMT who participated in the IMT-002 trial. All IMT-002 patients completing follow-up in the IMT-002 study, i.e., a pool of approximately 178 patients, will be contacted and asked to participate in the IMT-002-LTM study. Participation will require new informed consent form to be signed by IMT-002 patients, since these patients completed and exited the IMT-002 trial.

STUDY PARAMETERS

Endothelial cell density (implanted and fellow eyes)
Slit lamp examination (corneal health and posterior capsular opacification)
Intraocular pressure
Best corrected distance visual acuity (implanted and fellow eyes)
Adverse events and complications

5.0 PATIENT POPULATION

All patients, approximately 178 IMT-002 candidate patients, who have completed the IMT002 trial, will be contacted and asked to participate in the study provided they conform to the following criteria.

- 5.1 INCLUSION CRITERIA**
- A. Patients must have completed participation in the IMT-002 trial.
 - B. Patients must be able to understand and comply with the requirements of the clinical study, and be able to abide by the requirements and restrictions of the study.
 - C. Patients must be able to provide voluntary informed consent, and must sign and be given a copy of the written Informed Consent form.

6.0 INVESTIGATIONAL PROCEDURES

6.1 SUBJECT ENTRY

6.1.1 PATIENT CONTACT

All patients completing the IMT-002 trial will be contacted and asked to participate in the IMT-002-LTM study. Three attempts will be made to contact each study patient, two by phone and one in writing. The Investigator or a designee will explain the study purpose, procedures, and patient responsibilities to the potential participant. The patient's willingness and ability to meet the follow-up requirements will be determined by the investigator or a designee.

6.1.2 INFORMED CONSENT

When it has been established that the patient may be eligible, written informed consent will be obtained (Appendix 1). The patient will sign and date the consent form in the presence of a witness. The Investigator will also sign and date the consent form. One copy of the informed consent form will be retained with the patient records and a copy will be provided to the patient. The patient is now considered enrolled.

PATIENT REFUSAL, PATIENT INABILITY TO PARTICIPATE, OR INABILITY TO CONTACT

If the patient refuses or is unable to participate in the IMT-002-LTM study, the reason for refusal or inability to participate will be documented. Documentation will also be provided for patients who could not be contacted.

6.2 EXAMINATION SCHEDULE

Subjects will be examined and evaluated according to the following schedule of visits:

	(If outside the windows noted below)
> Study entry	
1. 30 to 34 Months	(+/- 3 months)
2. 36 Month	(+/- 3 months)
3. 42 Month	(+/- 3 months)
4. 48 Month	(+/- 3 months)
5. 54 Months	(+/- 3 months)
6. 60 Month	(+/- 3 months)

A full description of the examination schedule and clinical parameters can be found in APPENDIX 2.

NOTE: Follow-up visits from 30 month through 60 months should not occur less than six weeks after the previous visit.

6.3 CLINICAL PARAMETERS

The clinical parameters to be evaluated are:

- Best spectacle-corrected distance acuity, using ETDRS VA charts: all visits (implanted and fellow eyes)
- Intraocular pressure: all visits
- Slit lamp examination: all visits
- Specular microscopy of the central cornea: all visits (implanted and fellow eyes)
- Device failures
- Complications
- Adverse events.

Postoperative visual examinations may be performed by the Investigator, or by ophthalmic technicians, optometrists and/or ophthalmologists under the supervision of the Investigators using methods described in APPENDIX 2. Patients are allowed to utilize low vision counseling and rehabilitation services as needed. (This may not be the right place for this, or we may not need this in the protocol at all. I do want investigators to know that patients can use standard rehab services.)

6.4 DATA COLLECTION AND VALIDATION

A Case Report Form (CRF) booklet will be provided by the Sponsor or its designee for each patient enrolled in the study. A sample Case Report Form may be found in APPENDIX 3. The appropriate Case Report Form will be completed and signed by the Investigator at each examination. All Case Report Forms will be completed in a legible manner in black ink. Any corrections will be made by drawing a single line through the incorrect entry, entering the correct information, and initialing and dating the change. Data entries boxes or spaces should not be left blank, but instead should indicate: NA = not applicable, ND=not done, NE=not evaluable or NAV for missing or not available data. The original signed forms, not copies, will be returned to the Sponsor.

All clinical data generated in the study will be submitted to the Sponsor or its designee for quality assurance review, data entry, and statistical analysis. All forms will be reviewed for completeness and evident recording errors will be rectified by contact with the appropriate clinical site. Double-entry routines will be utilized to reduce data entry errors, and computerized editing routines will be used to identify unusual data entries for verification prior to statistical analysis. The database will be equivalent to that used for the IMT-002 trial, a validated database, which contained data for the Sponsor's PMA, M050004. Study data will be maintained on a secure computer with appropriate data security provisions.

6.5 STUDY COMPLETION PROCEDURES

6.5.1 PATIENT COMPLETION

Patients are considered to have completed the study if they have completed all follow-up examinations through 5 years post IMT implantation.

6.5.2 PATIENT TERMINATION

Patients may be terminated from the study at the discretion of the Investigator only if continuation would jeopardize the patients' health and/or welfare. Terminated patients will be considered to have completed the study. Every effort will be made to follow terminated patients for safety reasons using the appropriate case report forms until the planned end of the study period. NOTIFICATION OF A PATIENT TERMINATION WILL BE MADE IMMEDIATELY TO THE SPONSOR OR ITS DESIGNEE.

6.5.3 PATIENT EXIT

A patient exit form must be completed for all patients who either complete, discontinue, are considered lost to follow-up, or are terminated from the study. Before a patient is considered "lost to follow-up", there should be three documented attempts to reach patients. At least one of these attempts must be in writing by certified / return receipt mail, a copy of which should be included in the patient's medical / clinic chart.

7.0 STATISTICAL METHODS, REPORTING, DATA COLLECTION, DATA VALIDATION

7.1.1 STATISTICAL METHODS

Due to the observational, non-comparative nature of this study, the primary statistical analysis will be based on descriptive statistical techniques using 95% confidence intervals.

REPORTING

Planned analyses will be performed as follows:

Slit lamp findings

Endothelial cell density (ECD)

Endothelial cell density (ECD)

Change in endothelial cell density (ECD) from baseline

Percent change in endothelial cell density (ECD) from baseline

Change in ECD between consecutive postoperative visits

Percent change in ECD between consecutive postoperative visits

**Percent change in ECD between consecutive postoperative visits
pseudophakic fellow eyes of subject implanted with IMT**

Adverse events and complications

Posterior capsular opacification
Intraocular pressure
Ocular complications
Ocular adverse events

Distance visual acuity

Change in best corrected distance visual acuity stratified by IMT model and visit

8.0 ADVERSE EXPERIENCES REPORTING / DEVICE MALFUNCTIONS

8.1 ADVERSE EXPERIENCES

Throughout the course of the proposed study, all efforts will be made to remain alert to possible adverse experiences or untoward findings. If adverse experiences occur, the first concern will be the safety and welfare of the patient. Appropriate medical intervention will be made. Any adverse experiences or complications observed by the Investigator or reported by the patients, whether or not ascribed to the IMT, will be recorded in the appropriate section of the patient's Case Report Form.

ANY SERIOUS ADVERSE EXPERIENCES AND UNANTICIPATED, SEVERE, SIGHT-THREATENING ADVERSE REACTIONS, WHETHER OR NOT ASCRIBED TO THE IMT, WILL BE COMMUNICATED PROMPTLY, BY TELEPHONE, TO THE SPONSOR AND TO THE IRB. THESE REPORTS MUST BE CONFIRMED IN WRITING WITHIN FIVE DAYS OF THE OCCURRENCE. Any patients who are terminated from the study due to adverse experiences will be followed until their medical outcome is determined, and written reports will be provided to VisionCare Ophthalmic Technologies by the investigator.

Below is a list of potential or anticipated Adverse Events based on prior IMT clinical trials or known to be occasionally associated with similar types of anterior segment surgery. This list should not be considered comprehensive, but rather identifies events which can be reasonably anticipated.

Table 1 – Adverse Events

4.	Anterior chamber inflammation
5.	Choroidal detachment
6.	Choroidal neovascularization
7.	Choroidal hemorrhage
8.	Corneal decompensation
9.	Corneal edema
10.	Corneal transplant
11.	Cyclitic membrane
12.	Diplopia
13.	Distorted pupil
14.	Endophthalmitis
15.	Flat anterior chamber
16.	Hyphema
17.	Hypotony
18.	Hypopyon
19.	IMT dislocation
20.	IMT repositioning
21.	IMT removal
22.	Increased IOP requiring treatment
23.	Iridotomy
24.	Iris atrophy
25.	Iris damage
26.	Iris prolapse
27.	Iris transillumination
28.	Iritis
29.	Optic atrophy
30.	Precipitates or deposits on IMT
31.	Pupillary block
32.	Retinal detachment
33.	Retinal vascular occlusion
34.	Subretinal hemorrhage
35.	Synechiae
36.	Uveitis/Vitritis
37.	Vitreotomy/vitreous aspiration
38.	Vitreous hemorrhage
39.	Vitreous in anterior chamber
40.	Zonular dehiscence

DEVICE MALFUNCTIONS

A device malfunction is defined as a failure of the IMT to meet its performance specifications or otherwise perform as intended. Performance specifications include all claims made in this protocol or the product associated labeling.

All device malfunctions will be recorded in the appropriate field on the patient Case Report Forms.

9.0 MONITORING

Sponsor personnel or their designee will monitor all clinical studies in a manner consistent with applicable health authority regulations and the clinical research standards adopted by the Sponsor. Study monitoring will involve the following elements:

1. Sponsor personnel or designee may meet with Investigators prior to the initiation of the study in order to review the available patient population, facilities, and equipment with respect to the needs of the study, and to familiarize the Investigator with the study protocol.
2. Sponsor personnel or designee may meet with the Investigator(s) at the time study patients begin to be enrolled in order to ensure that patients are being properly recruited and that study data are being correctly recorded.
3. Sponsor personnel or designee may visit the clinical site at any time during the study to review and/or collect the Case Report Forms.
4. Interim monitoring visits and telephone consultation will occur as necessary during the course of the study to ensure the proper progress and documentation of the study findings.

APPENDIX 1 SUBJECT CONSENT FORM

VISIONCARE OPHTHALMIC TECHNOLOGIES, INC.

**FIVE YEAR FOLLOW-UP OF IMT-002 PATIENTS
A LONG-TERM MONITORING STUDY OF IMT-002 PATIENTS**

PROTOCOL IMT-002 LTM

1. PARTICIPANT'S NAME: _____

2. PURPOSE OF PROJECT:

You have been invited to participate in a research study sponsored by VisionCare Ophthalmic Technologies, Inc. (the study Sponsor) and

Dr. _____, the study Investigator.

The purpose of this study is to monitor the long-term safety of the Sponsor's Implantable Miniature Telescope (IMT™) for implantation in patients with age-related macular degeneration (AMD) who participated in the sponsor's IMT002 clinical trial. You are a candidate for this study because you participated in the IMT002 trial. You are being asked to participate in this study in order to obtain long-term data on the IMT device implanted in one of your eyes in the IMT002 clinical trial. You will be asked to visit your physician for eye examinations every 6 months for the next 3 years.

D. DESCRIPTION OF RESEARCH:

The study you are being asked to participate in is a long-term monitoring study for patients who participated in the IMT002 clinical trial. This study will last approximately 3 years and will involve visits to your eye doctor's office every 6 months until you reach the 5 year anniversary of the date you had surgery for the IMT device.

The first step in this study is to determine whether you are able to participate in this trial. This will be accomplished by answering several questions to make sure that

you understand the study requirements and can communicate clearly to the study personnel.

You will need to return for examinations on or around Months 30 to 36 (3 years), 42 (3 ½ years), 48 (4 years), 54 (4 ½ years), and 60 (5 years) from the original date of your IMT implantation surgery. At the follow-up examinations, some of the same testing that was performed in the IMT-002 trial will be repeated in order to evaluate changes in your vision and the condition of your eyes. This testing includes an eye examination using a slit lamp, intraocular pressure, distance visual acuity testing with an eye chart, and measuring the number of cells on the inside of your cornea using a non-contact specular microscope. All of the testing that will be performed on your eyes is the same as the testing that was done while you were participating in the original study of the IMT, but fewer tests will be performed.

4. RISKS

There are no new risks to you related to participating in the long-term follow-up study of the IMT. All of the risks associated with the IMT and the surgery to implant the IMT were discussed with you when you decided to enroll in the IMT clinical study. Those risks and any problems you may be having with the IMT will be evaluated during this longer-term follow-up study that you have been asked to participate in.

5. POTENTIAL BENEFITS

The potential benefit to you of participating in this research study is that you will have continued examination of your eyes to determine if you are having any problems with your IMT. This study will also provide needed information on the long-term safety of the IMT.

6. ALTERNATIVE TREATMENTS

Since you already have the IMT implanted in your eye, alternative treatments are not applicable to your situation.

7. CONFIDENTIALITY AND PATIENT AUTHORIZATION

You should understand that your medical records pertaining to participation in this study will be made available for review by your doctor to the Sponsor of the study and to governmental agencies such as the U.S. Food and Drug Administration (FDA). You should also understand that the information in these records will be kept confidential, but, that on rare occasions, disclosure to third parties may be required by law. By signing this form, you authorize access to your study related medical records by the US FDA and other governmental agencies.

You agree that results of your surgery and photographs of your eyes made as part of the study may be published for scientific purposes provided your identity is not revealed. Results of this study may be presented at scientific meetings and published in journals, however, no names will be used in any data summaries or publications and all medical data will be protected.

8. COMPENSATION FOR INJURY

You will not be compensated for participation in this study.

You will not receive a bill or be asked to pay for the cost of the study examinations. The study sponsor will cover the costs of testing performed specifically for the study. If a research-related illness or injury occurs at any time during the study, you will receive medical care at _____ Hospital under the supervision of the study Investigator. Any costs for the treatment of research related adverse events not covered by insurance will be paid for or reimbursed by the Sponsor. You will not be compensated monetarily by the study Sponsor, the hospital or other institution, or the study Investigator for lost wages, disability, or discomfort resulting from this type of illness or injury. You should understand that treatment, payment, or enrollment in a health plan or eligibility for benefits is not contingent upon signing this form.

9. VOLUNTARY PARTICIPATION

You should understand that your participation in this study is completely voluntary and that you may withdraw from the study at any time without prejudice to your future medical care. Should you decide to withdraw from the study for any reason, you should contact the Investigator immediately. You may be discontinued from the study at any time if the Investigator considers it to be in your best medical interest. Should your participation in the study be terminated, regardless of the reason, you will not suffer any penalties or loss of benefits to which you are otherwise entitled.

You will be informed of any significant information regarding new findings that may develop during the course of the research study that may relate to your willingness to continue participating as a subject in the study.

10. CONTACT PERSON

If, at any time, you have questions regarding your participation in this study, you can call Dr. _____, your study Investigator, at: (____) _____.

11. CONSENT

I have been given an opportunity to ask any questions concerning the research, and my participation, and the study Investigator has answered my questions. By signing this consent form I understand that I have not waived any of my legal rights.

I understand that I will receive a copy of this consent and authorization form, which will show all signatures and dates.

I hereby willingly give my consent to participate in the above-described clinical study.

Patient Signature _____ Date: _____

Printed Name of Patient _____

Witness Signature _____ Date: _____

I have discussed this research study with the patient using language that is understandable and appropriate. I believe that I have fully informed this patient of the nature of this study, and its possible benefits and risks, and I believe the patient understood this explanation.

Investigator Signature _____ Date: _____

APPENDIX 2 STUDY EXAMINATIONS : SCHEDULE & METHODS

APPENDIX 2
CONTENTS

APPENDIX 2.1	EXAMINATION SCHEDULE & CLINICAL PARAMETERS.....	20
APPENDIX 2.2	BCVA TEST PROTOCOL.....	21
APPENDIX 2.3	SPECULAR MICROSCOPY.....	28

APPENDIX 2.1
 EXAMINATION SCHEDULE AND CLINICAL PARAMETERS

TABLE 1. SCHEDULE OF EXAMS AND CLINICAL PARAMETERS

EXAM / TEST	VISIT						
	STUDY ENTRY VISIT IF PATIENT IS OUT OF CYCLE						
		30 months	36 months	42 months	48 months	54 months	60 months
DISTANCE BEST CORRECTED VISUAL ACUITY (BOTH EYES)	✓	✓	✓	✓	✓	✓	✓
IOP	✓	✓	✓	✓	✓	✓	✓
SLIT LAMP EXAM	✓	✓	✓	✓	✓	✓	✓
SPECULAR MICROSCOPY (BOTH EYES)	✓	✓	✓	✓	✓	✓	✓
DEVICE FAILURES	✓	✓	✓	✓	✓	✓	✓
COMPLICATIONS	✓	✓	✓	✓	✓	✓	✓
ADVERSE EVENTS	✓	✓	✓	✓	✓	✓	✓

APPENDIX 2.2

BCVA TESTING PROTOCOL

PLEASE ADD THE REFRACTION PROTOCOL BACK TO THIS DOCUMENT – YOU CAN'T DO A BCVA WITHOUT A REFRACTION

⌘ INTRODUCTION & SCOPE ⌘

Visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A set of two of these charts (Lighthouse Chart C-110 and C-105 respectively, which have different letter sequences or Precision Vision Chart R (Catalog #2110), Chart 1 (Catalog #2111) and Chart 2 (Catalog #2112) and a retro-illuminated box providing standardized chart illumination¹ will be used to determine visual acuity.

Distance visual acuity testing will be performed at a distance of 2 meters (or at 1 meter for patients who are unable to read 20 letters of the first four lines of the chart at 2 meters).

FACILITIES & MATERIALS

VISUAL ACUITY CHARTS

Charts 1 and 2 are used for testing visual acuity. Chart R is used for refraction. The ETDRS charts consist of 14 lines of 5 high-contrast Sloan letters of equal difficulty and geometric progression of letter size with results in an arithmetic progression of the logarithm of minimum angle of resolution from line to line. Charts 1, 2 and R have different letter sequences. Patients should be prevented from seeing Charts 1 and 2 until refraction has been completed and the visual acuity test begins.

VISUAL ACUITY BOX

The dimensions of the light box are 24-3/4 inches (62.9 cm) by 25-3/4 inches (65.4 cm) by 7 inches (17.8 cm). The light box should be mounted on the wall or on a cylindrical stand manufactured by the Lighthouse Low Vision Services (L-225). The stand is mounted on a five-pronged wheelbase, with each prong about 14 inches (35.6 cm) long. Two of the five wheels are lockable. When the box is mounted on the stand, its height can be varied. The light box should be mounted at a height such that the top of the third row of letters (0.8 log MAR) is 49 ± 2 inches (124.5 cm \pm 5 cm) from the floor.

RETRO ILLUMINATED BOX

The room lights should be turned off during the visual acuity test. The box itself provides sufficient illumination for the examiner to record the results. Additional light can have an adverse effect. With the box light off, not more than 15 foot candles (161.4 candela/m²) of light should fall on the center of the chart. The luminance of the ETDRS VA chart in the plane of the entrance pupil of the eye to be tested should be within 10% of 160

¹ manufactured by Lighthouse Low Vision Products (L-220)

candelas per square meter (cd/m^2 or nits). A photometer should be used for primary calibration. A secondary measuring device, a simple light meter, is calibrated to match the primary determination, and is then used for day-to-day calibration of the VA chart. This meter is placed against the surface of the transilluminated EDTRS chart at a predetermined and constant location. The calibration value is marked on the meter (e.g., an arrow, line, etc.) Luminous emittance of the light box containing the EDTRS chart is then adjusted to this predetermined level. (This secondary reference standard technique is similar to that used on the Goldmann Haag-Streit perimeter.)

The visual acuity light box is equipped with two 20-watt fluorescent tubes and ballast. The Sponsor recommends these lights be changed out for new bulbs at the start of the IMT-002 Study and at least yearly thereafter or in the event of a bulb failure. At the beginning of each examination, proper functioning of the two fluorescent tubes should be verified.

ROOM FOR VISION TESTING

The room for visual acuity testing must have space for a 2 meter (78.7 inches) lane, the visual acuity box, the stand, and the participant. The lane represents a distance of exactly 2 meters between the patient's eyes and the visual acuity chart. In addition to the 2 meter lane, 13 inches (33 cm) must be allowed for two of the stand's castors to touch the rear wall (or a line marked on the floor when there is no wall) plus space for the patient to sit.

Low level, ambient, indirect room illumination should be at a level of 10-12 cd/m^2 or less as measured with the photometer at the patient's eye. Not more than 15 foot-candles of light should fall on the center of the chart. No specular reflection from the chart surface directed towards the patient's eyes is permitted. This is determined with transillumination of the chart turned off and ambient light on.

MARKING THE 1 METER (39.7 INCHES) AND 2 METER (78.9 INCHES) DISTANCES

Floor marks cannot be used reliably to mark either the 1 or 2 meter distances. The horizontal distance between the patient's eye and the chart must be measured individually for each examination. The distance is best measured with one and two meter sticks or a measured non-elastic string from the eye of the patient, who is comfortably seated in a chair with his or her back firmly placed against the chair's back, to the center of the second letter (for left eye) or fourth letter (for right eye) of the third line of the chart.

PROCEDURES

All measurements should be obtained by a physician, optometrist or trained technician supervised directly by the physician or optometrist, before the patient's pupils have been dilated.

TESTING BEST CORRECTED VISUAL ACUITY

TESTING DISTANCE

Visual acuity testing is performed at a distance of 2 meters for all patients, including those who could not be refracted at the two-meter distance. Visual acuity is tested at 1 meter only if the number of letters read correctly at 2 meters is less than 20.

The distance from the patient's eyes to the visual acuity chart must be exactly 2 meters. The patient must sit for the 2 meter visual acuity test. His or her back should be firmly touching the back of the chair. The examiner should ensure that the participant is sitting comfortably, that the head does not move forward or backward during the test, and that the participant's eyes remain at the 2 meter distance.

USING THE ETDRS CHART

First, non-implanted eye after surgery and then IMT implanted eye is tested. All visual acuities will be evaluated with the subject's eyes in the straight-ahead, primary position of gaze. This will help to assure that visual acuity in the non-implanted eye is measured without the use of peripheral vision. The IMT implanted eye will have no peripheral vision, but for reasons of consistency should be conducted in the same manner.

TESTING PRINCIPLES

- As previously mentioned, room lights should be turned off during visual acuity testing. The retro-illuminated box will provide sufficient light for the examiner to record results of the test.
- The patient should be told that the chart has letters only and no numbers. If the patient forgets this instruction and reads a number, he or she should be reminded that the chart contains no numbers and the examiner should request a letter in lieu of the number. Examiners should point to the chart and to specific letters on the chart. Examiners should never read any of the letters during the test.
- Because each letter will be scored, the patient should be asked to read slowly (at a rate not faster than about one letter per second) in order to achieve the best identification of each letter. The examiner should not proceed with the next letter or line of letters until the patient has given a definitive answer for each letter. It may be useful for the examiner to demonstrate the letter-a-second pace by reciting "A, B, C." If, at any point, the participant reads too quickly, he or she should be asked to stop and read slowly.

- Each participant will be encouraged to read the letters on the chart as they become smaller and more difficult to read. Each time a participant says he/she cannot read a letter, the examiner will encourage him/her to figure letters but not to randomly guess at them. If the participant identifies a letter as one of two or more letters, he/she should be asked to choose one only. The examiner should remind the participant to blink normally during all testing. All visual acuities are to be evaluated with the patient's eyes in the straight-ahead, primary position of gaze. The testing and recording of answers will continue until the patient states that he/she can no longer read or figure out the letters. The examiner may stop the test at this point provided that the patient has previously made some errors that indicate that the best possible acuity level has been reached. Patients are encouraged to make a best possible choice for several reasons: 1) statements that they cannot identify a letter are often unreliable, and 2) bias may be reduced when effort is maximized through guessing. Furthermore, inter-center variability of visual acuity measurement is minimized when uniform instructions for testing are employed.
- Where a wrong answer is given, have the patient proceed with the next letter, but re-evaluate the "wrong" letter again after completing the line. If patient loses their place, he/she should be asked to go back to the top line, and start again, reading only the first or last letter in the line for those lines which were complete, once the missed line is reached, continue with standard examination. This procedure, called the First Letter Technique is used in all examinations with low vision charts, also during rehabilitation.

SCORING

The examiner records each letter identified correctly by circling the corresponding letters on the Visual Acuity Form. Letters read incorrectly and letters for which no guesses are made are not marked on the form. Each letter read correctly is scored as one point. The score for each line (which is zero if no letters are read correctly) and the total score for each eye is recorded on the Visual Acuity Form after testing is completed.

SCORING FOR 2 METER TESTING

If testing at 1 meter is not required, 15 points are automatically scored for the 1-meter test. The total combined score (i.e., the sum of the 2 meter and the 15 points awarded for the 1 meter test) is recorded on the Visual Acuity Form.

SCORING FOR 1 METER TESTING

Eyes reading less than 20 letters correctly at 2 meters should be tested at 1 meter. Both the 2 and 1 meter totals should be recorded on the Visual Acuity Form. If the trial frame is to be removed when changing the test distance from 2 meters to 1 meter, the testing chart should first be removed from view to prevent the participant from reading the chart with the fellow eye.

Before testing at 1 meter, a +0.50 sphere should be added to the 2-meter correction already in the trial frame to compensate for the closer testing distance. The participant must sit for the 1-meter test. The avoidance of any head movement forward or backward is particularly important during the 1-meter test.

NOTE: The above Refraction and BCVA Testing Protocol represents a modified version of one published by Lighthouse. The calibration requirements outlined involving a photometer are encouraged if the device is available, but is NOT required as part of the IMT-002-LTM Study. The Sponsor does encourage the site to periodically confirm the luminance quality with the use of a standard light meter.

Appendix 2.3 SPECULAR MICROSCOPY

The main safety concern to be addressed by specular microscopy is the possibility of a chronic loss of endothelial cell density, which, even at a low yearly rate could, over time, lead to corneal edema and decompensation.

To determine endothelial cell density loss, specular microscopy will be performed at all scheduled examinations, i.e., month 30, 36, 42, 48, 54, and 60.

Analyses of specular microscopy data will include the determination of the mean cell density loss over time and a frequency distribution. The mean rate of cell density loss will be calculated via a paired analysis in order to calculate the mean of the differences.

Collection of data

The methods used for the collection and analysis of specular microscopy data are critically important to minimizing the variability associated with these measurements. Common sources of variability in specular microscopy are:

- 3.0 difficulty in returning to same location on the cornea at each visit;
- 4.0 poor image quality (less than 100 countable cells);
- 5.0 technician error; and
- 6.0 improper reader analysis.

To address differences in location of the image within a given area of the cornea, three acceptable images should be taken at each visit. The mean density from the three images should be used.

Problems due to poor image quality and/or technician error will be ameliorated by using appropriate equipment and trained, experienced clinical sites equipped with non-contact specular microscopes. Images will be stored on 35 mm slides, half-inch video, or in electronic format such as CD's, floppy disks and/or zip drives. Sites may also produce high quality photographic images which can be electronically scanned and digitized.

Specular cameras that can record digitized images on disk are preferable for ease of data transfer.

Prior to the beginning of the study, each site will be required to take an initial set of images for an evaluation of image quality. Training (or retraining) will be performed as necessary and include the following important points:

An acceptable image has:

- distinct cells;
- maximum identifiable (countable) cells, >75 cells preferred; and
- cells that can be grouped in a uniform area.

To capture a good image:

- make sure the patient is comfortable;
- instruct the patient to blink;
- instruct patient not to move and to open eyes wide;
- instruct patient to focus straight ahead or on the green light;
- be patient; and
- if necessary, use the manual setting. (Note that the use of the manual setting may require additional training.)

A central reading center will be retained for both grading the quality of specular micrographs and for analyzing the specular images. The reading center or technician performing the image analysis will be advised of the following:

- The center method for counting cells is recommended.
- The quality of cells in an image is critical. Since the presence of disease can increase variability (e.g., polymegathism/pleomorphism post-contact lens wear, keratoconus), the area with the fewest distortions (not in shadow, washed-out, or blurred) should be used for the image analysis.

SPECULAR MICROSCOPY PROCEDURE A non-contact specular microscope will be used at each site.
The mean density from three images of the same location of the cornea will be made.

ENDOTHELIAL IMAGE PHOTOGRAPHY

- The location to be photographed is selected by clicking on the mark that indicates the location of the fixation target. An image will be taken of the central cornea.
- Patients will be asked to place their chin on the left chin rest for photography of the right eye and on the right chin rest for photography of the left eye. Adjust the height of the chin rest so that an image of the patient's eye can be seen on the monitor screen with the pupil in the approximate center of the screen. The patient is asked to stare at the fixation target, or straight ahead if unable to see the target, until an image is photographed.
- An endothelial image is recorded by clicking on the appropriate indicator button on the instrument. The instrument aligns, focuses and takes the endothelial photograph automatically and the endothelial image will appear on the screen immediately.
- All endothelial images will be recorded and sent to DataMed Devices for archiving before being sent to the specular microscopy reading center for image analysis.

Appendix 3

CASE REPORT FORM

Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT-002-LTM

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

POSTOPERATIVE REPORT

Page 1 of 3

30 Months 36 Months 42 Months 48 Months 54 Months 60 Months

Interim, reason: _____

Check if patient is unavailable for this scheduled examination but continuing in study. Submit form and mark (not available) NAV. Reason: _____

1. Manifest Refraction: (indicate + or - sphere and - cylinder)

OD			OS		
<input type="checkbox"/> +/-	<input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>	<input type="checkbox"/> +/-	<input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>
	Sphere	Cylinder	Axis	Sphere	Cylinder
			Axis		Axis

2. Distance Best Corrected Visual Acuity* (ETDRS):

	OD	OS
Distance chart used: (check 1)	<input type="checkbox"/> 1m <input type="checkbox"/> 2m	<input type="checkbox"/> 1m <input type="checkbox"/> 2m
Logmar:	<input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> <input type="text"/>

(Please submit visual acuity worksheet with completed CRFs)

3. Slit Lamp Examination:

Slit Lamp Examination:

Cornea:

- 1 Normal
- 2 1 + Edema
- 3 2 + Edema
- 4 3 + Edema
- 5 4 + Edema

Endothelium:

- 1 Normal
- 2 1 + Folds
- 3 2 + Folds
- 4 3 + Folds
- 5 Keratic precipitates
- 6 Guttata

Anterior Chamber:

Cells

- 1 Normal
- 2 Trace (0-5 cells)
- 3 6-10 cells
- 4 11-20 cells
- 5 21-50 cells
- 6 >50 cells

Flare

- 1 None
- 2 Trace
- 3 Moderate
- 4 Marked
- 5 Severe
- 6 Other (specify): _____

Iris:

- 1 Normal
- 2 Fibrin deposits
- 3 Other (specify)

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor

Site No.:

Patient Initials:

Investigator No.:

Patient No.:

Protocol: IMT- 002-LTM

Date of Exam: M D Y

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

5. Intraocular Pressure: OD mmHg OS mmHg

6. Posterior Capsular Opacification: (check one)

None Minimal Opacity Moderate Opacity Dense Opacity

7. IMT Positioning: (check each that applies)

Centered
 Tilted
 Malpositioned (specify) _____

8. Specular Microscopy Images - obtain for both eyes - Yes No

9. Secondary Surgical Intervention: Yes No If yes, Complete Adverse Event Form

10. Adverse Events: Yes No If yes, Complete Adverse Event Form

- | | |
|--|--|
| <input type="checkbox"/> Anterior chamber inflammation | <input type="checkbox"/> Iridotomy |
| <input type="checkbox"/> Choroidal detachment | <input type="checkbox"/> Iris atrophy |
| <input type="checkbox"/> Choroidal hemorrhage | <input type="checkbox"/> Iris damage |
| <input type="checkbox"/> Choroidal neovascularization | <input type="checkbox"/> Iris prolapse |
| <input type="checkbox"/> Corneal decompensation | <input type="checkbox"/> Iritis |
| <input type="checkbox"/> Corneal edema | <input type="checkbox"/> Iris transillumination defect |
| <input type="checkbox"/> Corneal transplant | <input type="checkbox"/> Optic atrophy |
| <input type="checkbox"/> Cyclitic membrane | <input type="checkbox"/> Precipitates or deposits on IMT |
| <input type="checkbox"/> Diplopia | <input type="checkbox"/> Pupillary block |
| <input type="checkbox"/> Distorted pupil | <input type="checkbox"/> Retinal detachment |
| <input type="checkbox"/> Endophthalmitis | <input type="checkbox"/> Retinal vascular occlusion |
| <input type="checkbox"/> Flat anterior chamber | <input type="checkbox"/> Subretinal hemorrhage |
| <input type="checkbox"/> Hyphema | <input type="checkbox"/> Synechiae |
| <input type="checkbox"/> Hypotony | <input type="checkbox"/> Treatment of PCO (Nd:YAG, Needling) |
| <input type="checkbox"/> Hypopyon | <input type="checkbox"/> Uveitis/Vitritis |
| <input type="checkbox"/> IMT dislocation | <input type="checkbox"/> Vitrectomy/vitreous aspiration |
| <input type="checkbox"/> IMT repositioning | <input type="checkbox"/> Vitreous hemorrhage |
| <input type="checkbox"/> IMT removal | <input type="checkbox"/> Vitreous in anterior chamber |
| <input type="checkbox"/> Increased IOP requiring treatment | <input type="checkbox"/> Zonular dehiscence |

Other: Specify _____

Investigator's Signature: _____ Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor



Site No.: [][][]

Patient Initials: [][][]

Investigator No.: [][]

Patient No.: [][][]

Protocol: IMT-002 - LTM

Date of Exam: M [][] D [][] Y [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

EXIT FORM

Page 1 of 1

1. Date of Subject Exit: M [][] D [][] Y [][]

2. Outcome: (mark one) Completed Terminated Discontinued

Termination: Subject's participation in the study ended for reasons related to the IMT.
Discontinuation: Subject's participation in the study ended for reasons unrelated to the IMT (e.g., non-compliance, voluntary withdrawal, etc.).

3. Reason for Termination/Discontinuation: (check one)

Explain as Needed:

- 1 Due to non-study-related medical reasons (other than Adverse Events)
2 Voluntary withdrawals
3 Due to inability to continue (e.g., moved, personal, etc.)
4 Due to improper entry of subject (e.g., did not meet entry criteria)
5 Adverse Event (AE); please specify:
Date of AE onset: D [][] M [][] Y [][]
6 Lost to follow-up
7 Death
8 Other

Horizontal lines for explaining reasons for termination/discontinuation.

4. Who Terminated/Discontinued subject: (check one)

- Patient
Investigator
Sponsor

5. Were any secondary surgical interventions performed on the subject's study eye due to an adverse event?

No Yes If Yes, specify:

Procedure:
Horizontal lines for specifying procedure.

Date Performed:
Horizontal lines for specifying date.

Investigator's Signature: _____

Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor



Site No.: [][] Patient Initials: [][]

Investigator No.: [][] Patient No.: [][]

Protocol: IMT-002 - LTM

Date of Exam: M [][] D [][] Y [][] Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

ADVERSE EVENT FORM

Page 1 of 1

1. Date of Adverse Event Onset: M [][] D [][] Y [][]

2. Eye Affected: OD OS OU

3. Adverse Events: Yes No

- Anterior chamber inflammation, Choroidal detachment, Choroidal hemorrhage, Choroidal neovascularization, Corneal decompensation, Corneal edema, Corneal transplant, Cyclitic membrane, Diplopia, Distorted pupil, Endophthalmitis, Flat anterior chamber, Hyphema, Hypotony, Hypopyon, IMT dislocation, IMT repositioning, IMT removal, Increased IOP requiring treatment, Iridotomy, Iris atrophy, Iris damage, Iris prolapse, Iritis, Iris transillumination defect, Optic atrophy, Precipitates or deposits on IMT, Pupillary block, Retinal detachment, Retinal vascular occlusion, Subretinal hemorrhage, Synechiae, Treatment of PCO (Nd:YAG, Needling), Uveitis/Vitritis, Vitrectomy/vitreous aspiration, Vitreous hemorrhage, Vitreous in anterior chamber, Zonular dehiscence

Other: Specify _____

5. Severity of Adverse Event at Follow-up: (check one)
 1 Mild 2 Moderate 3 Severe

6. Additional Treatment of Adverse Event: (describe all)

Yes No
Surgical If Yes, specify: _____
Medical If Yes, specify: _____

7. Prognosis: (check one)
 1 Excellent 2 Good 3 Fair 4 Poor

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor



Site No.: [][] [][]

Patient Initials: [][] [][]

Investigator No.: [][] [][]

Patient No.: [][][] [][][]

Protocol: IMT- 002 - LTM

Date of Exam: M [][] [][] D [][] [][] Y [][] [][]

Operative Eye: OD OS

ALL ITEMS MUST BE COMPLETED. MISSING OR INCORRECTLY COMPLETED ITEMS WILL REQUIRE ADDITIONAL FOLLOW-UP.

8. Outcome: (current status of patient)

- Event resolved with no sequelae (Date of Resolution): M [][][][] [][][][] [][][][]
- Event resolved with sequelae (Date of Resolution): M [][][][] [][][][] [][][][]
- Event unresolved (If event unresolved, complete AR Follow-up Form)

9. Relationship of adverse event to IMT, in the opinion of the investigator:

- Not related
- Unlikely to be related
- Possibly related
- Probably related
- Definitely related

Comments: _____

Investigator's Signature: _____

Date: _____

White: Sponsor Pink: Investigator's Copy Yellow: Sponsor

ATTACHMENT 6

**LIST OF CLINICAL INVESTIGATORS
FOR PROTOCOL IMT-002-LTM**

**List of Investigators for
Protocol IMT-002-LTM**

Telephone

Altos Eye Physicians

762 Altos Oaks Drive, Suite 1
Los Altos, CA 94024

Chang, David, MD - Investigator/Surgeon (650) 948-9123

Associated Eye Care

2950 Curve Crest Blvd
Stillwater, MN 55082

Lane, Stephen S., MD - Principal Investigator (651) 439-8500

Associated Retinal Consultants

Beaumont Hospital Research Institute

3811 W. 13 Mile Road
Royal Oak, MI 48073

Trese, Michael T., MD - Investigator (248) 288-2280

Discover Vision Centers

4741 South Cochise Drive
Independence, MO 64055

Dehning, Doug, MD - Investigator (816) 478-1230

Doheny Retina Institute

University of Southern California
1450 San Pablo Street, DEI 3615
Los Angeles, CA 90033

Sadda, Srinivas Reddy, MD - Principal Investigator (323) 442-6503

Duke University Eye Center

2351 Erwin Road
Box 3802, Erwin Road, Room 304
Durham, NC 27710

Sharon Fekrat, MD - Principal Investigator (919) 681-0341

Emory Eye Center

1365B Clifton Road, N.E., Suite 2600
Atlanta, GA 30322

Stulting, R. Doyle, MD - Investigator (404) 250-9700

Fine, Hoffman & Packer

1550 Oak Street, Suite 5
Eugene, OR 97401

Fine, Howard, MD - Principal Investigator (541) 687-2110

Hoffman, Richard, MD - Co-Investigator (541) 687-2110

Packer, Mark, MD - Co-Investigator (541) 687-2110

Johns Hopkins University

Lions Vision Research
550 N. Broadway, 6th Floor
Baltimore, MD 21205

Schein, Oliver D. MD - Principal Investigator (410) 955-8179

Massachusetts Eye & Ear Infirmary

Schepens Eye Research Institute
243 Charles St., Suite 808
Boston, MA 02114

Miller, Joan, MD - Co-Investigator	(617) 573-3915
Colby, Kathryn, MD - Co-Investigator/Surgeon	(617) 573-5537
McGee, Dean A. Eye Institute	
608 Stanton L. Young Blvd, Suite 554	
Oklahoma City, OK 73104	
Leonard, Robert, MD - Principal Investigator	(405) 271-1692
Medical Center Ophthalmology Associates	
9157 Heubner Road	
San Antonio, Texas 78240	
Fisher, Steven MD - Principal Investigator	(210) 697-2004
OCB Boston	
50 Staniford Street, Suite 600	
Boston, MA 02114	
Heier, Jeffrey S, MD - Principal Investigator	(617) 314-2611
Paducah Retinal Center	
1900 Broadway, Suite 2	
Paducah, KY 42001	
Baker, Carl W., MD - Investigator	(270) 443-4393
Retina Associates of Cleveland	
3401 Enterprise Parkway, Suite 300	
Beachwood, OH 44122	
Singerman, Lawrence J., MD - Principal Investigator	(216) 831-5700
Retina Centers, P.C.	
6585 N. Oracle Road, Suite A	
Tucson, AZ 85704	
Hudson, Henry, MD - Principal Investigator	(520) 742-7444
Retina Group of Washington	
5454 Wisconsin Avenue, Suite 1540	
Chevy Chase, MD 20815	
Berinstein, Daniel, MD - Principal Investigator	(301) 656-8100
Sarasota Retinal Institute	
3400 Bee Ridge Road, Suite 200	
Sarasota, FL 34239	
Wong, Keye, MD - Principal Investigator/Admin	(941) 921-5335
South East Clinical Research	
6035 Fairview Road, 4th Floor	
Charlotte, NC 28210	
Stewart, Donald, Dr. - PI/Surgeon	(704) 295-3552
University of California - Irvine	
118 Med Surge I	
Irvine, CA 92697	
101 The City Drive South, Bldg 10, Room 210	
Orange, CA 92868	
Kuppermann, Baruch D., MD - Principal Investigator	(949) 824-6256
University of Michigan	
W.K. Kellogg Eye Center	
1000 Wall Street	
Ann Arbor, MI 48105	
Lichter, Paul R., MN - Principal Investigator	(734) 764-6468
Vanderbilt University	
Department of Ophthalmology & Visual Sciences	
Clinical Trials Unit	
8019B Medical Center East	

Nashville, TN 37232	
Sternberg, Paul, MD - Principal Investigator	(615) 936-3465
Vitreoretinal Foundation	
825 Ridgeland Blvd	
Memphis, TN 38120	
Yoser, Seth, MD - Investigator	(901) 685-2208
Manhattan Eye & Ear	
210 E. 64th St., 8th Floor	
New York, NY 10021	
Slakter, Jason S., MD - Principal Investigator	(212) 861-9797
Wills Eye Hospital, Retina Research	
840 Walnut Street, Suite 1020	
Philadelphia, PA 19107	
Maguire, Joseph, MD - Principal Investigator	(215) 928-3092

ATTACHMENT 7

**PHAKIC IOL LABELING (ARTISIAN[®] PHAKIC
INTRAOCULAR LENS, DIRECTIONS FOR USE)**

**ARTISAN® Phakic Intraocular Lens
Directions for Use**

CAUTION: Federal Law restricts this device to sale by or on the order of a physician.

Description

OPHTEC's ARTISAN® Phakic Intraocular Lenses (IOLs) are single-piece lenses manufactured from Perspex CQ UV ultraviolet light absorbing polymethylmethacrylate (PMMA) with a refractive index of 1.49, which are designed for implantation into the anterior chamber of the phakic human eye for the treatment of myopia. The lenses are affixed to the anterior mid-periphery of the iris stroma by two iridoplastic bridges with enclavation mechanisms. The optic portion of the lens is available in a 5.0 mm or 6.0 mm diameter, with a convex-concave configuration. The 5.0 mm lens is available in a diopter range of -5 to -20 D. The 6.0 mm lens is available in a diopter range of -5 to -15 D. The optic carrier is elliptical in shape and has an overall length of 8.5 mm with a slight anterior vault. One fixation (enclavation) arm mechanism is located on each side of the two peripheral supports.

Indications for Use

ARTISAN® Phakic Intraocular Lenses (IOLs) are indicated for:

- the reduction or elimination of myopia in adults with myopia ranging from -5 D to -20 D with less than or equal to 2.5 D of astigmatism at the spectacle plane and whose eyes have an anterior chamber depth greater than or equal to 3.2 millimeters; and
- patients with documented stability of manifest refraction for the prior 6 months, as demonstrated by a spherical equivalent change of less than 0.50 D.

Contraindications

The ARTISAN® Phakic IOL is contraindicated in patients:

- Who are less than 21 years old
- With an anterior chamber depth (ACD) less than 3.2 mm
- With an abnormal iris, such as peaked pupil or elevated iris margin
- Who are pregnant and nursing
- Who do not meet the minimum endothelial cell density

Endothelial Cell Density

Age	Minimum endothelial cell density
21-25	3550 cells/mm ²
26-30	3175 cells/mm ²
31-35	2825 cells/mm ²
36-40	2500 cells/mm ²
41-45	2225 cells/mm ²
> 45	2000 cells/mm ²

The table indicates the minimum endothelial cell density (ECD) per age group at time of implantation. This table was developed using a rate of 2.31% (the upper 90% confidence interval of the average cell loss for eyes with ACDs of 3.2 mm or greater.) It sets minimum endothelial cell density criteria as a function of age that should result in at least 1000 cells/mm² at 75 years of age. The patient's ECD should be monitored periodically at the physician's discretion.

Warnings

1. Do not resterilize this intraocular lens by any method. (See Returned Lens Policy.)
2. Do not store lenses at temperatures over 45°C (113°F).
3. Surgical difficulties at the time of intraocular lens implantation, which might increase the potential for complications (e.g. persistent bleeding, significant vitreous prolapse or loss).
4. The effectiveness of ultraviolet light absorbing lenses in reducing the incidence of retinal disorders has not been established.
5. The long-term effect to the corneal endothelial cells has not been established.
6. The relationship between the ARTISAN® Phakic IOL and future lens opacities and retinal detachment is undetermined.
7. The effect of the ARTISAN® Phakic IOL on the future risk of glaucoma is unknown because its effects on the anterior chamber angle were not analyzed in the clinical trial. Approximately 1% of the subjects had elevated eye pressure that required glaucoma medication.
8. The long-term effect to the corneal endothelial cells has not been established.
9. The occurrence of lens opacities in the future is unknown.

Precautions

1. Prior to surgery, the surgeon must provide prospective patients with a copy of the patient information brochure for this product and inform these patients of the possible benefits and complications associated with the use of this device.
2. A high level of surgical skill and training specific to iris-fixed IOLs is required for lens implantation.
3. One or more iridotomies/iridectomies should be performed to reduce risk of pupillary block.
4. A cohesive high molecular weight viscoelastic is recommended for corneal protection and complete removal is recommended to reduce the chance of post-op intraocular pressure (IOP) spikes. Low molecular weight non-cohesive viscoelastics should not be used.
5. Patients with any of the following conditions may not be suitable candidates for this intraocular lens because the lens may exacerbate an existing

25

ARTISAN® Phakic Intraocular Lens

Directions for Use

condition or may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the patient's eyesight:

- a. Abnormality of the iris or ocular structure that would preclude fixation, such as aniridia, hemi-iridectomy, severe iris atrophy, coloboma, or microphthalmos.
 - b. Congenital bilateral cataracts.
 - c. Recurrent anterior or posterior segment inflammation.
 - d. Patients in whom the intraocular lens may interfere with the ability to observe, diagnose or treat posterior segment diseases.
 - e. Previous history of retinal detachment.
 - f.
 - g. Patients with only one eye with potentially good vision.
 - h. Glaucoma.
 - i. Corneal endothelial dystrophy.
 - j. Proliferative diabetic retinopathy.
6. The long-term effects of intraocular lens implantation have not been determined. Therefore, physicians should continue to monitor implant patients postoperatively on a regular basis. Annual exams are recommended.
 7. Elevated intraocular pressure has been reported occasionally in patients who received lens implants. The intraocular pressure of patients should be monitored postoperatively.
 8. Trauma is a risk factor for IOL dislocation.
 9. Visual acuity could be diminished in situations where there is low level lighting.
 10. When pupil size is greater than optic size, there may be visual aberrations.

Adverse Events and Complications

A total of 662 subjects were evaluated in the clinical trial to determine the safety of the ARTISAN® Phakic IOL.

The complications experienced during the clinical trial of the ARTISAN® Phakic IOL include (in order of frequency): Hyphema (cumulative) (0.2%), retinal detachment (cumulative) (0.6%), IOL dislocation (0.8%) and surgical reintervention (4.2%). No incidences of macular edema, endophthalmitis, hypopyon, or persistent corneal edema were reported during the study.

Incidences of complications (compared with the FDA Grid for cataract extraction and posterior chamber IOL implantation) and incidences of surgical reinterventions are shown in the following table.

Adverse Event	Cumulative % (n/N)	FDA Grid %	Persistent (3 Years) % (n/N)	FDA Grid %
Endophthalmitis	0.0 (0/662)	0.1	-	-
Hyphema	0.2 (1/662)	2.2	-	-
Hypopyon	0.0 (0/662)	0.3	-	-
IOL Dislocation	0.8 (5/662)*	0.1	-	-
Cystoid Macular Edema	0.0 (0/662)	3.0	0.0 (0/232)	0.5

Pupillary Block	0.0 (0/662)	0.1	-	-
Retinal Detachment	0.6 (4/662) [†]	0.3	-	-
Surgical Reintervention	4.2 (28/662)	0.8	-	-
Corneal Edema	-	-	0.0 (0/232)	0.3
Iritis	0.5(3/662) [‡]	-	0.0 (0/232)	0.3
Raised IOP Requiring Treatment	-	-	0.0 (0/232)	0.4
Surgical Treatments Not Monitored in the FDA Grid				
Preventative Lens Repositioning	2.1 (14/662)	-	-	-
Refractive Procedures**	2.6 (17/662)	-	-	-
Nd:Yag Peripheral Iridotomy	3.0 (20/662)	-	-	-
Aqueous Release Resuture Wound Leak	1.8 (12/662)	-	-	-
	1.2 (8/662)	-	-	-

*Four events due to inadequate surgical fixation; one event due to blunt trauma

[‡]There is no FDA Grid value for cumulative iritis

[†]Comparison should be made to literature for retinal detachment rates for high myopes:

- Retinal detachment rates increase with increasing myopia¹
The risk of retinal detachment within one year of implantation of this device is 0.6%. The risk of retinal detachment for high myopes following implantation is more than 10 times the risk without surgery, i.e. greater than 10-fold the background rate of retinal detachment for high myopes (greater than minus 3 diopters).
- 5.0% in myopic eyes > 6 D²
- 0.8% to 7.5% in pseudophakic eyes with high axial myopia³

¹ Ogawa, A and Tanaka, M. The relationship between refractive errors and retinal detachment, Jpn J. Ophthalmology 32:310, 1988.

² Dellone-Larkin G, Dellone CA. Retinal detachment. Available at <http://www.emedicine.com/emerg/topic504.htm>. Accessed January 13, 2004.

³ Jacobi, F and Hessemer, V. Pseudophakic retinal detachment in high axial myopia, J. Cat. Refract Surg 23:1095, 1997.

**Refractive procedures include: LASIK (11/17); AK (3/17); LRI (2/17) and PRK (1/17).

Surgical reinterventions (see table below) were not shown to have an impact on safety or efficacy.

Adverse Event	n	%*
Lens Explant	10	1.5%
High Myopia/Age Related Cataract	0	
Inflammatory Response	3	
Trauma	4	
Patient Anxiety	1	
Patient Not Satisfied	1	
Pupil Larger than Lens Optic	1	
Lens Exchange	9	1.4%
Pupil Calculation Error	6	
Pupil Larger than Lens Optic	2	
Inadequate Lens Fixation	1	
Lens Reattachment	5	0.7%
Trauma	1	
Inadequate Lens Fixation	4	
Retinal Repair	4	0.6%
Retinal Detachment	4	
Total	28	4.2%

* All Core Subjects N=662

ARTISAN® Phakic Intraocular Lens
Directions for Use

Other Complications

Eyes with brown irides were found to have significantly less pigment dispersion (15.3%) compared to eyes with non-brown irides (25.2%). However, eyes with brown irides had similar rates of IOP spikes greater than 30 mmHg (5.2%) compared to eyes with non-brown irides (3.9%). The interaction between pigment dispersion and brown irides was found to be a significant predictor of IOP spikes. Eyes with brown irides and pigment dispersion had a statistically significantly (Fisher's Exact Test, p=0.02) higher rate of IOP spikes (11.7%) than eyes with non-brown irides and pigment dispersion (3.1%).

Clinical Study Results

The ARTISAN® Phakic IOL was evaluated in a prospective, nonrandomized study of 662 subjects, 493 of which were followed for one year and 232 followed for three years.

The 662 subject Cohort population in the clinical trial consisted of 64.5% females (427/662) and 35.5% males (235/662). 85.0% were Caucasian, 3.2% were Black, 4.1 % were Hispanic and 6.2% were Asian. The mean age was 39.6 years.

Visual Acuity

The postoperative results demonstrated that the ARTISAN® Phakic IOL provides correction for high myopia. The visual acuities at one and three years are described in the following tables:

UCDVA=Uncorrected Distance Visual Acuity, Snellen		
Where emmetropia was the goal (+/-0.50D) and Preop Best Corrected Visual Acuity (BCVA) better than or equal to 20/20		
	1 yr	3 yr
N	204	88
20/20 or better	47.1%	44.3%
20/40 or better	93.6%	92.0%
20/80 or better	100.0%	97.7%
worse than 20/80	0.0%	2.3%

BCDVA=Best Corrected Distance Visual Acuity, Snellen		
Eyes with preoperative BCVA 20/20 or better		
	1 yr	3 yr
N	288	127
20/20 or better	95.1%	95.3%
20/40 or better	100.0%	100.0%
20/80 or better	100.0%	100.0%
worse than 20/80	0.0%	0.0%

Predictability of refraction

The refraction was predictable, with 91.5% of patients achieving +/- 1.0 D from target at the one-year examination.

Spherical Equivalence (Target Variance) Distribution:		
	1 yr	3 yr
N	492	226
Plano to +/- 0.5D	72.0%	71.7%
Plano to +/- 1.0D	94.5%	94.7%

Stability of refraction

The refraction was stable, with 95.9% of patients achieving less than +/- 1.0 D of shift at 3 years.

Manifest Refraction Spherical Equivalence (MRSE) Change between visits			
	6 mo - 1 yr	1 yr - 2 yr	2 yr - 3 yr
N	485	349	215
+/- 0.5D	82.9%	85.4%	82.5%
+/- 1.0D	97.1%	97.7%	95.9%
+/- 2.0D	99.6%	99.7%	99.5%
>2.0D	0.4%	0.3%	0.5%

Endothelial Cell Density

The analysis of the change in endothelial cell (EC) density indicated that the EC density remained relatively constant over the three-year study period in relation to normal endothelial cell loss.

An endothelial cell density substudy was performed using a single reading center to minimize standard deviations inherent in this test method. For this subset of 215 subjects (315 eyes), a percent change from baseline to three years of -4.76% (SD=7.8%) was found. This result is consistent with expected normal endothelial cell loss of 1.5% to 2.0% per year. No statistically significant differences in the percent change between consecutive study intervals were found. Covariate analyses including age, anterior chamber depth, lens model, and IOP showed no significant correlations.

Mean EC density results for a consistent cohort group of 57 eyes with useable data available at postop visits are shown in the following table:

Visit	Mean	Standard Deviation	Standard Error	95% Confidence Limits	
PreOp	2818.33	425.01	56.29	2708.00	2928.67
6 Months	2812.86	465.79	61.70	2691.94	2933.78
1 Year	2768.25	460.42	60.98	2648.72	2887.77
2 Years	2760.26	478.54	63.38	2636.03	2884.50
3 Years	2692.98	478.64	63.40	2568.73	2817.24

The available 3-year data from the clinical study indicates a continual steady loss of endothelial cells of -1.8% per year and this rate has not been established as safe. If endothelial cell loss continues at the rate of 1.8% per year, 39% of patients are expected to lose 50% of their corneal endothelial cells within 25 years of implantation. The long-term effect

ARTISAN® Phakic Intraocular Lens

Directions for Use

on the cornea's health of a 50% loss in corneal endothelial cells is unknown.

The following table shows the predicted endothelial cell loss for the estimated proportion of patients based on percent loss and time from implantation.

	Percent Loss						
	0	10	20	30	40	50	60
1	48	34	22	13	7	3	1
2	57	46	36	26	18	12	8
3	63	54	44	35	27	20	14
4	67	59	50	42	34	26	20
5	71	63	55	47	39	31	24
6	74	67	60	52	44	36	29
7	77	71	63	56	48	40	32
8	80	74	67	59	51	43	36
9	82	76	70	63	55	47	39
10	84	79	73	66	58	50	42
11	86	81	75	68	61	53	44
12	88	84	78	71	64	55	47

Optical Visual Symptoms

The following table shows the postoperative outcomes by proportion as compared to preoperative levels for glare, halos and starbursts, etc., stratified by the mesopic pupil sizes measured preoperatively.

Optical Visual Symptom	Pupil Size	Questionnaire Responses*		
		Subjects with no change in symptoms preop to postop	Subjects with change in symptoms preop to postop	
			Preop NO, Postop YES	Preop YES, Postop NO
Glare	All	73.6%	13.5%	12.9%
	<4.5 mm	70.4%	14.3%	15.3%
	>4.5 to <5.5 mm	71.6%	13.4%	15.1%
	>5.5 mm	76.3%	16.8% [†] (p=0.04)	6.9%
Starbursts	All	78.5%	11.8%	9.7%
	<4.5 mm	77.8%	12.1%	10.1%
	>4.5 to <5.5 mm	74.5%	16.3%	9.3%
	>5.5 mm	81.2%	10.9%	7.9%
Halos	All	72.0%	18.2% [†] (p 0.002)	9.8%
	<4.5 mm	72.8%	17.2%	10.1%
	>4.5 to <5.5 mm	69.2%	19.2%	11.6%
	>5.5 mm	72.2%	23.8% [†] (p<0.001)	4.0%

*412 subjects completed the questionnaire, data presented for those subjects that answered nighttime symptom questions; pupil size groups: <4.5 mm (n=99), >4.5 to 5.5 mm (n=172), >5.5 mm (n=101).

[†] Statistically significant (McNemar's Test) for those subjects reporting a change in symptom occurrence preoperatively to postoperatively

Additional Outcome Data Including Bilateral Eyes

The following table stratifies the predictability of intended refraction for ± 0.5 and ± 1.0 D by lens power for all eyes implanted (662 subjects, 478 bilaterally implanted).

Lens Group	Exam Interval	N	MRSE vs. Intended Target		
			± 0.5 D	± 1.0 D	± 2.0 D
All Diopter Powers	1-6 Day	1037	58.0%	84.4%	92.8%
	2-3 Week	1070	67.1%	93.9%	96.4%
	4-8 Week	1086	70.2%	93.6%	96.8%
	4-6 Month	996	74.8%	95.5%	98.6%
	7-11 Month	878	76.7%	94.5%	98.4%
	1 Year	840	73.6%	95.0%	98.6%
	2 Year	604	72.0%	94.0%	98.7%
3 Year	376	69.9%	94.7%	98.4%	
>5 to -7 Diopters	1 Year	27	77.8%	100.0%	100.0%
	2 Year	14	85.7%	100.0%	100.0%
	3 Year	18	55.6%	100.0%	100.0%
>7 to -10 Diopters	1 Year	161	73.3%	93.8%	99.4%
	2 Year	109	68.8%	94.5%	100.0%
	3 Year	69	73.9%	94.2%	100.0%
>-10 to -15 Diopters	1 Year	543	76.1%	95.6%	98.5%
	2 Year	388	74.2%	95.1%	98.5%
	3 Year	235	69.8%	94.0%	97.9%
>-15 Diopters	1 Year	109	60.6%	92.7%	97.2%
	2 Year	93	64.5%	88.2%	97.8%
	3 Year	54	70.4%	96.3%	98.1%

The following table shows the UCVA by lens power for all eyes implanted that were targeted for emmetropia.

Lens Group	Plane to:	N	20/20 or Better	20/40 or Better
All Diopter Powers	1-6 Day	720	13.1%	54.4%
	2-3 Week	686	18.8%	70.3%
	4-8 Week	687	26.5%	81.5%
	4-6 Month	623	35.0%	89.7%
	7-11 Month	556	39.6%	90.6%
	1 Year	521	39.9%	92.3%
	2 Year	379	36.9%	90.8%
3 Year	225	35.6%	88.0%	
>5 to -7 Diopters	1 Year	11	45.5%	100.0%
	2 Year	7	0.0%	85.7%
	3 Year	8	0.0%	75.0%
>7 to -10 Diopters	1 Year	90	51.1%	93.3%
	2 Year	60	50.0%	98.3%
	3 Year	32	50.0%	96.9%
>-10 to -15 Diopters	1 Year	347	38.9%	93.1%
	2 Year	252	36.9%	89.7%
	3 Year	148	36.5%	85.8%
>-15 Diopters	1 Year	73	30.1%	86.3%
	2 Year	60	28.3%	88.3%
	3 Year	37	27.0%	91.9%

Directions For Use

1. Check the label on the lens package for proper lens model, dioptric power, and expiration date.
2. Inspect the blister pack. Ensure that it is not damaged.
3. Tap lightly on the lid before opening the lens container.
4. While keeping the container in a horizontal position, unscrew the cap and lift it.

ARTISAN® Phakic Intraocular Lens

Directions for Use

Page 5 of 5

5. Grasp the lens gently with forceps.
6. Examine the lens carefully under the microscope for damage or particulate matter.
7. Rinsing the IOL with sterile balanced salt solution will remove the electrostatic charge.

NOTE: The IOL can become electrostatically charged and may stick to the lid of the lens container. The lens should be carefully examined to ensure that particles have not been attracted to it.

Calculation of Lens Power

The physician should determine preoperatively the power of the lens to be implanted.

Lens power calculation methods are described in the following reference:

- van der Heijde, G.L., Some optical aspects of implantation of an IOL in a myopic eye, European Journal of Implant Refractive Surgery, Vol 1, Dec 1989, pgs 245-248

Physicians requiring additional information on lens power calculation should contact OPHTEC.

Patient Registration Instructions and Reporting Registration

Each patient who receives an ARTISAN® Phakic IOL must be registered with OPHTEC at the time of lens implantation. Registration is accomplished by completing the Implant Registration Card that is enclosed in the lens package and mailing it to OPHTEC. Patient registration is essential for OPHTEC's long-term patient follow-up program and will assist OPHTEC in responding to Adverse Reaction Reports and/or potentially sight-threatening complications.

An Implant Identification Card is supplied in the lens package. This card should be given to the patient with instructions to keep it as a permanent record of the implant and to show the card to any eye care practitioner seen in the future.

Reporting

Adverse Reactions and/or potentially sight-threatening complications that may reasonably be regarded as lens related and that were not previously expected in nature, severity or degree of incidence should be reported to OPHTEC immediately but no later than 10 days after occurrence. This information is being requested from all surgeons in order to document potential long-term effects of intraocular lens implantation, especially in younger patients.

Physicians must report these events in order to aid in identifying emerging or potential problems with ARTISAN® Phakic IOLs. These problems may be related to a specific lot of lenses or may be indicative of long-term problems associated with these lenses or with IOLs in general.

Physicians should use the following number when reporting adverse reactions or potentially sight

threatening complications involving OPHTEC intraocular lenses. National: (561) 989-8767.

How Supplied

The IOL is supplied sterile and dry in a lens container, which is sealed in a blister pack and placed in a box together with the identifying labels.

Expiration Date

Sterility is guaranteed unless the sterile pouch is damaged or opened. In addition, there is a sterility expiration date that is clearly indicated on the outside of the shelf-pack. The lens should not be used after the indicated date.

Returned Lens Policy

The lens may be returned to the manufacturer for credit within 30 days of purchase. After 30 days it can be replaced or exchanged at no charge if not opened or damaged.

DISTRIBUTED BY:

OPHTEC USA, Inc.
6421 Congress Avenue, Suite 112
Boca Raton, FL 33487
(561) 989-8767

MANUFACTURED BY:

OPHTEC BV
Schweitzerlaan 15
9728 NR Groningen
The Netherlands

Sept 10-04 rev 1

29

ATTACHMENT 8

BI EXPONENTIAL MODEL

BIEXPONENTIAL MODEL

The biexponential model is defined by the equation:

$$\text{ECD}_{\text{month}} = p \times e^{-a \times \text{month}} + q \times e^{-b \times \text{month}} + \varepsilon.$$

The model is used to fit the ECD pattern from baseline to 48 months after IMT implantation. For each eye at each visit, the average of all available ECD readings was used as the ECD measurement for the eye at that visit. ECD readings made after IMT explantation were not used since these readings were confounded by the removal of the IMT and implantation of a conventional IOL, however all available ECD readings made prior to IMT explantation were included in the model. The methods employed in the modeling were discussed with W. Bourne, M.D., Professor of Ophthalmology, Mayo Clinic, who was retained as a consultant to VisionCare on methods for analysis of endothelial cell loss. Dr. Bourne confirmed that the methods, as presented in this document, employed by VisionCare are appropriate.

The first term, $p \times e^{-a \times \text{month}}$, of the bi-exponential model represents the "rapid" rate of loss rate associated with the surgical trauma while the second term, $q \times e^{-b \times \text{month}}$ represents the "slow" rate of loss that occurs after stabilization. The quantity ε is an error term.

Having fit the model, the annual loss after stabilization is estimated as $(1 - e^{-b \times 12}) \times 100\%$. The predicted mean ECD at 3, 12, 24, 36, and 48 months and the corresponding 95% confidence intervals were calculated from the fitted model.

In addition to predicting mean ECD post-implantation, the probability that an individual eye would have ECD <1000, < 750 and <500 was predicted for various times after IMT-implantation using the empirical distribution of residuals as follows:

- For each observed ECD measurement, residual = observed ECD – predicted ECD.
- Since $(\text{observed ECD} < 1000) \cong (\text{residual} + \text{predicted ECD} < 1000) \cong (\text{residual} < 1000 - \text{predicted ECD})$, the probability of observed ECD at certain month <1000 is predicted by the proportion of residuals at the corresponding month less than 1000 minus the predicted ECD at the corresponding month.

Selection of the threshold limits of <1000 cells/mm², <750 cells/mm² and <500 cells/mm² in IMT-implanted eyes was based on a number of considerations, including age of the population indicated for IMT implantation, the probability of ECD falling below these limits over time, and existing clinical and regulatory precedent.